# Pfizer Inc: Form 10-Q for the period ended Sep 29, 2019

- Company: [Pfizer Inc](/companies/pfe.md) (CIK 78003)
- Form: 10-Q
- Filed: 2019-11-07
- Accepted by EDGAR: Nov 7, 2019, 20:55 ET
- Period: 2019-09-29
- Accession: 0000078003-19-000082
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/78003/000007800319000082/pfe-09292019x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/78003/000007800319000082/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-09-29.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2019-07-01 to 2019-09-29 | $12.68bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2019-01-01 to 2019-09-29 | $39.06bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2019-07-01 to 2019-09-29 | $2.60bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2019-01-01 to 2019-09-29 | $7.61bn | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months, 2019-07-01 to 2019-09-29 | $3.26bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2019-01-01 to 2019-09-29 | $10.11bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months, 2019-07-01 to 2019-09-29 | $409.0m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2019-01-01 to 2019-09-29 | $1.16bn | us-gaap:InterestExpense |
| Income tax | 3 months, 2019-07-01 to 2019-09-29 | $3.05bn | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2019-01-01 to 2019-09-29 | $2.57bn | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2019-07-01 to 2019-09-29 | $7.68bn | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2019-01-01 to 2019-09-29 | $16.61bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2019-07-01 to 2019-09-29 | $1.36 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2019-01-01 to 2019-09-29 | $2.92 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2019-07-01 to 2019-09-29 | $1.38 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2019-01-01 to 2019-09-29 | $2.98 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2019-07-01 to 2019-09-29 | 5,649,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2019-01-01 to 2019-09-29 | 5,690,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2019-01-01 to 2019-09-29 | $8.82bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2019-01-01 to 2019-09-29 | $1.50bn | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months, 2019-01-01 to 2019-09-29 | $8.87bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2019-09-29 | $2.79bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2019-09-29 | $33.46bn | us-gaap:AssetsCurrent |
| Total assets | at 2019-09-29 | $170.45bn | us-gaap:Assets |
| Current liabilities | at 2019-09-29 | $36.97bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2019-09-29 | $105.05bn | us-gaap:Liabilities |
| Long-term debt | at 2019-09-29 | $36.04bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2019-09-29 | $2.43bn | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | at 2019-09-29 | $12.91bn | us-gaap:CommercialPaper |
| Shareholders' equity | at 2019-09-29 | $65.10bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 279,172 characters.

### Introduction

See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout this MD&A. Our MD&A is provided in addition to the accompanying condensed consolidated financial statements and footnotes to assist readers in understanding Pfizer’s results of operations, financial condition and cash flows. The MD&A is organized as follows:

|  |  |  |
| --- | --- | --- |
| ● | Overview of Our Performance, Operating Environment, Strategy and Outlook | Beginning on page 54 |
|  | This section provides information about the following: Our Business; our performance during the third quarter and first nine months of 2019 and 2018; Our Operating Environment; The Global Economic Environment; Our Strategy; Our Business Development Initiatives, such as acquisitions, dispositions, licensing and collaborations; and Our Financial Guidance for 2019. |  |
| ● | Significant Accounting Policies and Application of Critical Accounting Estimates and Assumptions | Beginning on page 69 |
|  | This section discusses updates to our 2018 Financial Report disclosures for those accounting policies and estimates that we consider important in understanding our consolidated financial statements. |  |
| ● | Analysis of the Condensed Consolidated Statements of Income | Beginning on page 70 |
|  | This section includes the following sub-sections: |  |
|  | ○ Revenues by Operating Segment and Geography | Beginning on page 71 |
|  | This sub-section provides an overview of revenues by operating segment and geography as well as revenue deductions. |  |
|  | ○ Revenues - Selected Product Discussion | Beginning on page 75 |
|  | This sub-section provides an overview of several of our biopharmaceutical products. |  |
|  | ○ Product Developments - Biopharmaceutical | Beginning on page 81 |
|  | This sub-section provides an overview of important biopharmaceutical product developments. |  |
|  | ○ Costs and Expenses | Beginning on page 85 |
|  | This sub-section provides a discussion about our costs and expenses. |  |
|  | ○ Provision for Taxes on Income | Beginning on page 88 |
|  | This sub-section provides a discussion of items impacting our tax provisions. |  |
|  | ○ Non-GAAP Financial Measure (Adjusted Income) | Beginning on page 88 |
|  | This sub-section provides a discussion of an alternative view of performance used by management. |  |
| ● | Analysis of Operating Segment Information | Beginning on page 94 |
|  | This section provides a discussion of the performance of each of our operating segments. |  |
| ● | Analysis of the Condensed Consolidated Statements of Comprehensive Income | Beginning on page 102 |
|  | This section provides a discussion of changes in certain components of other comprehensive income. |  |
| ● | Analysis of the Condensed Consolidated Balance Sheets | Beginning on page 103 |
|  | This section provides a discussion of changes in certain balance sheet accounts. |  |
| ● | Analysis of the Condensed Consolidated Statements of Cash Flows | Beginning on page 104 |
|  | This section provides an analysis of our cash flows for the first nine months of 2019 and 2018. |  |
| ● | Analysis of Financial Condition, Liquidity and Capital Resources | Beginning on page 105 |
|  | This section provides an analysis of selected measures of our liquidity and of our capital resources as of September 29, 2019 and December 31, 2018, as well as a discussion of our outstanding debt and other commitments that existed as of September 29, 2019 and December 31, 2018. Included in the discussion of outstanding debt is a discussion of the amount of financial capacity available to help fund Pfizer’s future activities. |  |
| ● | New Accounting Standards | Beginning on page 109 |
|  | This section discusses accounting standards that we have recently adopted, as well as those that recently have been issued, but not yet adopted. |  |
| ● | Forward-Looking Information and Factors That May Affect Future Results | Beginning on page 110 |
|  | This section provides a description of the risks and uncertainties that could cause actual results to differ materially from those discussed in forward-looking statements presented in this MD&A. Also included in this section is a discussion of legal proceedings and contingencies. |  |

Certain amounts in our MD&A may not add due to rounding. All percentages have been calculated using unrounded amounts.

### OVERVIEW OF OUR PERFORMANCE, OPERATING ENVIRONMENT, STRATEGY AND OUTLOOK

### Our Business

We apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development and manufacture of healthcare products, including innovative medicines and vaccines. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Our revenues are derived from the sale of our products and, to a much lesser extent, from alliance agreements, under which we co-promote products discovered or developed by other companies or us (Alliance revenues).

At the beginning of our 2019 fiscal year, we began to manage our commercial operations through a new global structure consisting of three business segments––Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and through July 31, 2019, Consumer Healthcare. Biopharma and Upjohn are the only reportable segments. For additional information, see Notes to Condensed Consolidated Financial Statements––*Note 2B. Acquisitions, Equity-Method Investment and Assets and Liabilities Held for Sale and Research and Development Arrangement: Equity-Method Investment and Assets and Liabilities Held for Sale* and *Note 13A. Segment, Geographic and Other Revenue Information: Segment Information* and the “Our Strategy––Commercial Operations” section of this MD&A below.

The majority of our revenues come from the manufacture and sale of biopharmaceutical products. As explained more fully in our 2018 Form 10-K, the biopharmaceutical industry is highly competitive and highly regulated. As a result, we face a number of industry-specific factors and challenges, which can significantly impact our results. These factors include, among others: the loss or expiration of intellectual property rights and the expiration of co-promotion and licensing rights, the ability to replenish innovative biopharmaceutical products, healthcare legislation, pipeline productivity, the regulatory environment, pricing and access pressures and competition. We also face challenges as a result of the global economic environment. For additional information about these factors and challenges, see the “Our Operating Environment” and “The Global Economic Environment” sections of this MD&A and of our 2018 Financial Report and Part I, Item 1A, “Risk Factors” of our 2018 Form 10-K.

The financial information included in our condensed consolidated financial statements for our subsidiaries operating outside the U.S. is as of and for the three and nine months ended August 25, 2019 and August 26, 2018. The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the three and nine months ended September 29, 2019 and September 30, 2018.

References to operational variances in this MD&A pertain to period-over-period growth rates that exclude the impact of foreign exchange. The operational variances are determined by multiplying or dividing, as appropriate, our current period U.S. dollar results by the current period average foreign exchange rates and then multiplying or dividing, as appropriate, those amounts by the prior-year period average foreign exchange rates. Although exchange rate changes are part of our business, they are not within our control. Exchange rate changes, however, can mask positive or negative trends in the business; therefore, we believe presenting operational variances provides useful information in evaluating the results of our business.

Our significant recent business development activities include:

- Formation of a New Consumer Healthcare Joint Venture––On July 31, 2019, we completed the transaction in which we and GSK combined our respective consumer healthcare businesses into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name. The joint venture is a category leader in pain relief, respiratory and vitamins, minerals and supplements, and therapeutic oral health and is the largest global OTC consumer healthcare business.
- Acquisition of Array BioPharma Inc.––On July 30, 2019, we acquired Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need, for $48 per share in cash. The total fair value of the consideration transferred for Array was approximately $11.2 billion ($10.9 billion, net of cash acquired). Our financial statements for the third quarter and first nine months of 2019 reflect the assets, liabilities, operating results and cash flows of Array, commencing from the acquisition date.
- Agreement to Combine Upjohn with Mylan N.V.––On July 29, 2019, we announced that we entered into a definitive agreement to combine Upjohn with Mylan, creating a new global pharmaceutical company. Under the terms of the agreement, which is structured as an all-stock, Reverse Morris Trust transaction, Upjohn is expected to be spun-off or split-off to Pfizer’s shareholders and, immediately thereafter, combined with Mylan. Pfizer shareholders would own 57% of the combined new company, and former Mylan shareholders would own 43%. The transaction is expected to be tax free to Pfizer and Pfizer shareholders. The transaction is anticipated to close in mid-2020, subject to Mylan shareholder approval and satisfaction of other customary closing conditions, including receipt of regulatory approvals.
- Acquisition of Therachon Holding AG––On July 1, 2019, we acquired all the remaining shares of Therachon for $340 million upfront, plus potential milestone payments of up to $470 million, contingent on the achievement of key milestones in the development and commercialization of the lead asset. The total fair value of the consideration transferred for Therachon was approximately $322 million. Our financial statements for the third quarter and first nine months of 2019 reflect the assets, liabilities, operating results and cash flows of Therachon, commencing from the acquisition date and, in accordance with our international reporting period, reflect two months of Therachon operations and cash flows.

For additional information, see Notes to Condensed Consolidated Financial Statements––*Note 1A. Basis of Presentation and Significant Accounting Policies: Basis of Presentation,* Notes to Condensed Consolidated Financial Statements––*Note 2. Acquisitions, Equity-Method Investment and Assets and Liabilities Held for Sale and Research and Development Arrangement*, and the “Our Strategy––Commercial Operations” and the “Our Strategy––Our Business Development Initiatives” sections of this MD&A below.

#### Product Manufacturing

We periodically encounter difficulties or delays in manufacturing, including due to suspension of manufacturing or voluntary recall of a product, or legal or regulatory actions such as warning letters. For example, Hospira’s manufacturing facility in McPherson, Kansas is currently under the FDA inspection classification of Official Action Indicated (OAI). As a result of this classification, the FDA may refuse to grant premarket approval of applications and/or the FDA may refuse to grant export certificates related to products manufactured at our McPherson site until the site status is upgraded, which upgrade would be based on a re-inspection by the FDA. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of corrections implemented at the site. Communication with the FDA on the status of the McPherson site is ongoing. For additional information regarding the FDA inspection of the McPherson site, see Part I, Item 1A, “Risk Factors––Product Manufacturing, Sales and Marketing Risks” of our 2018 Form 10-K.

The product shortages we have been experiencing within our portfolio are primarily for products from the legacy Hospira portfolio and are largely driven by capacity constraints, technical issues and supplier quality concerns. We continue to remediate issues at legacy Hospira facilities manufacturing sterile injectables. Any continuing product shortage interruption at these manufacturing facilities could negatively impact our financial results, specifically in our Hospital portfolio. We continue to make progress on our comprehensive remediation plan to upgrade and modernize these facilities, and we expect our supply issues to be substantially improved by the end of 2019.

### Our Third Quarter 2019 Performance

#### Revenues

*Revenues* in the third quarter of 2019 decreased $618 million, or 5%, compared to the same period in 2018, which reflects an operational decrease of $403 million, or 3%, as well as the unfavorable impact of foreign exchange of $215 million, or 2%. *Revenues* in the first nine months of 2019 decreased $609 million, or 2%, compared to the same period in 2018, which reflects an unfavorable impact of foreign exchange of $1.2 billion, or 3%, partially offset by an operational increase of $586 million, or 1%.

The following provides an analysis of the changes in revenues for the third quarter and first nine months of 2019:

| (MILLIONS OF DOLLARS) | Three Months | Nine Months |
| --- | ---: | ---: |
| Revenues, for the three and nine months ended September 30, 2018 | $13,298 | $39,670 |
| Operational growth/(decline): |  |  |
| Continued growth from certain key brands(a) | 621 | 1,978 |
| Higher revenues for Biosimilars, certain rare disease products and Inlyta primarily in the U.S.; and, in the nine months ended September 29, 2019, volume growth from Celebrex and Effexor, primarily in Japan and China | 200 | 284 |
| Decline from Lipitor and Norvasc in the third quarter of 2019 and growth from Lipitor in the first nine months of 2019, partially offset by decline from Norvasc | (35) | 37 |
| Declines from Viagra and Pfizer’s authorized generic for Viagra in the U.S.; Enbrel internationally; Lyrica, primarily in the U.S., reflecting significant lower volume associated with multi-source generic competition that began in July 2019; Revatio and Relpax primarily in the U.S.; and in the third quarter of 2019, Prevnar 13/Prevenar 13 | (897) | (1,215) |
| Decline from Consumer Healthcare reflecting the July 31, 2019 completion of the Consumer Healthcare joint venture transaction with GSK | (451) | (462) |
| Growth/(decline) from the Hospital business | 112 | (46) |
| Other operational factors, net | 47 | 10 |
| Operational growth/(decline), net | (403) | 586 |
| Operational revenues | 12,895 | 40,256 |
| Unfavorable impact of foreign exchange | (215) | (1,194) |
| Revenues, for the three and nine months ended September 29, 2019 | $12,680 | $39,062 |

(a) Key brands represent Ibrance, Eliquis and Xeljanz as well as, for the first nine months of 2019, Prevnar 13/Prevenar 13.

For worldwide revenues and revenues by geography, for selected products, see the discussion in the “Analysis of the Condensed Consolidated Statements of Income––Revenues––Selected Product Discussion” section of this MD&A. For additional information regarding the primary indications or class of certain products, see Notes to Condensed Consolidated Financial Statements––*Note 13C. Segment, Geographic and Other Revenue Information: Other Revenue Information.*

See the “Analysis of the Condensed Consolidated Statements of Income––Revenues by Operating Segment and Geography” section below for more information, including a discussion of key drivers of our revenue performance.

#### Income from Continuing Operations Before Provision for Taxes on Income

The following provides an analysis of the increase in *Income from continuing operations before provision for taxes on income* for the third quarter and first nine months of 2019:

| (MILLIONS OF DOLLARS) | Three Months | Nine Months |
| --- | ---: | ---: |
| Income from continuing operations before provision for taxes on income, for the three and nine months ended September 30, 2018 | $4,177 | $12,831 |
| Unfavorable change in revenues | (618) | (609) |
| Favorable/(unfavorable) changes: |  |  |
| Gain on completion of Consumer Healthcare JV transaction in 2019 | 8,087 | 8,087 |
| Lower Cost of sales(a) | 92 | 562 |
| Lower Selling, information and administrative expenses(b) | 234 | 338 |
| Favorable change in the fair value of contingent consideration(c) | 101 | 226 |
| Higher royalty-related income(c) | 12 | 115 |
| Lower Amortization of intangible assets(c) | 42 | 61 |
| Income from insurance recoveries related to Hurricane Maria(c) | — | 50 |
| Non-recurrence of gain on equity investment in Cerevel(c) | (343) | (343) |
| Higher business and legal entity alignment costs(c) | (86) | (337) |
| Lower income from collaborations, out-licensing arrangements and sales of compound/product rights(c) | (119) | (331) |
| Lower net gains recognized during the period on investments in equity-securities(c) | (79) | (307) |
| Higher Research and development expenses(d) | (275) | (278) |
| Higher net interest expense(c) | (120) | (267) |
| Unfavorable change in certain legal matters, net(c) | (28) | (154) |
| Higher asset impairment charges(c) | (28) | (148) |
| Higher net losses on early retirement of debt(c) | — | (134) |
| Higher Restructuring charges and certain acquisition-related costs(e) | (280) | (123) |
| Lower net periodic benefit credits other than service costs(c) | (46) | (121) |
| Higher transaction and advisory costs to separate our Consumer Healthcare business(c) | (81) | (58) |
| Non-recurrence of gain on the contribution of Pfizer’s CAR T assets(c) | — | (50) |
| All other items, net | 83 | 180 |
| Income from continuing operations before provision for taxes on income, for the three and nine months ended September 29, 2019 | $10,727 | $19,190 |

(a) See the “Costs and Expenses––Cost of Sales” section of this MD&A.

(b) See the “Costs and Expenses––Selling, Informational and Administrative (SI&A) Expenses” section of this MD&A.

(c) See the Notes to Condensed Consolidated Financial Statements––*Note 4. Other (Income)/Deductions—Net.*

(d) See the “Costs and Expenses––Research and Development (R&D) Expenses” section of this MD&A.

(e) See the “Costs and Expenses––Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives” section of this MD&A.

(f) See the “Costs and Expenses––Amortization of Intangible Assets” section of this MD&A.

For information on our tax provision and effective tax rate see the “Provision for Taxes on Income” section of this MD&A and Notes to Condensed Consolidated Financial Statements––*Note 5. Tax Matters.*

### Our Operating Environment

### Industry-Specific Challenges

#### Intellectual Property Rights and Collaboration/Licensing Rights

The loss, expiration or invalidation of intellectual property rights, patent litigation settlements with manufacturers and the expiration of co-promotion and licensing rights can have a significant adverse effect on our revenues. Many of our branded products have multiple patents that expire at varying dates, thereby strengthening our overall patent protection. However, once patent protection has expired or has been lost prior to the expiration date as a result of a legal challenge, we typically lose exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce similar products and sell them for a lower price. The date at which generic competition commences may be different from the date that the patent or regulatory exclusivity expires. However, when generic competition does commence, the resulting price competition can substantially decrease our revenues for the impacted products, often in a very short period of time. Also, if one of our patents is found to be invalid by judicial, court or administrative proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio were challenged in inter partes review and post-grant review proceedings in the U.S. The Patent Trial and Appeal Board refused to initiate proceedings as to two patents. In June 2018, the Patent Trial and Appeal Board ruled on another patent, holding that one claim was valid and that all other claims were invalid. The party challenging that patent has appealed the decision. In March and June 2019, an additional patent was found invalid in separate proceedings by the Patent Trial and Appeal Board. We have appealed. Challenges to other patents remain pending in jurisdictions outside the U.S. The invalidation of all of the patents in our pneumococcal portfolio could potentially allow a competitor pneumococcal vaccine into the marketplace. In the event that any of the patents are found valid and infringed, a competitor pneumococcal vaccine might be prohibited from entering the market or required to pay Pfizer a royalty.

A number of our current products have experienced patent-based expirations or loss of regulatory exclusivity in certain markets in the last few years. For example, as a result of a patent litigation settlement, Teva Pharmaceuticals USA, Inc. launched a generic version of Viagra (a product in our Upjohn business) in the U.S. in December 2017. Lyrica (a product in our Upjohn business) lost patent protection in the U.S. in June 2019 and multi-source generic competition began in July 2019. Additional patent expiries will continue over several years, and we expect the impact of reduced revenues due to patent expiries will be significant in the rest of 2019 and in 2020, then moderating downward to a much lower level from 2021 through 2025.

Our biologic products, including BeneFIX, ReFacto, Xyntha, Bavencio, Prevnar 13/Prevenar 13 and Enbrel (we market Enbrel outside the U.S. and Canada), may face in the future, or already face, competition from biosimilars (also referred to as follow-on biologics). If competitors are able to obtain marketing approval for biosimilars referencing our biologic products, our biologic products may become subject to competition from these biosimilars, with attendant competitive pressure, and price reductions could follow. For example, Enbrel faces ongoing biosimilar competition in most developed Europe markets. The expiration or successful challenge of applicable patent rights could trigger this competition, assuming any relevant regulatory exclusivity period has expired.

See the “Intellectual Property Rights and Collaboration/Licensing Rights” section of our 2018 Financial Report for additional information about recent losses and expected losses of product exclusivity in the U.S., Europe and/or Japan impacting product revenues.

For additional information, including the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires, see the “Patents and Other Intellectual Property Rights” section in Part I, Item 1, “Business” of our 2018 Form 10-K.

We will continue to vigorously defend our patent rights whenever we deem appropriate. For a discussion of certain recent developments with respect to patent litigation, see Notes to Condensed Consolidated Financial Statements––*Note 12A1. Contingencies and Certain Commitments: Legal Proceedings––Patent Litigation.*

#### Regulatory Environment/Pricing and Access––U.S. Healthcare Legislation

In March 2010, the ACA was enacted in the U.S. For additional information, see the “Government Regulation and Price Constraints” section in Part I, Item 1, “Business” of our 2018 Form 10-K.

*We recorded the following amounts as a result of the U.S. Healthcare Legislation:*

| (MILLIONS OF DOLLARS) | Three Months Ended September 29, 2019 | September 30, 2018 | Nine Months Ended September 29, 2019 | September 30, 2018 |
| --- | ---: | ---: | ---: | ---: |
| Reduction to Revenues, related to the Medicare “coverage gap” discount provision | $307 | $217 | $596 | $435 |
| Selling, informational and administrative expenses, related to the fee payable to the federal government (which is not deductible for U.S. income tax purposes), based on our prior-calendar-year share relative to other companies of branded prescription drug sales to specified government programs. The first nine months of 2018 also reflected a favorable true-up associated with the updated 2017 invoice received from the federal government, which reflected a lower expense than what was previously estimated for invoiced periods. | 52 | 43 | 173 | 118 |

58

#### Regulatory Environment/Pricing and Access––Government and Other Payer Group Pressures

The pricing of medicines by pharmaceutical manufacturers and the cost of healthcare, which includes medicines, medical services and hospital services, continues to be important to payers, governments, patients, and other stakeholders. We believe that medicines are amongst the most powerful tools for patients in curing, treating and preventing illness and disability, and that all patients should have appropriate access to the medicines their doctors prescribe. We may consider a number of factors when determining a medicine’s price, including, for example, its impact on patients and their disease, other available treatments, the medicine’s potential to reduce other healthcare costs (such as hospital stays), and affordability. Within the U.S., in particular, we may also engage with patients, doctors and healthcare plans regarding their views. We also negotiate with insurers, including PBMs and MCOs, often providing significant discounts to them from the list price. The price that patients pay in the U.S. for the medicines their physicians prescribe is ultimately set by healthcare providers and insurers. On average, in the U.S., insurers impose a higher out-of-pocket burden on patients for prescription medicines than for comparably-priced medical services. We will continue to work with insurance providers, governments and others to improve access to today’s innovative treatments.

Governments, MCOs and other payer groups continue to seek increasing discounts on our products through a variety of means, such as leveraging their purchasing power, implementing price controls, and demanding price cuts (directly or by rebate actions). In Europe, Japan, China, Canada, South Korea and some other international markets, governments provide healthcare at low-to-zero direct cost to consumers at the point of care and have significant power as large single payers to regulate pharmaceutical prices or patient reimbursement levels to control costs for the government-sponsored healthcare system, particularly under recent global economic pressures.

In response to the evolving U.S. and global healthcare spending landscape, we continue to work with health authorities, health technology assessment and quality measurement bodies and major U.S. payers throughout the product-development process to better understand how these entities value our compounds and products. Further, we seek to develop stronger internal capabilities focused on demonstrating the value of the medicines that we discover or develop, register and manufacture, by recognizing patterns of usage of our medicines and competitor medicines along with patterns of healthcare costs.

***U.S.––***In the U.S., government action to reduce federal spending on entitlement programs including Medicare and Medicaid may affect payment for our products or services provided using our products. Any significant spending reductions or cost controls affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented could have an adverse impact on our results of operations.

Consolidation among MCOs has increased the negotiating power of MCOs and other third-party payers. Private third-party payers, as well as governments, increasingly employ formularies to control costs by taking into account discounts in connection with decisions about formulary inclusion or favorable formulary placement. Failure to obtain or maintain timely or adequate pricing or favorable formulary placement for our products, or failure to obtain such formulary placement at favorable pricing, could adversely impact revenue.

Efforts by government officials or legislators to implement measures to regulate prices or payment for pharmaceutical products, including legislation on drug importation, could adversely affect our business if implemented. There continues to be considerable public and government scrutiny of pharmaceutical pricing and measures to address the perceived high cost of pharmaceuticals are being considered by Congress, the Presidential Administration and select states. In addition to new state transparency laws and the introduction of several Federal pricing bills, we have also seen the inclusion of new pricing rules in continuing resolutions such as the treatment of authorized generics in the calculation of average manufacturer price. We expect to see continued focus in regulating pricing resulting in additional legislation that could adversely impact revenue.

We believe medicines are the most efficient and effective use of healthcare dollars based on the value they deliver to the overall healthcare system. We continue to work with law makers and advocate for solutions that effectively improve patient health outcomes, lower costs to the healthcare system, and ensure access to medicines within an efficient and affordable healthcare system.

There have been significant efforts at the federal and state levels to reform the healthcare system by enhancing access to healthcare, improving the delivery of healthcare and further rationalizing payment for healthcare. We face uncertainties due to federal legislative and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the ACA. There is additional uncertainty given the December 2018 ruling in *Texas v. Azar* to invalidate the law as unconstitutional, and the subsequent decision by the U.S. Department of Justice not to defend the law. At this time, the law remains in effect pending appeals of the decision. Given the outcomes of the 2018 U.S. midterm elections with Democrats taking over the U.S. House of Representatives and Republicans growing their majority in the U.S. Senate, we believe it is unlikely Congress will find bipartisan consensus to advance any significant changes to the ACA until the legal process unfolds. The revenues generated for Pfizer by the health insurance exchanges and Medicaid expansion under the ACA are not material, so the impact of the change in law and similar recent Presidential Administration actions is expected to be limited. Any future replacement, modification or repeal of the ACA may adversely affect our business and financial results, particularly if the legislation reduces incentives for employer-sponsored insurance coverage. As another example, the Bipartisan Budget Act of 2018, which increased the discount we pay in the Medicare Part D “coverage gap” from 50% to 70%, will modestly increase our future Medicare Part D rebates. Any future healthcare reform efforts may adversely affect our business and financial results.

The potential for additional pricing and access pressures in the commercial sector continues to be significant. Many employers have adopted high deductible health plans, which can increase out-of-pocket costs for medicines. This is a trend that is likely to continue. Private third-party payers, such as health plans, increasingly challenge pharmaceutical product pricing, which could result in lower prices, lower reimbursement rates and a reduction in demand for our products. Pricing pressures for our products may occur as a result of highly competitive insurance markets. Healthcare provider purchasers, directly or through group purchasing organizations, are seeking enhanced discounts or implementing more rigorous bidding or purchasing review processes.

Overall, there is increasing pressure on U.S. providers to deliver healthcare at a lower cost and to ensure that those expenditures deliver demonstrated value in terms of health outcomes. Longer term, we are seeing a shift in focus away from fee-for-service payments towards outcomes-based payments and risk-sharing arrangements that reward providers for cost reductions and improved patient outcomes. These new payment models can, at times, lead to lower prices for, and restricted access to, new medicines. At the same time, these models can also promote utilization of drugs by encouraging physicians to screen and diagnose and consider drugs as a means of forestalling more costly medical interventions.

***Outside the U.S.––***Certain governments, including the different EU Member States, China, Japan, Canada and South Korea, have significant power as large single payers to regulate prices and may use a variety of cost-containment measures for our pharmaceutical products, including price cuts, mandatory rebates, public or private health technology assessments, forced localization as a condition of market access and international reference pricing (i.e., the practice of a country linking its regulated medicine prices to those of other countries). As a result, we expect that such pressures on the pricing component of operating results will continue. In addition, the international patchwork of price regulation and differing economic conditions and incomplete value assessments across countries has led to varying health outcomes and some third-party trade in our products between countries.

In particular, international reference pricing adds to the regional impact of price cuts in individual countries and hinders patient access and innovation. Price variations, exacerbated by international reference pricing systems, also have resulted from exchange rate fluctuations. The downward pricing pressure resulting from this dynamic can be expected to continue as a result of reforms to international reference pricing policies and measures targeting pharmaceuticals in some European countries.

In addition, several important multilateral organizations, such as the United Nations (UN), including the World Health Organization (WHO), and the Organization for Economic Cooperation and Development (OECD), are increasing scrutiny of international pharmaceutical pricing through issuing reports and policy recommendations. In 2019, the WHO continued exerting pressure on pharmaceutical pricing practices by supporting strategies to reduce medicine prices, including calling for greater transparency around the cost of research and development and production of medicines, as well as disclosure of net prices.

In China, healthcare is largely driven by a public payer system, with public medical insurance as the largest single payer for pharmaceuticals, and pricing pressures have increased in recent years. Government officials have consistently emphasized the importance of improved health outcomes, the need for healthcare reform and decreased drug prices as key indicators of progress towards reform. While the government provides basic health insurance for the vast majority of Chinese citizens, that insurance is not adequate to cover many innovative medicines, and alternative funding sources for innovative medicines remain suboptimal.

In 2017 and 2018, China’s government negotiated with companies to add approximately 60 innovative drugs (mainly oncology medicines) to the National Reimbursement Drug List. Prices for drugs were reduced dramatically through this government-led process. While these negotiations included a path to access for companies, market access is not assured. In addition, significant questions about the processes and negotiations for provincial tendering remain, as well as the need for multi-layered negotiations across provincial, municipal and hospital levels.

In the off-patent space, in 2013, China began to implement a quality consistency evaluation (QCE) process in order to improve the quality of domestically-manufactured generic drugs, primarily by requiring such drugs to pass a test to assess their bioequivalence to a qualified reference drug (typically the originator drug). In 2018, numerous local generics were officially deemed bioequivalent under QCE. A pilot project for centralized volume-based procurement was then initiated including 25 molecules of drugs covering 11 major Chinese cities. Under this procurement model, a tender process has been established where a certain portion of included molecule volumes are guaranteed to tender winners. The program is intended to contain healthcare cost by driving utilization of generics that have passed QCE, which has resulted in dramatic price cuts for off-patent medicines.

Upjohn and most off-patent originators were not successful in the first bidding process, which was finalized in December 2018 and implemented in March 2019, and those contracts went to local generic companies. The first bidding process resulted in significant price cuts by the successful bidders, with some reducing the price of their products by as much as 96%, as companies attempted to secure volumes of the Chinese pharmaceutical market. The drugs which lost the bidding were also requested to reduce their selling price up to 30% based on the price difference with the successful bidder. In July 2019, China’s government announced a plan for a nationwide expansion of the volume-based procurement model, which was finalized in September 2019 and will be implemented in late 2019 or early 2020. The expanded model allows for as many as three successful bidders and includes an additional 25 provinces and regions, and applies to certain drugs that are purchased for public hospitals as well as some military and private medical institutions. Our Upjohn business unit and most originator brands were not successful in the bidding process for this nationwide expansion, and those contracts mostly went to local Chinese generic companies. The QCE-qualified generic makers of atorvastatin and amlodipine bid aggressively, lowering prices even further from the March 2019 tender. Our Upjohn business unit continues to take steps to mitigate the revenue impact of these initiatives but anticipates that they will continue to affect our Upjohn business in China going forward. We expect to utilize our presence in the retail channel and tendering capabilities to mitigate some of these pricing pressures. In addition, we believe that our geographic expansion to under-penetrated and lower-tiered cities and counties and additional focus on non-tendered products will increase sales volumes in greater China and partially mitigate pressures from QCE.

Furthermore, the Chinese government has discussed moving toward efforts to unify the reimbursement price between QCE-approved generic medicines and the applicable original medicines. The government currently plans to implement this universal reimbursement price initiative within the next two to three years. If this policy is implemented, the new reimbursement level for Upjohn’s products will likely be lower than the current reimbursement level, placing additional pressures on price and/or patient copays. There remains uncertainty as to whether, when and how this policy may be officially implemented. The Chinese government could also enact other policies that may increase pricing pressures or have the effect of reducing the volume of sales available to Upjohn’s products. This potential policy, and any other policies like it that could increase pricing and copay pressures on Upjohn’s drug products in China, could have an adverse effect on our business, financial condition and results of operations. The government has indicated that additional post-LOE drugs could be subjected to QCE qualification in future rounds, which could also be tied to volume-based procurement. The scope of future QCE products is currently unknown and while it may impact our business in China, we do not believe it will be significant to Pfizer’s business and financial condition. We will continue to monitor the market for developments.

For additional information, see the “Regulatory Environment––Pipeline Productivity” and “Competition” sections of our 2018 Financial Report and the “Government Regulation and Price Constraints” section in Part I, Item 1, “Business” of our 2018 Form 10-K.

### The Global Economic Environment

In addition to the industry-specific factors discussed above, we, like other businesses of our size, are exposed to the economic cycle, which impacts our biopharmaceutical operations globally.

- Governments, corporations, and insurance companies, which provide insurance benefits to patients, have implemented increases in cost-sharing and restrictions on access to medicines, potentially causing patients to switch to generic or biosimilar products, delay treatments, skip doses or use less effective treatments. As discussed above, government financing pressures can lead to negative pricing pressure in various markets where governments take an active role in setting prices, access criteria (e.g., through public or private health technology assessments), or other means of cost control. Examples include the different EU Member States, Japan, China, Canada, South Korea and a number of other international markets. The U.S. continues to maintain competitive insurance markets, but has also seen significant increases in patient cost-sharing and growing government influence as government programs continue to grow as a source of coverage.
- Significant portions of our revenues, costs and expenses, as well as our substantial international net assets, are exposed to changes in foreign exchange rates. We seek to manage our foreign exchange risk in part through operational means, including managing same-currency revenues in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. Depending on market conditions, foreign exchange risk also is managed through the use of derivative financial instruments and foreign currency debt. As we operate in multiple foreign currencies, including the euro, the Japanese yen, the Chinese renminbi, the U.K. pound, the Canadian dollar and approximately 100 other currencies, changes in those currencies relative to the U.S. dollar will impact our revenues and expenses. If the U.S. dollar were to weaken against another currency, assuming all other variables remained constant, our revenues would increase, having a positive impact on earnings, and our overall expenses would increase, having a negative impact on earnings. Conversely, if the U.S. dollar were to strengthen against another currency, assuming all other variables remained constant, our revenues would decrease, having a negative

impact on earnings, and our overall expenses would decrease, having a positive impact on earnings. Therefore, significant changes in foreign exchange rates can impact our results and our financial guidance.

The impact of possible currency devaluations in countries experiencing high inflation rates or significant exchange fluctuations, including Venezuela and Argentina, can impact our results and financial guidance. For further information about our exposure to foreign currency risk, see the “Analysis of Financial Condition, Liquidity and Capital Resources” and the “Our Financial Guidance for 2019” sections of this MD&A.

- In June 2016, the U.K. electorate voted in a referendum to leave the EU, which is commonly referred to as “Brexit”. In March 2017, the U.K. government formally notified the European Council of its intention to leave the EU after it triggered Article 50 of the Lisbon Treaty to begin the two-year negotiation process establishing the terms of the exit and outlining the future relationship between the U.K. and the EU. Formal negotiations officially started in June 2017. After multiple votes in the British Parliament in 2019 failing to approve a Brexit withdrawal agreement with the EU, the EU has agreed in principle to extend the date of the U.K.’s withdrawal until January 31, 2020, or earlier in the event the current proposed Brexit withdrawal agreement is agreed and approved by both U.K. and EU parliaments. A General Election will now be held on December 12, 2019. The outcome of the election on the Brexit process, and the consequences of the U.K. leaving the EU (when or if that happens), also continue to be uncertain, which may pose certain implications to our research, commercial and general business operations in the U.K. and the EU, including the approval and supply of our products. At present, it is still unclear whether and to what extent the U.K. will remain within or aligned to the EU system of medicines regulation, depending on the ultimate outcome of the negotiations. However, both the U.K. and the EU have issued detailed guidance for the industry on how medicines, medical devices and clinical trials will be separately regulated in their respective territories in the event of a ‘hard Brexit’, meaning an outcome where no negotiated settlement is reached.

We generated approximately 2% of our worldwide revenues from the U.K. in 2018 and in the first nine months of 2019, including the foreign currency exchange impact from the weakening U.K. pound relative to the U.S. dollar to date.

Pfizer’s preparations for Brexit, including for a ‘hard Brexit’, are well advanced to make the changes necessary to meet all relevant requirements in the EU and the U.K. after Brexit, especially in the regulatory, research, manufacturing and supply chain areas. The principal aim is to ensure the continuity of supply to patients in Europe (EU and the U.K.) and other global markets impacted by these changes. Between 2018 and 2021, we now expect to spend up to approximately $60 million in one-time costs to make these adaptations.

Pfizer maintains a strong financial position while operating in a complex global environment. Due to our significant operating cash flows, financial assets, access to capital markets and available lines of credit and revolving credit agreements, we continue to believe that we have, and will maintain, the ability to meet our liquidity needs for the foreseeable future. Our long-term debt is rated high quality by both S&P and Moody’s. As market conditions change, we continue to monitor our liquidity position. We have taken and will continue to take a conservative approach to our financial investments. Both short-term and long-term investments consist primarily of high-quality, highly liquid, well-diversified, available-for-sale debt securities. For further discussion of our financial condition and credit ratings, see the “Analysis of Financial Condition, Liquidity and Capital Resources” section of this MD&A.

These and other industry-wide factors that may affect our businesses should be considered along with information presented in the “Forward-Looking Information and Factors That May Affect Future Results” section of this MD&A and in Part I, Item 1A, “Risk Factors” of our 2018 Form 10-K.

### Our Strategy

We believe that our medicines provide significant value for both healthcare providers and patients, not only from the improved treatment of diseases but also from a reduction in other healthcare costs, such as emergency room or hospitalization costs, as well as improvements in health, wellness and productivity. We continue to actively engage in dialogues about the value of our medicines and how we can best work with patients, physicians and payers to prevent and treat disease and improve outcomes. We continue to work within the current legal and pricing structures, as well as continue to review our pricing arrangements and contracting methods with payers, to maximize patient access and minimize any adverse impact on our revenues. We remain firmly committed to fulfilling our company’s purpose: *Breakthroughs that change patients’ lives*. By doing so, we expect to create value for the patients we serve and for our colleagues and shareholders.

#### Organizing for Growth

We believe we have one of the strongest pipelines in over a decade, and believe we are well positioned for future growth. Additional patent expiries will continue over several years, and we expect the impact of reduced revenues due to patent expiries will be significant in the rest of 2019 and in 2020, then moderating downward to a much lower level from 2021 through 2025. This confluence of events has given us an opportunity to look at and refine how we organize our business to best achieve sustainable growth and to deliver our medicines and vaccines to the maximum number of people who need them.

At the beginning of our fiscal year 2019, we began to manage our commercial operations through a new global structure consisting of three businesses, each led by a single manager—Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and, through July 31, 2019, Pfizer’s Consumer Healthcare business. We designed this new global structure to take advantage of new growth opportunities driven by the evolving and unique dynamics of relevant markets.

See the “Commercial Operations” section below for additional information about each business.

We also reorganized our R&D operations as part of our Organizing for Growth reorganization:

- The former Worldwide, Research and Development organization is renamed Worldwide Research, Development and Medical (WRDM) as we have created a new Worldwide Medical & Safety organization in WRDM that incorporates the former Chief Medical Office as well as the Worldwide Safety function;
- The R&D organization within our former Essential Health business has been integrated into the WRDM, GPD and Upjohn organizations, including moving biosimilars into WRDM and GPD and realigning them with the relevant therapeutic areas (e.g., Oncology and Inflammation & Immunology);
- The Regulatory function has been moved from the WRDM organization into the GPD organization; and
- Late-stage portfolio spend has been moved from our former Innovative Health business to GPD and from our former Essential Health business to GPD and Upjohn.

We re-aligned our commercial operations in 2019 for a number of reasons, including:

- Bringing biosimilars into our Oncology and Inflammation & Immunology therapeutic categories gives us the potential to leverage our R&D, regulatory and commercial infrastructure within the Biopharma business to more efficiently bring those assets to market;
- Creating a business unit (i.e., the Hospital unit within Biopharma) that is solely focused on medicines that are used in hospitals can potentially bring greater focus and attention to serving those customers and developing those relationships;
- Giving Upjohn more autonomy with a focus on maximizing the value of its products, particularly in emerging markets, provides it the opportunity to operate as a standalone business within Pfizer with the potential for sustainable modest growth; and
- We believe this new structure better positions each business to achieve its growth potential as we transition to a period post-2020 where we expect higher and more sustained revenue growth due to declining LOEs and the potential of our late-stage pipeline.

Biopharma seeks to leverage a strong pipeline, organize around operational growth drivers, and capitalize on trends creating long-term growth opportunities, including:

- an aging global population that is generating increased demand for innovative medicines that address patients’ unmet needs;
- advances in both biological science and digital technology that are enhancing the delivery of breakthrough new medicines; and
- the increasingly significant role of hospitals in healthcare systems.

Urbanization and the rise of the middle class in emerging markets, particularly in Asia, provide growth opportunities for the Upjohn business. Our ability to work collaboratively within local markets and to be fast, focused and flexible is intended to position this business to seize these opportunities. Upjohn has distinct and dedicated manufacturing, marketing, regulatory and, subject to limited exceptions, enabling functions that report directly into the business providing autonomy and positioning Upjohn to operate as a true stand-alone division. We created this new structure to, among other things, position Upjohn to optimize its distinct growth potential and provide us with the flexibility to access further opportunities to enhance value.

Subsequent to the re-alignment of our commercial operations in 2019, on July 29, 2019, we announced that we entered into a definitive agreement to combine Upjohn with Mylan, creating a new global pharmaceutical company. We believe the new company will transform and accelerate Upjohn’s and Mylan’s ability to serve patients’ needs and expand their capabilities across more than 165 markets. The combination will drive a sustainable, diverse and differentiated portfolio of prescription medicines, complex generics, over-the-counter products and biosimilars supported by commercial and regulatory expertise, established infrastructure, R&D capabilities and manufacturing and supply chain excellence.

As we prepare for expected growth, we are focused on creating a simpler, more efficient organization by streamlining structures, processes and governance within each business and the functions that support them. As our innovative pipeline matures based on anticipated progression of current trials and the initiation of new pivotal trials, including new trials for medicines we may acquire or in-license, we will need to increase our R&D investments. In addition, as our pipeline potentially delivers new commercialization opportunities, we will need to increase our investments in new-market-creation activities. We have initiated an enterprise-wide digital effort to accelerate drug development, enhance experiences (patient and physician), and leverage technology and robotics to simplify and automate our processes.

In the fourth quarter of 2018, we took steps to simplify the organization, increase spans of control and reduce organizational layers, which impacted some managerial roles and responsibilities. We also offered enhancements to certain employee benefits for a short period of time. The expenses related to these enhancements for certain employee benefits did not have a material impact on our 2018 results of operations and any expected future impact of these enhancements are reflected in the totality of our annual guidance for 2019. To partially offset the incremental cost increases of increased R&D investments and marketing activities in future periods, we expect to generate cost reduction opportunities, particularly in indirect SI&A.

#### Commercial Operations

As discussed under “Organizing for Growth”, at the beginning of our 2019 fiscal year, we began to manage our commercial operations through a new global structure consisting of three business segments––Biopharma, Upjohn and through July 31, 2019, Consumer Healthcare, each led by a single manager. Each operating segment has responsibility for its commercial activities. Upjohn and Consumer Healthcare are responsible for their own R&D activities while Biopharma receives its R&D services from GPD and WRDM. These services include IPR&D projects for new investigational products and additional indications for in-line products. Each business has a geographic footprint across developed and emerging markets.

|  |  |
| --- | --- |
| Some additional information about our Biopharma and Upjohn business segments follows: |  |
| **Pfizer Biopharmaceuticals Group** |  |
| Biopharma is a science-based innovative medicines business that includes six business units – Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. The new Hospital unit commercializes our global portfolio of sterile injectable and anti-infective medicines and includes Pfizer’s contract manufacturing operation, Pfizer CentreOne. At the beginning of our 2019 fiscal year, we also incorporated our biosimilar portfolio into our Oncology and Inflammation & Immunology business units and certain legacy established products into the Internal Medicine business unit. Each business unit is committed to delivering breakthroughs that change patients’ lives. | Upjohn is a global, primarily off-patent branded and generic medicines business, which includes a portfolio of 20 globally recognized solid oral dose brands, as well as a U.S.-based generics platform, Greenstone. |
| Select products include: - Prevnar 13/Prevenar 13 - Ibrance - Eliquis - Xeljanz - Enbrel (outside the U.S. and Canada) - Chantix/Champix - Sutent - Xtandi | Select products include: - Lyrica - Lipitor - Norvasc - Celebrex - Viagra - Certain generic medicines |

On July 29, 2019, we announced that we entered into a definitive agreement to combine Upjohn with Mylan, creating a new global pharmaceutical company. For additional information, see the “Our Strategy––Our Business Development Initiatives” section of this MD&A below.

On July 31, 2019, Pfizer’s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK’s consumer healthcare business to form a new consumer healthcare joint venture. For additional information, see Notes to Condensed Consolidated Financial Statements—*Note 1A. Basis of Presentation and Significant Accounting Policies: Basis of Presentation* and *Note 2B. Acquisitions, Equity-Method Investment and Assets and Liabilities Held for Sale and Research and Development Arrangement: Equity-Method Investment and Assets and Liabilities Held for Sale.*

For additional information about our operating structure, see Notes to Condensed Consolidated Financial Statements—*Note 13A. Segment, Geographic and Other Revenue Information: Segment Information.*

For additional information about the performance for each of our operating segments, see the “Analysis of Operating Segment Information” section of this MD&A.

#### Description of Research and Development Operations

Innovation is critical to the success of our company, and drug discovery and development are time-consuming, expensive and unpredictable. Pfizer’s purpose is to deliver breakthroughs that change patients’ lives. R&D is at the heart of fulfilling Pfizer’s purpose as we work to translate advanced science and technologies into the therapies that matter most. Our R&D priorities include:

- delivering a pipeline of highly differentiated medicines and vaccines where Pfizer has a unique opportunity to bring the most important new therapies to patients in need;
- advancing our capabilities that can position Pfizer for long-term R&D leadership; and
- advancing new models of partnerships with creativity, flexibility and urgency to deliver innovation to patients as quickly as possible.

To that end, our R&D primarily focuses on:

- Oncology;
- Inflammation and Immunology;
- Rare Diseases;
- Hospital;
- Vaccines; and
- Internal Medicine.

In 2019, we continue to strengthen our global R&D organization and pursue strategies intended to improve innovation and overall productivity in R&D to achieve a sustainable pipeline that is positioned to deliver value in the near term and over time.

Our R&D spending is conducted through a number of matrix organizations:

- Research Units within our WRDM organization are generally responsible for research and early-stage development assets for our Biopharma business (assets that have not yet achieved proof-of-concept). Our Research Units are organized by therapeutic area to enhance flexibility, cohesiveness and focus. Because of our structure, we are able to rapidly redeploy resources within a Research Unit between various projects as necessary because in many instances the workforce shares similar skills, expertise and/or focus.
- Our science-based and other platform-services organizations, where a significant portion of our R&D spending occurs, provide technical expertise and other services to the various R&D projects, and are organized into science-based functions (which are part of our WRDM organization), such as Pharmaceutical Sciences, Medicine Design, and non-science-based functions, such as Facilities, Digital and Finance. As a result, within each of these functions, we are able to migrate resources among projects, candidates and/or targets in any therapeutic area and in most phases of development, allowing us to react quickly in response to evolving needs. In addition, the Worldwide Medical and Safety group ensures that Pfizer provides all stakeholders, including patients, healthcare providers, pharmacists, payers and health authorities with complete and up-to-date information on the risks and benefits associated with Pfizer products so that they can make appropriate decisions on how and when to use Pfizer’s medicines.
- Our R&D organization within the Upjohn business supports the off-patent branded and generic established medicines and helps develop product enhancements, new indications and new market registrations based on these medicines.
- Our GPD organization is a unified center for clinical development and regulatory activities that is generally responsible for the clinical development strategy and operational execution of clinical trials for both early-stage assets in the WRDM portfolio as well as late-stage assets in the Biopharma portfolio. For WRDM assets, GPD works in close collaboration with the Early Clinical Development group, which has expertise in various disciplines such as Biostatistics, Clinical Pharmacology and Digital Medicine. GPD enables more efficient and effective development and enhances our ability to accelerate and progress assets through our pipeline. GPD also provides operational support to Upjohn for select clinical development and regulatory activities.

We manage R&D operations on a total-company basis through our matrix organizations described above. Specifically, a portfolio governance committee, comprised of senior executives, is accountable for aligning resources among all of our WRDM, GPD and Biopharma R&D projects and for seeking to ensure optimal capital allocation across the innovative R&D portfolio. We believe that this approach also serves to maximize accountability and flexibility. Our Upjohn R&D organization manages its resources separately from the WRDM and GPD organizations.

Generally, we do not disaggregate total R&D expense by development phase or by therapeutic area since, as described above, we do not manage a significant portion of our R&D operations by development phase or by therapeutic area. Further, as we are able to adjust a significant portion of our spending quickly, as conditions change, we believe that any prior-period information about R&D expense by development phase or by therapeutic area would not necessarily be representative of future spending.

While a significant portion of R&D is done internally, we continue to seek out promising chemical and biological lead molecules and innovative technologies developed by third parties to incorporate into our discovery and development processes or projects, as well as our product lines, by entering into collaboration, alliance and license agreements with other companies, as well as leveraging acquisitions and equity- or debt-based investments. These agreements enable us to co-develop, license or acquire promising compounds, technologies or capabilities. We also enter into agreements pursuant to which a third party agrees to fund a portion of the development costs of one or more of our pipeline products in exchange for rights to receive potential milestone payments, revenue sharing payments, profit sharing payments and/or royalties. Collaboration, alliance, license and funding agreements and equity- or debt-based investments allow us to share risk and cost and to access external scientific and technological expertise, and provide us the opportunity to advance our own products as well as the in-licensed or acquired products.

For additional information about R&D by operating segment, see the “Analysis of Operating Segment Information” section of this MD&A. For additional information about our pending new drug applications and supplemental filings, see the “Analysis of the Consolidated Statements of Income––Product Developments––Biopharmaceutical” section of this MD&A. For additional information about recent transactions and strategic investments that we believe have the potential to advance our pipeline, see the “Our Strategy––Our Business Development Initiatives” section of this MD&A.

#### Intellectual Property Rights

We continue to vigorously defend our patent rights against increasingly aggressive infringement, and we will continue to support efforts that strengthen worldwide recognition of patent rights while taking necessary steps to ensure appropriate patient access. In addition, we will continue to employ innovative approaches designed to prevent counterfeit pharmaceuticals from entering the supply chain and to achieve greater control over the distribution of our products, and we will continue to participate in the generics market, whenever appropriate. Also, the pursuit of valid business opportunities may require us to challenge intellectual property rights held by other companies that we believe were improperly granted. Such challenges may include negotiation and litigation, which may not always be successful. For additional information about our current efforts to enforce our intellectual property rights and certain other patent proceedings, see Notes to Condensed Consolidated Financial Statements––*Note 12A1. Contingencies and Certain Commitments: Legal Proceedings––Patent Litigation.* For information on risks related to patent protection and intellectual property claims by third parties, see Part I, Item 1A, “Risk Factors––Risks Related to Intellectual Property” in our 2018 Form 10-K.

#### Capital Allocation and Expense Management

We seek to maintain a strong balance sheet and robust liquidity so that we continue to have the financial resources necessary to take advantage of prudent commercial, research and business development opportunities and to directly enhance shareholder value through share repurchases and dividends. For additional information about our financial condition, liquidity, capital resources, share repurchases (including accelerated share repurchases) and dividends, see the “Analysis of Financial Condition, Liquidity and Capital Resources” section of this MD&A. For additional information about our recent business development activities, see the “Our Strategy––Our Business Development Initiatives” section of this MD&A.

We remain focused on achieving an appropriate cost structure for our company. For additional information about our cost-reduction and productivity initiatives, see the “Costs and Expenses––Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives” section of this MD&A and Notes to Condensed Consolidated Financial Statements––*Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.*

Increasing Investment in the U.S.––After evaluating the expected positive net impact the TCJA will have on us, in early 2018, we decided to take several actions:

- Over the five-year period from 2018 through 2022, we plan to invest approximately $5.0 billion in capital projects in the U.S., including the strengthening of our manufacturing presence in the U.S. As part of this plan:
- in July 2018, we announced that we will increase our commitment to U.S. manufacturing with a $465 million investment to build one of the most technically advanced sterile injectable pharmaceutical production facilities in the world in Portage, Michigan. This U.S. investment will strengthen our capability to produce and supply critical, life-saving injectable medicines for patients around the world, creating an estimated 450 new jobs over the next several years; and
- in August 2019, we announced an additional half billion dollar investment for the construction of a state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina. This facility is anticipated to support our continuing investment in gene therapy R&D, similar to Pfizer’s Chapel Hill and Kit Creek, North Carolina R&D sites. This facility would expand our presence in North Carolina. The expanded facility is projected to add approximately 300 new jobs.
- We made a $500 million voluntary contribution to the U.S. Pfizer Consolidated Pension Plan in February 2018.
- In the first quarter of 2018, we paid a special, one-time bonus to virtually all Pfizer colleagues, excluding executives, of $119 million in the aggregate.

#### Our Business Development Initiatives

We are committed to capitalizing on growth opportunities by advancing our own pipeline and maximizing the value of our in-line products, as well as through various forms of business development, which can include alliances, licenses, joint ventures, collaborations, equity- or debt-based investments, dispositions, mergers and acquisitions. We view our business development activity as an enabler of our strategies, and we seek to generate earnings growth and enhance shareholder value by pursuing a disciplined, strategic and financial approach to evaluating business development opportunities. We continue to evaluate business development transactions that have the potential to strengthen our businesses and their capabilities, such as our recently-announced agreement to combine Upjohn with Mylan, our acquisitions of Array, Medivation, Anacor and AstraZeneca’s small molecule anti-infectives business, as well as collaborations, and alliance and license agreements with other companies. We assess our businesses, assets and scientific capabilities/portfolio as part of our regular, ongoing portfolio review process and also continue to consider business development activities that will advance our businesses.

The more significant recent transactions and events are described below:

- License Agreement with Akcea Therapeutics, Inc.––In October 2019, we announced that we entered into a worldwide exclusive licensing agreement for AKCEA-ANGPTL3-LRx, an investigational antisense therapy being developed to treat patients with certain cardiovascular and metabolic diseases, with Akcea, a majority-owned affiliate of Ionis. Under the terms of the agreement, Akcea and Ionis will split equally a $250 million upfront license fee and will split equally development, regulatory and sales milestone payments of up to $1.3 billion and tiered, double-digit royalties on annual worldwide net sales upon marketing approval of AKCEA-ANGPTL3-LRx, if any. Pfizer is responsible for all development and regulatory activities and costs beyond those associated with the ongoing Phase 2 study. This transaction is expected to close in the fourth quarter of 2019 and is subject to clearance under the Hart-Scott Rodino Antitrust Improvements Act as well as satisfaction of other customary closing conditions.
- Formation of a New Consumer Healthcare Joint Venture––On July 31, 2019, we completed the transaction in which we and GSK combined our respective consumer healthcare businesses into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name. The joint venture is a category leader in pain relief, respiratory and vitamins, minerals and supplements, and therapeutic oral health and is the largest global OTC consumer healthcare business. For additional information, see Notes to Condensed Consolidated Financial Statements––*Note 1A. Basis of Presentation and Significant Accounting Policies: Basis of Presentation* and Notes to Condensed Consolidated Financial Statements––*Note 2B. Acquisitions, Equity-Method Investment and Assets and Liabilities Held for Sale and Research and Development Arrangement: Equity-Method Investment and Assets and Liabilities Held for Sale.*
- Acquisition of Array BioPharma Inc.––On July 30, 2019, we acquired Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need, for $48 per share in cash. The total fair value of the consideration transferred for Array was approximately $11.2 billion ($10.9 billion, net of cash acquired). Array’s portfolio includes the approved combined use of Braftovi (encorafenib) and Mektovi (binimetinib) for the treatment of BRAFV600E- or BRAFV600K-mutant unresectable or metastatic melanoma. For additional information, see Notes to Condensed Consolidated Financial Statements––*Note 1A. Basis of Presentation and Significant Accounting Policies: Basis of Presentation* and Notes to Condensed Consolidated Financial Statements––*Note 2A. Acquisitions, Equity-Method Investment and Assets and Liabilities Held for Sale and Research and Development Arrangement: Acquisitions.*
- Agreement to Combine Upjohn with Mylan N.V.––On July 29, 2019, we announced that we entered into a definitive agreement to combine Upjohn with Mylan, creating a new global pharmaceutical company. Under the terms of the agreement, which is structured as an all-stock, Reverse Morris Trust transaction, Upjohn is expected to be spun-off or split-off to Pfizer’s shareholders and, immediately thereafter, combined with Mylan. Pfizer shareholders would own 57% of the combined new company, and former Mylan shareholders would own 43%. The transaction is expected to be tax free to Pfizer and Pfizer shareholders. The transaction is anticipated to close in mid-2020, subject to Mylan shareholder approval and satisfaction of other customary closing conditions, including receipt of regulatory approvals. See the “Analysis of Financial Condition, Liquidity and Capital Resources” section of this MD&A for additional information.
- Acquisition of Therachon Holding AG––On July 1, 2019, we acquired all the remaining shares of Therachon, a privately-held clinical-stage biotechnology company focused on rare diseases, with assets in development for the treatment of achondroplasia, a genetic condition and the most common form of short-limbed dwarfism. We acquired Therachon for $340 million upfront, plus potential milestone payments of up to $470 million, contingent on the achievement of key milestones in the development and commercialization of the lead asset. The total fair value of the consideration transferred for Therachon was approximately $322 million. For additional information, see Notes to Condensed Consolidated Financial Statements––

*Note 2A. Acquisitions, Equity-Method Investment and Assets and Liabilities Held for Sale and Research and Development Arrangement: Acquisitions.*

For a description of the more significant recent transactions through February 28, 2019, the filing date of our 2018 Form 10-K, see the “Our Strategy––Our Business Development Initiatives” section of our 2018 Financial Report.

### Our Financial Guidance for 2019

On October 29, 2019, we updated our 2019 financial guidance primarily to reflect our financial results through the first nine months of 2019 and our confidence in the business going forward. We raised the midpoint of our 2019 guidance range for revenues by $200 million to a range of $51.2 to $52.2 billion, composed of $400 million of operational revenue improvement, partially offset by a $200 million unfavorable impact from changes in foreign exchange rates since mid-July 2019. We also increased the midpoint of our 2019 guidance range for Adjusted Diluted EPS by $0.16 to a range of $2.94 to $3.00, reflecting an $0.18 operational improvement, partially offset by a $0.02 unfavorable impact from changes in foreign exchange rates. The operational improvement primarily reflects the aforementioned improved revenue outlook as well as an improved outlook for Adjusted cost of sales as a percentage of revenues, driven by a more favorable product mix than previously anticipated.

|  |  |
| --- | --- |
| Pfizer’s updated 2019 financial guidance is presented below(a), (b): |  |
| Revenues | $51.2 to $52.2 billion |
|  | (previously $50.5 to $52.5 billion) |
| Adjusted cost of sales as a percentage of revenues | 19.3% to 19.8% |
|  | (previously 20.1% to 21.1%) |
| Adjusted selling, informational and administrative expenses | $13.5 to $14.0 billion |
|  | (previously $13.0 to $14.0 billion) |
| Adjusted research and development expenses | $7.7 to $8.1 billion |
|  | (previously $7.9 to $8.3 billion) |
| Adjusted other (income)/deductions | Approximately $200 million of income |
| Effective tax rate on adjusted income | Approximately 16.0% |
| Adjusted diluted EPS | $2.94 to $3.00 |
|  | (previously $2.76 to $2.86) |

(a) The 2019 financial guidance reflects the following:

- Does not assume the completion of any business development transactions not completed as of September 29, 2019.
- Includes revenues and expenses associated with Pfizer’s Consumer Healthcare business through July 31, 2019 as well as Pfizer’s pro rata share of anticipated earnings from the Consumer Healthcare JV with GSK from August 1, 2019, which will be recorded on a quarterly basis in Adjusted other (income)/deductions. Pfizer will record its share of the JV’s anticipated earnings on a one-quarter lag; therefore, 2019 financial guidance for Adjusted other (income)/deductions and Adjusted diluted EPS reflects Pfizer’s share of two months of the JV’s earnings that are expected to be generated in third-quarter 2019, which will be recorded by Pfizer in fourth-quarter 2019.
- Reflects an anticipated negative revenue impact of $2.1 billion due to recent and expected generic and biosimilar competition for certain products that have recently lost or are anticipated to soon lose patent protection.
- Exchange rates assumed are a blend of the actual exchange rates in effect through third-quarter 2019 and mid-October 2019 rates for the remainder of the year. Reflects the anticipated unfavorable impact of approximately $1.4 billion on revenues and approximately $0.10 on adjusted diluted EPS as a result of changes in foreign exchange rates relative to the U.S. dollar compared to foreign exchange rates from 2018.
- Guidance for adjusted diluted EPS assumes diluted weighted-average shares outstanding of approximately 5.7 billion shares, which reflects the weighted-average impact of share repurchases totaling $8.9 billion already completed in 2019. Dilution related to share-based employee compensation programs is currently expected to offset the reduction in shares associated with these share repurchases by approximately half.

(b) For an understanding of Adjusted income and its components and Adjusted diluted EPS (all of which are non-GAAP financial measures), see the “Non-GAAP Financial Measure (Adjusted Income)” section of this MD&A.

Pfizer does not provide guidance for GAAP Reported financial measures (other than revenues) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP Reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of pending litigation, unusual gains and losses, acquisition-related expenses, net gains or losses on investments in equity securities and potential future asset impairments without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP Reported results for the guidance period.

For information about our actual costs and anticipated costs and cost savings associated with our 2017-2019 initiatives and Organizing for Growth, see the “Costs and Expenses––Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives” section of this MD&A and Notes to Condensed Consolidated Financial Statements––*Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.*

Our 2019 financial guidance is subject to a number of factors and uncertainties as described in the “Our Operating Environment”, “The Global Economic Environment”, “Our Strategy” and “Forward-Looking Information and Factors That May Affect Future Results” sections of this MD&A; and Part I, Item 1A, “Risk Factors” of our 2018 Form 10-K.

### SIGNIFICANT ACCOUNTING POLICIES AND APPLICATION OF CRITICAL ACCOUNTING ESTIMATES AND ASSUMPTIONS

For a description of our significant accounting policies, see Notes to Consolidated Financial Statements––*Note 1. Basis of Presentation and Significant Accounting Policies* in our 2018 Financial Report. Of these policies, the following are considered critical to an understanding of our consolidated financial statements as they require the application of the most subjective and the most complex judgments: Acquisitions (Note 1D); Fair Value (Note 1E); Revenues (Note 1G ); Asset Impairments (Note 1L); Tax Assets and Liabilities and Income Tax Contingencies (Note 1P); Pension and Postretirement Benefit Plans (Note 1Q); and Legal and Environmental Contingencies (Note 1R).

For a discussion about the critical accounting estimates and assumptions impacting our consolidated financial statements, see the “Significant Accounting Policies and Application of Critical Accounting Estimates and Assumptions” section of our 2018 Financial Report. See also Notes to Consolidated Financial Statements––*Note 1C. Basis of Presentation and Significant Accounting Policies: Estimates and Assumptions* in our 2018 Financial Report for a discussion about the risks associated with estimates and assumptions.

For a discussion of recently adopted accounting standards and significant accounting policies, see Notes to Condensed Consolidated Financial Statements––*Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards, Note 1C. Basis of Presentation and Significant Accounting Policies: Revenues and Trade Accounts Receivable* and *Note 1D. Basis of Presentation and Significant Accounting Policies: Leases.*

### ANALYSIS OF THE CONDENSED CONSOLIDATED STATEMENTS OF INCOME

*The following table provides the components of the condensed consolidated statements of income:*

| (MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA) | Three Months Ended September 29, 2019 | September 30, 2018 | % Change | Nine Months Ended September 29, 2019 | September 30, 2018 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenues | $12,680 | $13,298 | (5) | $39,062 | $39,670 | (2) |
| Cost of sales(a) | 2,602 | 2,694 | (3) | 7,611 | 8,173 | (7) |
| % of revenues | 20.5% | 20.3% |  | 19.5% | 20.6% |  |
| Selling, informational and administrative expenses(a) | 3,260 | 3,494 | (7) | 10,110 | 10,448 | (3) |
| % of revenues | 25.7% | 26.3% |  | 25.9% | 26.3% |  |
| Research and development expenses(a) | 2,283 | 2,008 | 14 | 5,827 | 5,549 | 5 |
| % of revenues | 18.0% | 15.1% |  | 14.9% | 14.0% |  |
| Amortization of intangible assets | 1,212 | 1,253 | (3) | 3,578 | 3,640 | (2) |
| % of revenues | 9.6% | 9.4% |  | 9.2% | 9.2% |  |
| Restructuring charges and certain acquisition-related costs | 365 | 85 | \* | 295 | 172 | 72 |
| % of revenues | 2.9% | 0.6% |  | 0.8% | 0.4% |  |
| (Gain) on completion of Consumer Healthcare JV transaction | (8,087) | — | \* | (8,087) | — | \* |
| % of revenues | 63.8% | — | \* | 20.7% | — | \* |
| Other (income)/deductions––net | 319 | (414) | \* | 537 | (1,143) | \* |
| Income from continuing operations before provision for taxes on income | 10,727 | 4,177 | \* | 19,190 | 12,831 | 50 |
| % of revenues | 84.6% | 31.4% |  | 49.1% | 32.3% |  |
| Provision for taxes on income | 3,047 | 66 | \* | 2,566 | 1,270 | \* |
| Effective tax rate | 28.4% | 1.6% |  | 13.4% | 9.9% |  |
| Income from continuing operations | 7,680 | 4,111 | 87 | 16,625 | 11,562 | 44 |
| % of revenues | 60.6% | 30.9% |  | 42.6% | 29.1% |  |
| Discontinued operations––net of tax | 4 | 11 | (66) | 4 | 10 | (61) |
| Net income before allocation to noncontrolling interests | 7,684 | 4,122 | 86 | 16,628 | 11,571 | 44 |
| % of revenues | 60.6% | 31.0% |  | 42.6% | 29.2% |  |
| Less: Net income attributable to noncontrolling interests | 4 | 8 | (56) | 19 | 25 | (23) |
| Net income attributable to Pfizer Inc. | $7,680 | $4,114 | 87 | $16,609 | $11,546 | 44 |
| % of revenues | 60.6% | 30.9% |  | 42.5% | 29.1% |  |
| Earnings per common share––basic: |  |  |  |  |  |  |
| Income from continuing operations attributable to Pfizer Inc. common shareholders | $1.38 | $0.70 | 98 | $2.98 | $1.96 | 52 |
| Net income attributable to Pfizer Inc. common shareholders | $1.38 | $0.70 | 98 | $2.98 | $1.96 | 52 |
| Earnings per common share––diluted: |  |  |  |  |  |  |
| Income from continuing operations attributable to Pfizer Inc. common shareholders | $1.36 | $0.69 | 98 | $2.92 | $1.92 | 52 |
| Net income attributable to Pfizer Inc. common shareholders | $1.36 | $0.69 | 98 | $2.92 | $1.92 | 52 |

\* Calculation not meaningful or results are equal to or greater than 100%.

(a) Excludes amortization of intangible assets, except as disclosed in Notes to Condensed Consolidated Financial Statements––*Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.*

### Revenues by Operating Segment and Geography

The following graphs show revenues by operating segment and geography:

### Third Quarter

| 2019 Revenues by Geography | % of Total |
| --- | ---: |
| U.S. | 46% |
| International | 54% |

| 2018 Revenues by Geography | % of Total |
| --- | ---: |
| U.S. | 48% |
| International | 52% |

### First Nine Months

| 2019 Revenues by Geography | % of Total |
| --- | ---: |
| U.S. | 47% |
| International | 53% |

| 2018 Revenues by Geography | % of Total |
| --- | ---: |
| U.S. | 48% |
| International | 52% |

71

*The following tables provide worldwide revenues by operating segment and geography:*

| (MILLIONS OF DOLLARS) Operating Segments(a): | Three Months Ended Worldwide Sept. 29, 2019 Sept. 30, 2018 | U.S. Sept. 29, 2019 Sept. 30, 2018 | International Sept. 29, 2019 Sept. 30, 2018 | World-wide U.S. Inter-national % Change in Revenues |
| --- | ---: | ---: | ---: | ---: |
| Biopharma | $10,108 $9,422 | $5,218 $4,684 | $4,890 $4,738 | 7 11 3 |
| Upjohn | 2,195 3,036 | 509 1,231 | 1,686 1,805 | (28) (59) (7) |
| Consumer Healthcare | 377 839 | 124 445 | 253 394 | (55) (72) (36) |
| Total revenues | $12,680 $13,298 | $5,850 $6,361 | $6,830 $6,937 | (5) (8) (2) |
|  | Nine Months Ended |  |  |  |
|  | Worldwide | U.S. | International | World-wide U.S. Inter-national |
| (MILLIONS OF DOLLARS) | Sept. 29, 2019 Sept. 30, 2018 | Sept. 29, 2019 Sept. 30, 2018 | Sept. 29, 2019 Sept. 30, 2018 | % Change in Revenues |
| Operating Segments(a): |  |  |  |  |
| Biopharma | $28,887 $27,737 | $14,481 $13,582 | $14,406 $14,155 | 4 7 2 |
| Upjohn | 8,077 9,302 | 2,891 3,921 | 5,186 5,381 | (13) (26) (4) |
| Consumer Healthcare | 2,098 2,631 | 988 1,357 | 1,110 1,273 | (20) (27) (13) |
| Total revenues | $39,062 $39,670 | $18,360 $18,861 | $20,701 $20,810 | (2) (3) (1) |

(a) For additional information about each operating segment, see the “Our Strategy––Commercial Operations” and “Analysis of Operating Segment Information” sections of this MD&A and Notes to Condensed Consolidated Financial Statements––*Note 13A. Segment, Geographic and Other Revenue Information: Segment Information.*

#### Third Quarter of 2019 vs. Third Quarter of 2018

*The following provides an analysis of the worldwide change in revenues by geographic areas in the third quarter of 2019:*

| (MILLIONS OF DOLLARS) Operational growth/(decline): | Three Months Ended September 29, 2019 Worldwide | U.S. | International |
| --- | ---: | ---: | ---: |
| Continued growth from certain key brands(a) | $621 | $323 | $298 |
| Higher revenues for the Hospital products business, primarily driven by continued growth from anti-infective products in China as well as the November 2018 U.S. launch of Panzyga | 112 | 54 | 58 |
| Higher revenues for rare disease products driven by Vyndaqel following the U.S. launch in May 2019 for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM); and in international markets, primarily driven by continued uptake for the transthyretin amyloid polyneuropathy indication, primarily in developed Europe, as well as the March 2019 launch of the ATTR-CM indication in Japan, partially offset by lower revenues for the hemophilia franchises (Refacto AF/Xyntha and BeneFIX), primarily due to competitive pressures, and Genotropin in developed markets, mainly due to unfavorable channel mix in the U.S. | 86 | 65 | 21 |
| Higher revenues for Inlyta, primarily in the U.S. driven by increased demand resulting from the second quarter of 2019 U.S. FDA approvals for the combinations of certain checkpoint inhibitors plus Inlyta for the first-line treatment of patients with advanced RCC, partially offset by the decline in other developed markets due to increased competition | 70 | 65 | 4 |
| Growth from Biosimilars, primarily in the U.S. | 44 | 51 | (7) |
| Lower worldwide revenues for Lyrica, primarily in the U.S., reflecting the expected significantly lower volumes associated with multi-source generic competition that began in July 2019 | (687) | (675) | (12) |
| Lower revenues for Consumer Healthcare reflecting the July 31, 2019 completion of the Consumer Healthcare joint venture transaction with GSK. As a result, third-quarter 2019 revenues reflect one month of Consumer Healthcare domestic operations and two months of Consumer Healthcare international operations | (451) | (321) | (130) |
| Lower revenues for Enbrel internationally, reflecting continued biosimilar competition in most developed Europe markets | (99) | — | (99) |
| Decline in revenues for Revatio driven by lower U.S. Oral Suspension formulation sales and pricing pressures due to a recent generic entry, and for Relpax, driven by continued generic competition across developed markets | (53) | (39) | (14) |
| Lower revenues for Prevnar 13 in the U.S., primarily reflecting lower government purchases for the pediatric indication as well as the continued decline in revenues for the adult indication due to a declining “catch up” opportunity compared to the prior year quarter, partially offset by an increase in international revenues mostly due to higher volumes reflecting continued uptake following the 2017 launch in China, partially offset by the unfavorable impact of timing associated with government purchases for the pediatric indication in certain emerging markets | (43) | (81) | 37 |
| Decline from Norvasc and Lipitor, primarily in China, driven by pricing pressures from the March 2019 government implementation of the VBP in certain cities. The decline in Lipitor was also due to discontinued sales in Saudi Arabia and lower volumes in Japan. The decline in Norvasc was also due to lower volumes in Japan and South Korea. These declines were partially offset by volume growth and geographic expansion in provinces in China where the VBP has not yet been implemented | (35) | 1 | (36) |
| Lower revenues for Viagra primarily in the U.S. resulting from the loss of exclusivity in December 2017 | (14) | (11) | (3) |
| Other operational factors, net | 47 | 57 | (9) |
| Operational growth/(decline), net | (403) | (510) | 107 |
| Unfavorable impact of foreign exchange | (215) | — | (215) |
| Revenues decrease | $(618) | $(510) | $(107) |

(a) Certain key brands represent Ibrance, Eliquis and Xeljanz. See the “Analysis of the Condensed Consolidated Statements of Income––Revenues––Selected Product Discussion” section of this MD&A for product analysis information.

Emerging markets revenues increased $44 million, or 1%, in the third quarter of 2019 to $3.1 billion, reflecting an operational increase of $180 million, or 6%, partially offset by an unfavorable impact from foreign exchange of approximately 4%. The operational increase in emerging markets was primarily driven by Ibrance, Prevenar 13 and Eliquis in our Biopharma segment.

#### First Nine Months of 2019 vs. First Nine Months of 2018

*The following provides an analysis of the change in worldwide revenues by geographic areas in the first nine months of 2019:*

| (MILLIONS OF DOLLARS) Operational growth/(decline): | Nine Months Ended September 29, 2019 Worldwide | U.S. | International |
| --- | ---: | ---: | ---: |
| Continued growth from certain key brands(a) | $1,978 | $761 | $1,216 |
| Higher revenues for Inlyta, primarily in the U.S. driven by increased demand resulting from the second quarter of 2019 U.S. FDA approvals for the combinations of certain checkpoint inhibitors plus Inlyta for the first-line treatment of patients with advanced RCC, partially offset by the decline in other developed markets due to increased competition | 100 | 97 | 3 |
| Higher revenues for Biosimilars, primarily in the U.S. | 95 | 112 | (18) |
| Volume-driven growth from Celebrex and Effexor, primarily in Japan and China | 68 | (6) | 74 |
| Growth from Lipitor, primarily due to volume growth and geographic expansion in provinces in China where the VBP has not yet been implemented, partially offset by pricing pressures for Lipitor and Norvasc from the implementation of the VBP in certain cities in China, lower volumes in Japan for Norvasc and the discontinued sales of Lipitor in Saudi Arabia | 37 | (7) | 44 |
| Higher revenues for rare disease products driven by Vyndaqel following the U.S. launch in May 2019 for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM); and in international markets, primarily driven by continued uptake for the transthyretin amyloid polyneuropathy indication, primarily in developed Europe, as well as the March 2019 launch of the ATTR-CM indication in Japan, partially offset by lower revenues for certain rare disease products, including the hemophilia franchises (Refacto AF/Xyntha and BeneFIX), primarily due to competitive pressures, and Genotropin in developed markets, mainly due to unfavorable channel mix | 21 | 26 | (5) |
| Lower worldwide revenues for Lyrica, primarily in the U.S., reflecting the expected significantly lower volumes associated with multi-source generic competition that began in July 2019 | (736) | (719) | (17) |
| Lower revenues for Consumer Healthcare reflecting the July 31, 2019 completion of the Consumer Healthcare joint venture transaction with GSK. As a result, the first nine months of 2019 revenues reflect seven months of Consumer Healthcare domestic operations and eight months of Consumer Healthcare international operations | (462) | (370) | (93) |
| Lower revenues for Enbrel internationally, reflecting continued biosimilar competition in most developed Europe markets | (200) | — | (200) |
| Lower revenues for Viagra and Upjohn’s authorized generic for Viagra in the U.S. resulting from increased generic competition | (181) | (191) | 9 |
| Decline in revenues for Revatio driven by lower U.S. Oral Suspension formulation sales and pricing pressures due to a recent generic entry, and for Relpax, driven by continued generic competition across developed markets | (98) | (67) | (31) |
| Lower revenues for the Hospital products business, primarily reflecting declines in developed markets, mostly due to the continued expected negative impact from generic competition for products that have previously lost marketing exclusivity, partially offset by continued growth from anti-infective products in China as well as the 2018 U.S. launches of our immune globulin intravenous products (Panzyga and Octagam) | (46) | (91) | 45 |
| Other operational factors, net | 10 | (47) | 56 |
| Operational growth/(decline), net | 586 | (500) | 1,085 |
| Unfavorable impact of foreign exchange | (1,194) | — | (1,194) |
| Revenues decrease | $(609) | $(500) | $(108) |

(a) Certain key brands represent Ibrance, Eliquis, Xeljanz and Prevnar 13/Prevenar 13. See the “Analysis of the Condensed Consolidated Statements of Income––Revenues––Selected Product Discussion” section of this MD&A for product analysis information.

Emerging markets revenues increased $135 million, or 1%, in the first nine months of 2019 to $9.5 billion from $9.4 billion, reflecting an operational increase of $839 million, or 9%. Foreign exchange had an unfavorable impact of approximately 8% on emerging markets revenues. The operational increase in emerging markets was primarily driven by Prevenar 13, Ibrance and Eliquis in our Biopharma segment and Lipitor, Viagra, Celebrex and Norvasc in our Upjohn segment.

### Revenue Deductions

Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. Such variable consideration represents chargebacks, rebates, sales allowances and sales returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment is required when estimating the impact of these revenue deductions on gross sales for a reporting period. Historically, our adjustments of estimates, to reflect actual results or updated expectations, have not been material to our overall business. On a quarterly basis, our adjustments of estimates to reflect actual results generally have been less than 1% of revenues, and have resulted in either a net increase or a net decrease in revenues. Product-specific rebates, however, can have a significant impact on year-over-year individual product growth trends.

*The following table provides information about revenue deductions:*

| (MILLIONS OF DOLLARS) | Three Months Ended September 29, 2019 | September 30, 2018 | Nine Months Ended September 29, 2019 | September 30, 2018 |
| --- | ---: | ---: | ---: | ---: |
| Medicare rebates(a) | $295 | $443 | $1,080 | $1,266 |
| Medicaid and related state program rebates(a) | 503 | 502 | 1,531 | 1,500 |
| Performance-based contract rebates(a), (b) | 923 | 854 | 2,784 | 2,467 |
| Chargebacks(c) | 1,328 | 1,654 | 4,252 | 4,850 |
| Sales allowances(d) | 1,350 | 1,448 | 4,164 | 4,142 |
| Sales returns and cash discounts | 262 | 358 | 1,065 | 1,067 |
| Total(e) | $4,660 | $5,259 | $14,875 | $15,292 |

(a) Rebates are product-specific and, therefore, for any given year are impacted by the mix of products sold.

(b) Performance-based contract rebates include contract rebates with MCOs within the U.S., including health maintenance organizations and PBMs, who receive rebates based on the achievement of contracted performance terms and claims under these contracts. Outside the U.S., performance-based contract rebates include rebates to wholesalers/distributors based on achievement of contracted performance for specific products or sales milestones.

(c) Chargebacks primarily represent reimbursements to U.S. wholesalers for honoring contracted prices to third parties.

(d) Sales allowances primarily represent price reductions that are contractual or legislatively mandated outside the U.S., discounts and distribution fees.

(e) For the three months ended September 29, 2019, associated with the following segments: Biopharma ($3.0 billion), Upjohn ($1.6 billion) and Other ($0.1 billion). For the three months ended September 30, 2018, associated with the following segments: Biopharma ($2.6 billion), Upjohn ($2.5 billion) and Other ($0.2 billion). For the nine months ended September 29, 2019, associated with the following segments: Biopharma ($8.7 billion), Upjohn ($5.8 billion) and Other ($0.4 billion). For the nine months ended September 30, 2018, associated with the following segments: Biopharma ($7.4 billion), Upjohn ($7.4 billion) and Other ($0.5 billion).

Total revenue deductions for the third quarter of 2019 decreased 11% compared to the third quarter of 2018, and total revenue deductions for the first nine months of 2019 decreased 3%, compared to the first nine months of 2018, primarily as a result of:

- a decrease in chargebacks, primarily related to Upjohn products, including Viagra and Lyrica; and
- a decrease in Medicare rebates, driven by a significant decrease in Lyrica sales in the U.S., due to multi-source generic competition that began in July 2019,

partially offset by:

- an increase in performance-based contract rebates, primarily in the U.S. due to increased sales of certain Biopharma products, slightly offset by decreased Lyrica sales.

For information on our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts, including the balance sheet classification of these accruals, see Notes to Condensed Consolidated Financial Statements––*Note 1C. Basis of Presentation and Significant Accounting Policies: Revenues and Trade Accounts Receivable.*

### Revenues––Selected Product Discussion

The tables below provide worldwide revenues and revenues by geography, for selected products. References to total change pertain to period-over-period growth rates that include foreign exchange. The difference between the total change and operational change represents the impact of foreign exchange. Amounts may not add due to rounding. All percentages have been calculated using unrounded amounts. An asterisk (\*) indicates the calculation is not meaningful or results are equal to or greater than 100%.

- **Prevnar 13/Prevenar 13** (Biopharma):

| (MILLIONS OF DOLLARS) | Three Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. | Nine Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $1,008 | $1,089 | (7) |  | $2,498 | $2,597 | (4) |  |
| International | 595 | 571 | 4 | 7 | 1,770 | 1,694 | 4 | 9 |
| Worldwide revenues | $1,603 | $1,660 | (3) | (3) | $4,268 | $4,290 | (1) | 1 |

The declines in the third quarter and first nine months of 2019 in the U.S. primarily reflect lower government purchases for the pediatric indication as well as the continued decline in revenues for the adult indication due to a high initial capture rate of the eligible population following its successful fourth-quarter 2014 launch, which resulted in a smaller remaining “catch up” opportunity (i.e., the opportunity to reach adults aged 65 years and older who have not been previously vaccinated with Prevnar 13).

The operational growth in the third quarter of 2019 internationally was mostly due to higher volumes reflecting continued uptake following the 2017 launch in China, partially offset by the unfavorable impact of timing associated with government purchases for the pediatric indication in certain emerging markets.

The operational growth in the first nine months of 2019 internationally was primarily due to higher volumes resulting from increased shipments associated with Gavi, the Vaccine Alliance, and higher volumes reflecting continued uptake following the second quarter 2017 launch in China, partially offset by the non-recurrence of volumes associated with an adult national immunization program in first quarter of 2018.

In 2014, the ACIP voted to recommend Prevnar 13 for routine use to help protect adults aged 65 years and older against pneumococcal disease, which for adults includes pneumonia caused by the 13 pneumococcal serotypes included in the vaccine. These ACIP recommendations were subsequently approved by the directors at the CDC and U.S. Department of Health and Human Services, and were published in the Morbidity and Mortality Weekly Report in September 2014 by the CDC. The CDC regularly monitors the impact of vaccination and reviews the recommendations. During the February 2019 ACIP meeting, the CDC presented a formal evaluation of evidence to the recommendation framework (grading) for ACIP’s input. On June 26, 2019, the ACIP voted to revise the pneumococcal vaccination guidelines and recommend Prevnar 13 for adults 65 and older based on the shared clinical decision making of the provider and patient, which means the decision to vaccinate should be made at the individual level between health care providers and their patients, maintaining reimbursement. This revised recommendation reaffirms that there remains vaccine preventable pneumococcal disease in the population of adults 65 years or older, which may be prevented through direct vaccination, and we expect the ACIP’s provisional recommendation to be approved by the directors at the CDC and U.S. Department of Health and Human Services, and is expected to be published by the CDC in the Morbidity and Mortality Weekly Report in the fourth quarter of 2019. We do not expect the ACIP’s latest recommendation will have a significant impact on Prevnar 13 revenues for the remainder of 2019.

- **Ibrance** (Biopharma):

| (MILLIONS OF DOLLARS) | Three Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. | Nine Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $832 | $708 | 18 |  | $2,405 | $2,178 | 10 |  |
| International | 451 | 317 | 42 | 48 | 1,273 | 807 | 58 | 70 |
| Worldwide revenues | $1,283 | $1,025 | 25 | 27 | $3,677 | $2,985 | 23 | 27 |

Operational growth in international markets reflects the continued strong uptake in developed Europe and Japan as well as in certain emerging markets following launches. The growth in the U.S. was mainly driven by cyclin-dependent kinase (CDK) class share growth and Ibrance’s continued CDK class share leadership in its approved metastatic breast cancer indications.

- **Eliquis alliance revenues and direct sales** (Biopharma): Eliquis has been jointly developed and is commercialized by Pfizer and BMS. Pfizer funds between 50% and 60% of all development costs depending on the study. Profits and losses are shared equally on a global basis, except in certain countries where Pfizer commercializes Eliquis and pays BMS compensation based on a percentage of net sales. We have full commercialization rights in certain smaller markets. BMS supplies the product to us at cost, plus a percentage of the net sales to end-customers in these markets. Eliquis is part of the Novel Oral Anticoagulant (NOAC) market; the agents in this class were developed as alternative treatment options to warfarin in appropriate patients.

| (MILLIONS OF DOLLARS) | Three Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. | Nine Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $541 | $455 | 19 |  | $1,768 | $1,371 | 29 |  |
| International | 484 | 416 | 16 | 20 | 1,353 | 1,153 | 17 | 24 |
| Worldwide revenues | $1,025 | $870 | 18 | 20 | $3,121 | $2,524 | 24 | 27 |

The worldwide operational growth in the third quarter and first nine months of 2019 was mostly driven by continued increased adoption in non-valvular atrial fibrillation, as well as oral anti-coagulant market share gains, partially offset by a higher Medicare “coverage gap” discount provision on U.S. revenues compared to the prior year.

- **Lyrica** (Upjohn):

| (MILLIONS OF DOLLARS) | Three Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. | Nine Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $200 | $875 | (77) |  | $1,924 | $2,643 | (27) |  |
| International | 326 | 338 | (4) | (4) | 964 | 1,006 | (4) | (2) |
| Worldwide revenues | $527 | $1,213 | (57) | (57) | $2,888 | $3,649 | (21) | (20) |

The declines in the third quarter and first nine months of 2019 in the U.S. were due to the expected significantly lower volumes driven by multi-source generic competition which began in July 2019.

The operational decline internationally in the third quarter of 2019 was mostly due to generic competition in developed Europe markets. The operational decline internationally in the first nine months of 2019 was primarily due to generic competition in developed Europe markets and pricing pressures across international markets, partially offset by increased volumes in Japan attributable to growth in the orally dissolving tablet formulation, and increased volumes in Russia and China.

- **Xeljanz** (Biopharma):

| (MILLIONS OF DOLLARS) | Three Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. | Nine Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $444 | $332 | 34 |  | $1,201 | $964 | 25 |  |
| International | 154 | 100 | 54 | 61 | 434 | 256 | 69 | 83 |
| Worldwide revenues | $599 | $432 | 38 | 40 | $1,634 | $1,221 | 34 | 37 |

The growth in the U.S. in the third quarter and first nine months of 2019 was primarily due to continued growth in the RA indication driven by access improvements, and by volume growth from the launches of the UC and PsA indications in 2018, partially offset by higher rebating from new commercial contracts. The third quarter of 2019 also benefited from the non-recurrence of a one-time true-up payment in the prior year quarter for improved access with one customer.

The operational growth internationally in the third quarter and first nine months of 2019 was mainly driven by continued uptake in the RA indication in developed Europe, emerging markets, Japan and Canada as well as from the recent launch of the UC indication in certain developed markets.

In July 2019, the FDA updated the U.S. prescribing information for Xeljanz to include two additional boxed warnings as well as changes to the indication and dosing for UC. These updates were based on the FDA’s review of data from the ongoing post-marketing requirement RA study A3921133. While we expect these updates to have an impact on prescribing, we expect Xeljanz to continue to grow globally across all indications due to improved access and reimbursement and due to the high unmet need for these disease states. See the “Analysis of Condensed Consolidated Statements of Income—Product Development—Biopharmaceuticals” section of this MD&A.

- **Lipitor** (Upjohn):

| (MILLIONS OF DOLLARS) | Three Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. | Nine Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $25 | $25 | 1 |  | $76 | $86 | (12) |  |
| International | 451 | 482 | (6) | (3) | 1,430 | 1,453 | (2) | 4 |
| Worldwide revenues | $476 | $507 | (6) | (3) | $1,506 | $1,539 | (2) | 3 |

77

The worldwide operational decline in the third quarter of 2019 was primarily driven by pricing pressures in China resulting from the March 2019 government implementation of the VBP in certain cities, discontinued sales in Saudi Arabia and lower volumes in Japan, partially offset by volume growth and geographic expansion in provinces in China where the VBP has not yet been implemented. The worldwide operational growth in the first nine months of 2019 was mostly due to overall increased demand in China in the first quarter of 2019 and continued geographic expansion during the third quarter in provinces where the VBP program has not yet been implemented, partially offset by pricing pressures in China resulting from the VBP implementation in certain cities and discontinued sales in Saudi Arabia.

- **Enbrel** (Biopharma, outside the U.S. and Canada):

| (MILLIONS OF DOLLARS) | Three Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. | Nine Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $— | $— | — |  | $— | $— | — |  |
| International | 415 | 531 | (22) | (19) | 1,285 | 1,589 | (19) | (13) |
| Worldwide revenues | $415 | $531 | (22) | (19) | $1,285 | $1,589 | (19) | (13) |

The worldwide operational declines in the third quarter and first nine months of 2019 were primarily due to ongoing biosimilar competition in most developed Europe markets, which is expected to continue.

- **Chantix/Champix** (Biopharma):

| (MILLIONS OF DOLLARS) | Three Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. | Nine Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $227 | $197 | 15 |  | $666 | $602 | 11 |  |
| International | 49 | 64 | (22) | (20) | 159 | 187 | (15) | (10) |
| Worldwide revenues | $276 | $261 | 6 | 7 | $825 | $789 | 5 | 6 |

The growth in the U.S. in the third quarter and first nine months of 2019 was primarily due to favorable channel mix. The operational declines internationally in the third quarter and first nine months of 2019 were mainly driven by generic entry in South Korea and Canada.

- **Norvasc** (Upjohn):

| (MILLIONS OF DOLLARS) | Three Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. | Nine Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $9 | $9 | 5 |  | $30 | $27 | 11 |  |
| International | 209 | 239 | (12) | (9) | 704 | 750 | (6) | (1) |
| Worldwide revenues | $219 | $248 | (12) | (9) | $735 | $777 | (6) | (1) |

The worldwide operational decline in the third quarter of 2019 was primarily driven by pricing pressures in China resulting from the VBP implementation in certain cities and lower volumes in Japan and South Korea, partially offset by volume growth and geographic expansion in provinces in China where the VBP has not yet been implemented. The worldwide operational decline in the first nine months of 2019 was primarily due to pricing pressures in China resulting from the VBP implementation in certain cities and lower volumes in Japan, partially offset by overall increased demand in China in the first quarter of 2019 and continued geographic expansion during the third quarter of 2019 in provinces where the VBP has not yet been implemented.

- **Sutent** (Biopharma):

| (MILLIONS OF DOLLARS) | Three Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. | Nine Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $64 | $80 | (20) |  | $217 | $262 | (17) |  |
| International | 160 | 168 | (5) | — | 488 | 524 | (7) | — |
| Worldwide revenues | $224 | $248 | (10) | (7) | $704 | $785 | (10) | (5) |

78

The worldwide operational declines in the third quarter and first nine months of 2019 reflect continued erosion as a result of increased competition in the U.S. and key developed markets, partially offset by growth in certain emerging markets.

- **Xtandi alliance revenues** (Biopharma): Xtandi is being developed and commercialized through a collaboration with Astellas. The two companies share equally in the gross profits (losses) related to U.S. net sales of Xtandi. Subject to certain exceptions, Pfizer and Astellas also share equally all Xtandi commercialization costs attributable to the U.S. market. Pfizer and Astellas also share certain development and other collaboration expenses, and Pfizer receives tiered royalties as a percentage of international Xtandi net sales (recorded in *Other (income)/deductions—net).*

| (MILLIONS OF DOLLARS) | Three Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. | Nine Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $225 | $180 | 25 |  | $594 | $510 | 17 |  |
| International | — | — | — | — | — | — | — | — |
| Worldwide revenues | $225 | $180 | 25 | 25 | $594 | $510 | 17 | 17 |

The growth in the U.S. in the third quarter and first nine months of 2019 was primarily driven by increased demand for Xtandi in metastatic (mCRPC) and non-metastatic (nmCRPC) castration-resistant prostate cancer, partially offset by higher patient assistance programs (PAP) utilization in the first nine months of 2019, compared to the same period in 2018.

- The **Premarin** family of products (Biopharma):

| (MILLIONS OF DOLLARS) | Three Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. | Nine Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $170 | $191 | (11) |  | $510 | $569 | (10) |  |
| International | 11 | 12 | (8) | (5) | 32 | 36 | (10) | (5) |
| Worldwide revenues | $182 | $204 | (11) | (11) | $542 | $605 | (10) | (10) |

The worldwide operational declines in the third quarter and first nine months of 2019 were primarily driven by competitive pressures in the U.S.

- **Celebrex** (Upjohn):

| (MILLIONS OF DOLLARS) | Three Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. | Nine Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $14 | $16 | (17) |  | $44 | $50 | (13) |  |
| International | 166 | 171 | (3) | (3) | 482 | 444 | 9 | 12 |
| Worldwide revenues | $179 | $188 | (5) | (4) | $526 | $494 | 7 | 9 |

The worldwide operational decline in the third quarter of 2019 was primarily due to lower volumes and pricing pressures in certain emerging markets. The worldwide operational growth in the first nine months of 2019 was mainly due to higher volumes in Japan and in China, driven by investments in geographic expansion, partially offset by pricing pressures in certain emerging markets.

- **Sulperazon** (Biopharma):

| (MILLIONS OF DOLLARS) | Three Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. | Nine Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $— | $— | — |  | $— | $— | — |  |
| International | 163 | 145 | 12 | 16 | 505 | 464 | 9 | 15 |
| Worldwide revenues | $163 | $145 | 12 | 16 | $505 | $464 | 9 | 15 |

The international operational growth in the third quarter and first nine months of 2019 was mostly due to increased demand in China.

- **Inflectra/Remsima** (Biopharma):

| (MILLIONS OF DOLLARS) | Three Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. | Nine Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $77 | $71 | 8 |  | $208 | $189 | 10 |  |
| International | 78 | 95 | (18) | (15) | 238 | 280 | (15) | (10) |
| Worldwide revenues | $155 | $166 | (7) | (5) | $446 | $469 | (5) | (2) |

The worldwide operational revenues declined in the third quarter and first nine months of 2019 due to pricing pressures globally as well as competitive pressures internationally, partially offset by continued volume growth in certain channels in the U.S., as well as in certain developed markets in Europe and Canada.

The growth in the U.S. in the third quarter and first nine months of 2019 was primarily driven by demand in open systems, partially offset by price erosion. While Inflectra has achieved parity access to Remicade® (infliximab) in Medicare Part B, nearly half of all commercial patients are not able to access Inflectra due to exclusionary contracting practices by J&J. In September 2017, Pfizer filed suit in the U.S. District Court for the Eastern District of Pennsylvania against J&J alleging that J&J’s exclusionary contracts and other anticompetitive practices concerning Remicade violate federal antitrust laws. In June 2019, Pfizer received a Civil Investigative Demand from the Federal Trade Commission (FTC) seeking documents and information relating to the alleged conduct and market conditions at issue in Pfizer’s lawsuit against J&J. Pfizer understands that the FTC’s investigation is focused on J&J’s alleged conduct at issue in Pfizer’s lawsuit against J&J.

- **Xalkori** (Biopharma):

| (MILLIONS OF DOLLARS) | Three Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. | Nine Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $36 | $34 | 7 |  | $111 | $118 | (6) |  |
| International | 94 | 93 | 1 | 4 | 274 | 299 | (8) | (3) |
| Worldwide revenues | $130 | $127 | 2 | 5 | $385 | $417 | (8) | (4) |

The worldwide operational growth in the third quarter of 2019 was primarily due to increased volumes in China following the impact of inclusion of Xalkori in the 2019 National Reimbursement Drug Listing (NRDL) in China, partially offset by volume declines in the ALK indication due to competitive pressure primarily across developed Europe and pricing pressures in China. In the first nine months of 2019, the worldwide operational decline in revenues primarily resulted from erosion due to competition in developed Europe and in the U.S., partially offset by growth in China, following the impact of inclusion of Xalkori in the NRDL.

- **Viagra** (Upjohn):

| (MILLIONS OF DOLLARS) | Three Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. | Nine Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $20 | $32 | (37) |  | $72 | $196 | (63) |  |
| International | 99 | 105 | (5) | (3) | 306 | 313 | (2) | 3 |
| Worldwide revenues | $120 | $137 | (13) | (11) | $379 | $509 | (26) | (22) |

The declines in the U.S. in the third quarter and first nine months of 2019 were driven by the loss of exclusivity in December 2017.

The operational decline internationally in the third quarter of 2019 was primarily due to lower volumes across developed markets. The operational growth internationally in the first nine months of 2019 was mostly due to increased demand in China driven by investments in geographic expansion, partially offset by pricing pressures in China and lower volumes across developed and certain emerging markets.

- **Inlyta** (Biopharma):

| (MILLIONS OF DOLLARS) | Three Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. | Nine Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $92 | $27 | \* |  | $185 | $88 | \* |  |
| International | 46 | 44 | 6 | 10 | 131 | 138 | (5) | 2 |
| Worldwide revenues | $139 | $71 | 95 | 98 | $316 | $226 | 40 | 44 |

The worldwide operational growth in the third quarter and first nine months of 2019 was primarily due to increased demand in the U.S. as a result of the FDA approvals in the second quarter of 2019 for combinations of certain checkpoint inhibitors plus Inlyta for the first-line treatment of patients with advanced RCC. The growth was partially offset by the decline in other developed markets due to increased competition.

- **Eucrisa** (Biopharma):

| (MILLIONS OF DOLLARS) | Three Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. | Nine Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $42 | $40 | 5 |  | $90 | $104 | (14) |  |
| International | 1 | — | \* | \* | 2 | — | \* | \* |
| Worldwide revenues | $43 | $40 | 7 | 7 | $92 | $104 | (12) | (12) |

The growth in the U.S. in the third quarter of 2019 was driven by volume growth that was partially offset by higher rebating and unfavorable channel mix. The decline in the U.S. in the first nine months of 2019 was driven by volume growth that was more than offset by higher rebating and unfavorable channel mix, in addition to favorable rebate adjustments in 2018.

- **Alliance revenues** (Biopharma):

| (MILLIONS OF DOLLARS) | Three Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. | Nine Months Ended September 29, 2019 | September 30, 2018 | % Change Total | Oper. |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| U.S. | $773 | $642 | 20 |  | $2,383 | $1,901 | 25 |  |
| International | 368 | 336 | 10 | 13 | 1,034 | 919 | 13 | 18 |
| Worldwide revenues | $1,141 | $977 | 17 | 18 | $3,418 | $2,820 | 21 | 23 |

The worldwide operational growth was mainly due to increases in Eliquis and Xtandi alliance revenues included in the above discussion.

- **Bavencio** (Biopharma) is being developed and commercialized in collaboration with Merck KGaA. Both companies jointly fund the majority of development and commercialization costs, and split equally any profits generated from selling any products containing avelumab from this collaboration. Bavencio is currently approved in metastatic MCC in the U.S., Europe and Japan and select other markets, as well as in second line treatment of locally advanced or metastatic urothelial carcinoma and first-line treatment of patients with advanced RCC in combination with Inlyta in the U.S.

See Notes to Condensed Consolidated Financial Statements––*Note 13C. Segment, Geographic and Other Revenue Information: Other Revenue Information* for additional information regarding the primary indications or class of the selected products discussed above.

See Notes to Condensed Consolidated Financial Statements—*Note 12. Contingencies and Certain Commitments* for a discussion of recent developments concerning patent and product litigation relating to certain of the products discussed above.

### Product Developments—Biopharmaceutical

We continue to invest in R&D to provide potential future sources of revenues through the development of new products, as well as through additional uses for in-line and alliance products. Notwithstanding our efforts, there are no assurances as to when, or if, we will receive regulatory approval for additional indications for existing products or any of our other products in development.

We continue to strengthen our global R&D organization and pursue strategies intended to improve innovation and overall productivity in R&D to achieve a sustainable pipeline that will deliver value in the near term and over time.

For additional information about our R&D organization, see the “Overview of Our Performance, Operating Environment, Strategy and Outlook—Our Strategy—Organizing for Growth” and “—Description of Research and Development Operations” sections of this MD&A.

A comprehensive update of Pfizer’s development pipeline was published as of October 29, 2019 and is available at www.pfizer.com/science/drug-product-pipeline. It includes an overview of our research and a list of compounds in development with targeted indication and phase of development, as well as mechanism of action for some candidates in Phase 1 and all candidates from Phase 2 through registration.

The following series of tables provides information about significant regulatory actions by, and filings pending with, the FDA and regulatory authorities in the EU and Japan, as well as additional indications and new drug candidates in late-stage development.

*RECENT FDA APPROVALS*

|  |  |  |
| --- | --- | --- |
| **PRODUCT** | **INDICATION** | **DATE APPROVED** |
| Ruxience™ (rituximab-pvvr)(a) | A biosimilar to Rituxan® (rituximab) for the treatment of adult patients with non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and granulomatosis with polyangiitis and microscopic polyangiitis | July 2019 |
| Zirabev (bevacizumab-bvzr)(b) | A biosimilar to Avastin® (bevacizumab) for the treatment of mCRC; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic RCC; and persistent, recurrent or metastatic cervical cancer | June 2019 |
| Bavencio (avelumab) | Bavencio (avelumab) in combination with Inlyta (axitinib) for the first-line treatment of patients with advanced RCC, which is being developed in collaboration with Merck KGaA, Germany | May 2019 |
| Vyndaqel (tafamidis meglumine) | Treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization | May 2019 |
| Vyndamax (tafamidis) | Treatment of the cardiomyopathy of wild-type or hereditary ATTR-CM in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization | May 2019 |
| Trazimera (trastuzumab-qyyp)(c) | A biosimilar to Herceptin® (trastuzumab) for all eligible indications of the reference product | March 2019 |
| Daurismo (glasdegib) | Treatment of newly-diagnosed acute myeloid leukemia in adult patients who are 75 years or older or who have comorbidities that preclude use of intensive induction chemotherapy | November 2018 |
| Lorbrena (lorlatinib) | Treatment of patients with ALK-positive metastatic NSCLC whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease | November 2018 |

(a) Rituxan® is a registered trademark of Biogen MA Inc.

(b) Avastin® is a registered trademark of Genentech, Inc.

(c) Herceptin® is a registered trademark of Genentech, Inc.

*PENDING U.S. NDAs AND SUPPLEMENTAL FILINGS*

|  |  |  |
| --- | --- | --- |
| **PRODUCT** | **PROPOSED INDICATION** | **DATE FILED\*** |
| Xtandi (enzalutamide) | Treatment of metastatic hormone-sensitive prostate cancer, which is being developed through a collaboration with Astellas | August 2019 |
| PF-06881894(a) | A potential biosimilar to Neulasta® (pegfilgrastim) | August 2019 |
| PF-06410293(b) | A potential biosimilar to Humira® (adalimumab) | January 2019 |
| Vyndaqel (tafamidis meglumine)(c) | Treatment of transthyretin familial amyloid polyneuropathy | February 2012 |

\* The dates set forth in this column are the dates on which the FDA accepted our submissions.

(a) Neulasta® is a registered U.S. trademark of Amgen Inc.

(b) Humira® is a registered trademark of AbbVie Biotechnology Ltd.

(c) In May 2012, the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted that the tafamidis meglumine data provide substantial evidence of efficacy for a surrogate endpoint that is reasonably likely to predict a clinical benefit. In June 2012, the FDA issued a “complete response” letter with respect to this tafamidis NDA. The FDA has requested the completion of a second efficacy study, and also has asked for additional information on the data within the current tafamidis NDA. Pfizer has completed study B3461028, a global Phase 3 study to support the new indication of transthyretin amyloid cardiomyopathy, which includes patients with wild type and variant transthyretin. We are working with the FDA to identify next steps.

*REGULATORY APPROVALS AND FILINGS IN THE EU AND JAPAN*

| PRODUCT | DESCRIPTION OF EVENT | DATE APPROVED | DATE FILED\* |
| --- | --- | ---: | --- |
| Braftovi (encorafenib) and Mektovi (binimetinib) | Application filed in the EU for second-or-third-line treatment of BRAF-mutant mCRC, which is being developed in collaboration with the Pierre Fabre Group | — | November 2019 |
| Bavencio (avelumab) | Application approved in the EU for Bavencio (avelumab) in combination with Inlyta (axitinib) for the first-line treatment of advanced RCC, which is being developed in collaboration with Merck KGaA, Germany | October 2019 | — |
| PF-06881894(a) | Application filed in the EU for a potential biosimilar to Neulasta® (pegfilgrastim) | — | October 2019 |
| Rituximab Pfizer (rituximab)(b) | Application approved in Japan for a biosimilar to Rituxan® (rituximab) for the treatment of CD20-positive, B-cell non-Hodgkin’s Lymphoma, CD20-positive, B-cell lymphoproliferative disease under immunosuppression, and Granulomatosis with polyangiitis, and microscopic polyangiitis | September 2019 | — |
| Bosulif (bosutinib) | Application filed in Japan for the treatment of chronic myelogenous leukemia (CML), which is being developed in collaboration with Avillion LLP | — | July 2019 |
| Xtandi (enzalutamide) | Application filed in the EU for the treatment of metastatic hormone-sensitive prostate cancer, which is being developed through a collaboration with Astellas | — | July 2019 |
| Talzenna (talazoparib) | Application approved in the EU for monotherapy for the treatment of adult patients with germline breast cancer susceptibility gene (gBRCA)1/2-mutations, who have human epidermal growth factor receptor 2-negative (HER2-) locally advanced or metastatic breast cancer | June 2019 | — |
| Bevacizumab Pfizer (bevacizumab)(c) | Application approved in Japan for a biosimilar to Avastin® (bevacizumab) for the treatment of metastatic colorectal cancer | June 2019 | — |
| Daurismo (glasdegib) | Application filed in the EU for treatment of newly-diagnosed acute myeloid leukemia in adult patients who are 75 years or older or who have co-morbidities that preclude use of intensive induction chemotherapy | — | May 2019 |
| Lorviqua (lorlatinib) | Application approved in the EU as monotherapy, for the treatment of adult patients with ALK- positive advanced non-small cell lung cancer whose disease has progressed after: • alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or • crizotinib and at least one other ALK TKI | May 2019 | — |
| Vizimpro (dacomitinib) | Application approved in the EU as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations, which is being developed in collaboration with SFJ | April 2019 | — |
| Vyndaqel (tafamidis meglumine) | Application approved in Japan for treatment of transthyretin amyloid cardiomyopathy | March 2019 | — |
| Zirabev(c) | Application approved in the EU for a biosimilar to Avastin® (bevacizumab) for the treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer, unresectable advanced, metastatic or recurrent NSCLC, advanced and/or metastatic renal cell cancer and persistent, recurrent, or metastatic carcinoma of the cervix | February 2019 | — |
| Vyndaqel (tafamidis free acid) | Application filed in the EU for the treatment of adults with transthyretin amyloid cardiomyopathy | — | January 2019 |
| Bavencio (avelumab) | Application filed in Japan for Bavencio (avelumab) in combination with Inlyta (axitinib) for the first-line treatment of advanced RCC, which is being developed in collaboration with Merck KGaA, Germany | — | January 2019 |
| Vizimpro (dacomitinib) | Application approved in Japan for the treatment of patients with locally advanced or metastatic non-small cell lung cancer with EGFR mutations, which is being developed in collaboration with SFJ | January 2019 | — |
| PF-06410293(d) | Application filed in the EU for a potential biosimilar to Humira® (adalimumab) | — | November 2018 |
| PF-05280586(b) | Application filed in the EU for a potential biosimilar to Rituxan® (rituximab) | — | August 2018 |
| crisaborole | Application filed in the EU for the treatment of mild-to-moderate atopic dermatitis | — | May 2018 |
| Xeljanz (tofacitinib) | Application filed in the EU for modified release 11mg tablet for RA | — | March 2018 |

\* For applications in the EU, the dates set forth in this column are the dates on which the EMA validated our submissions.

(a) Neulasta® is a registered trademark of Amgen Inc.

(b) Rituxan® is a registered trademark of Biogen MA Inc.

(c) Avastin® is a registered trademark of Genentech, Inc.

(d) Humira® is a registered trademark of AbbVie Biotechnology Ltd.

| LATE-STAGE CLINICAL PROGRAMS FOR ADDITIONAL USES AND DOSAGE FORMS FOR IN-LINE AND IN-REGISTRATION PRODUCTS |  |
| --- | --- |
| **PRODUCT** | **PROPOSED INDICATION** |
| Bavencio (avelumab) | A monoclonal antibody that inhibits PD-L1 for the first-line treatment of stage IIIb/IV non-small cell lung cancer, which is being developed in collaboration with Merck KGaA, Germany |
| Bavencio (avelumab) | A monoclonal antibody that inhibits PD-L1 for maintenance treatment, in the first-line setting, for patients with urothelial cancer, which is being developed in collaboration with Merck KGaA, Germany |
| Bavencio (avelumab) | A monoclonal antibody that inhibits PD-L1 for maintenance treatment of advanced or metastatic gastric/gastro-esophageal junction cancers, which is being developed in collaboration with Merck KGaA, Germany |
| Bavencio (avelumab) | A monoclonal antibody that inhibits PD-L1 for treatment of locally advanced squamous cell carcinoma of the head and neck, which is being developed in collaboration with Merck KGaA, Germany |
| Braftovi (encorafenib) and Mektovi (binimetinib) | Second-or-third-line treatment of BRAF-mutant mCRC (ex-EU) |
| Daurismo (glasdegib) | A smoothened inhibitor, in combination with azacitidine, for the treatment of acute myeloid leukemia |
| Ibrance (palbociclib) | Treatment of HER2+ advanced breast cancer, in collaboration with the Alliance Foundation Trials, LLC |
| Ibrance (palbociclib) | Treatment of high-risk early breast cancer, in collaboration with the German Breast Group |
| Ibrance (palbociclib) | Treatment of HR+ early breast cancer, in collaboration with the Alliance Foundation Trials, LLC, and the Austrian Breast Colorectal Cancer Study Group |
| Lorbrena (lorlatinib) | Treatment of patients with metastatic non-small cell lung cancer whose tumors are ALK-positive as detected by an FDA-approved test |
| Xeljanz (tofacitinib) | Treatment of ankylosing spondylitis |
| Xtandi (enzalutamide) | Treatment of non-metastatic hormone-sensitive prostate cancer, which is being developed through a collaboration with Astellas |
| Talzenna (talazoparib) | An oral PARP inhibitor, in combination with Xtandi (enzalutamide), for the treatment of metastatic castration-resistant prostate cancer |

In February 2019, the company took steps to transition rheumatoid arthritis study patients who were on tofacitinib 10 mg twice daily to tofacitinib 5 mg twice daily in the ongoing FDA post-marketing requirement study A3921133, a study performed in patients considered to be at high risk for certain side effects. This action was taken as the result of notification from the tofacitinib Rheumatology Data Safety Monitoring Board of a safety signal regarding the tofacitinib 10 mg twice daily treatment arm in study A3921133. The 5 mg twice daily dose is the FDA approved dose in the U.S. for adult patients with moderate to severe rheumatoid arthritis. In July 2019, the FDA updated the U.S. prescribing information for Xeljanz to include two additional boxed warnings as well as changes to the indication and dosing for UC. These updates were based on the FDA’s review of data from the ongoing post-marketing requirement RA study A3921133. In addition, the EU product labeling (SmPC) for Xeljanz was updated in July 2019 to reflect provisional measures required by the EMA’s pharmacovigilance committee (PRAC) while a review was conducted. The PRAC has completed its review and has recommended to the EMA’s scientific committee (CHMP) that caution should be utilized in treating patients with Xeljanz who are at risk for certain side effects. This recommendation will be reviewed by the CHMP who will issue a final opinion; this is expected during November 2019. The CHMP opinion will be provided to the European Commission to issue a legally-binding decision; this procedure is expected to be completed in early 2020.

| NEW DRUG CANDIDATES IN LATE-STAGE DEVELOPMENT |  |
| --- | --- |
| **CANDIDATE** | **PROPOSED INDICATION** |
| aztreonam-avibactam (PF-06947387) | A beta lactam/beta lactamase inhibitor for the treatment of patients with infections caused by Gram-negative bacteria, including those that produce metallo-beta-lactamases, for which there are limited or no treatment options |
| fidanacogene elaparvovec (PF-06838435) | An investigational gene therapy for the treatment of hemophilia B |
| PF-06482077 | A 20-Valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease and pneumonia caused by Streptococcus pneumoniae serotypes covered by the vaccine in adults 18 years of age and older |
| PF-06651600 | A selective dual Janus kinase 3 (JAK3) and Tyrosine kinase Expressed in hepatocellular Carcinoma (TEC) family inhibitor for the treatment of patients with moderate to severe alopecia areata |
| abrocitinib (PF-04965842) | A Janus kinase 1 (JAK1) inhibitor for the treatment of moderate-to-severe atopic dermatitis |
| PF-06425090 | A prophylactic vaccine for prevention of primary clostridium difficile infection (CDI) in individuals |
| PF-06802861 | An oral inhibitor of p38 mitogen-activated protein kinase for the treatment of patients with symptomatic dilated cardiomyopathy due to a Lamin A/C gene mutation |
| rivipansel (GMI-1070)(a) | A triple selectin inhibitor, with highest potency for E-selectin for the treatment of acute vaso-occlusive crises associated with sickle cell disease in patients aged 6 years and above, which was licensed from GlycoMimetics Inc. |
| somatrogon (PF-06836922) | A long-acting hGH-CTP for the treatment of growth hormone deficiency in children, which is being developed in collaboration with OPKO |
| somatrogon (PF-06836922) | A long-acting hGH-CTP for the treatment of growth hormone deficiency in adults, which is being developed in collaboration with OPKO |
| tanezumab(b) | An anti-nerve growth factor monoclonal antibody for the treatment of pain, which is being developed in collaboration with Lilly |

(a) In August 2019, we announced that the Phase 3 RESET (Rivipansel Evaluating Safety, Efficacy and Time to Discharge) pivotal study did not meet its primary or key secondary efficacy endpoints. The objective of the trial was to evaluate the efficacy and safety of rivipansel in patients aged six and older with sickle cell disease who were hospitalized for a vaso-occlusive crisis and required treatment with IV opioids. The primary endpoint was time to readiness-for-discharge and the key secondary efficacy endpoints were time-to-discharge, cumulative IV opioid consumption, and time to discontinuation of IV opioids. Detailed analyses of the RESET study, including additional data on efficacy and safety endpoints, which are not available at this time, will be submitted for presentation at a future scientific meeting. We are awaiting additional data to determine next steps.

(b) In April 2019, Pfizer and Lilly announced top-line results from a Phase 3 study (A4091058) evaluating subcutaneous (SC) administration of tanezumab 2.5 mg and 5 mg. The objective of the study was to compare the long-term joint safety and 16-week efficacy of tanezumab relative to nonsteroidal anti-inflammatory drugs in patients with moderate-to-severe osteoarthritis (OA) of the hip or knee. During additional routine quality-control activities that occurred after the study was completed and the database was locked, an adverse event of osteonecrosis, which required adjudication was identified in a patient treated with tanezumab 2.5 mg SC. Accounting for the one additional adjudicated case of osteonecrosis in the tanezumab 2.5 mg arm, the incidence of the primary joint safety endpoint for the 2.5 mg SC arm is 3.9 percent (vs. 3.8 percent, reported in the top-line report). This additional finding does not change the conclusion of the study. Detailed results from this study will be presented at the 2019 American College of Rheumatology and the Association of Rheumatology Professionals Annual Meeting on November 11 and 12, 2019.

Additional product-related programs are in various stages of discovery and development.

### Costs and Expenses

The changes in expenses below reflect, among other things, a decline in expenses resulting from the July 31, 2019 completion of the Consumer Healthcare JV transaction with GSK. Our financial results, and our Consumer Healthcare segment’s operating results, for the third quarter of 2019 reflect only one month of Consumer Healthcare segment domestic operations and two months of Consumer Healthcare segment international operations. Likewise, our financial results, and our Consumer Healthcare segment’s operating results, for the first nine months of 2019 reflect seven months of Consumer Healthcare segment domestic operations and eight months of Consumer Healthcare segment international operations. For additional information, see Notes to Condensed Consolidated Financial Statements—*Note 1A. Basis of Presentation and Significant Accounting Policies: Basis of Presentation.*

### Cost of Sales

| (MILLIONS OF DOLLARS) | Three Months Ended September 29, 2019 | September 30, 2018 | % Change | Nine Months Ended September 29, 2019 | September 30, 2018 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Cost of sales | $2,602 | $2,694 | (3) | $7,611 | $8,173 | (7) |
| As a percentage of Revenues | 20.5% | 20.3% |  | 19.5% | 20.6% |  |

*Cost of sales* decreased $92 million, or 3%, in the third quarter of 2019, compared to the same period in 2018, primarily due to:

- the favorable impact of the July 31, 2019 completion of the Consumer Healthcare joint venture transaction with GSK; and
- lower royalty expense for Lyrica due to the June 2019 loss of exclusivity in the U.S.,

partially offset by:

- a $127 million charge for rivipansel, primarily for inventory manufactured for expected future sale (see Notes to Condensed Consolidated Financial Statements––*Note 2C. Acquisitions, Equity-Method Investment and Assets and Liabilities Held for Sale and Research and Development Arrangement: Research and Development Arrangement).*

*Cost of sales* decreased $562 million, or 7%, in the first nine months of 2019, compared to the same period in 2018, primarily due to:

- the favorable impact of foreign exchange of $341 million;
- the favorable impact of hedging activity on intercompany inventory of $216 million;
- the favorable impact of the July 31, 2019 completion of the Consumer Healthcare joint venture transaction with GSK; and
- lower royalty expense for Lyrica due to the June 2019 loss of exclusivity in the U.S.,

partially offset by:

- an unfavorable change in product mix; and
- a $127 million charge for rivipansel, primarily for inventory manufactured for expected future sale (see Notes to Condensed Consolidated Financial Statements––*Note 2C. Acquisitions, Equity-Method Investment and Assets and Liabilities Held for Sale and Research and Development Arrangement: Research and Development Arrangement).*

The slight increase in *Cost of sales* as a percentage of revenues in the third quarter of 2019, compared to the same period in 2018, was primarily due to all of the factors discussed above, as well as the impact of the loss of exclusivity of Lyrica in the U.S., partially offset by an increase in alliance revenues, which have no associated cost of sales.

The decrease in *Cost of sales* as a percentage of revenues in the first nine months of 2019, compared to the same period in 2018, was primarily due to all of the factors discussed above, as well an increase in alliance revenues, which have no associated cost of sales, partially offset by the impact of the loss of exclusivity of Lyrica in the U.S.

### Selling, Informational and Administrative (SI&A) Expenses

| (MILLIONS OF DOLLARS) | Three Months Ended September 29, 2019 | September 30, 2018 | % Change | Nine Months Ended September 29, 2019 | September 30, 2018 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Selling, informational and administrative expenses | $3,260 | $3,494 | (7) | $10,110 | $10,448 | (3) |
| As a percentage of Revenues | 25.7% | 26.3% |  | 25.9% | 26.3% |  |

85

SI&A expenses decreased $234 million, or 7%, in the third quarter of 2019, compared to the same period in 2018, primarily due to:

- the favorable impact of the July 31, 2019 completion of the Consumer Healthcare joint venture transaction with GSK;
- lower advertising, promotional and field force expenses in developed markets, primarily related to Lyrica in the U.S., and
- the favorable impact of foreign exchange of $48 million,

partially offset by:

- additional investment across several of our products.

SI&A expenses decreased $338 million, or 3%, in the first nine months of 2019, compared to the same period in 2018, primarily due to:

- the favorable impact of foreign exchange of $254 million;
- lower advertising, promotional and field force expenses in developed markets, primarily related to Lyrica in the U.S.;
- the favorable impact of the July 31, 2019 completion of the Consumer Healthcare joint venture transaction with GSK; and
- the non-recurrence of a special, one-time bonus paid to virtually all Pfizer colleagues, excluding executives, of $119 million, in the aggregate, in the first quarter of 2018,

partially offset by:

- additional investment across several of our key products; and
- additional investments in China across key brands.

### Research and Development (R&D) Expenses

| (MILLIONS OF DOLLARS) | Three Months Ended September 29, 2019 | September 30, 2018 | % Change | Nine Months Ended September 29, 2019 | September 30, 2018 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development expenses | $2,283 | $2,008 | 14 | $5,827 | $5,549 | 5 |
| As a percentage of Revenues | 18.0% | 15.1% |  | 14.9% | 14.0% |  |

R&D expenses increased $275 million, or 14%, in the third quarter of 2019, compared to the same period in 2018, and increased $278 million, or 5%, in the first nine months of 2019, compared to the same period in 2018 primarily due to:

- investments in newly acquired Therachon and Array products (see Notes to Condensed Consolidated Financial Statements––*Note 2A. Acquisitions, Equity-Method Investment and Assets and Liabilities Held for Sale and Research and Development Arrangement: Acquisitions);*
- increased investments towards building new capabilities and driving automation; and
- increased spending on our Inflammation & Immunology and Rare Disease portfolios due to several phase 3 programs and

investment in gene therapy,

partially offset by:

- a decrease in the value of the portfolio performance share grants reflecting changes in the price of Pfizer’s common stock, as well as management’s assessment of the probability that the specific performance criteria will be achieved;
- decreased spending across the Oncology, Vaccines and Internal Medicine portfolios, as select programs have reached completion; and
- the timing of milestone activity.

For additional information on Cost of sales, SI&A and R&D expenses by operating segment, see the “Analysis of Operating Segment Information” section of this MD&A.

### Amortization of Intangible Assets

| (MILLIONS OF DOLLARS) | Three Months Ended September 29, 2019 | September 30, 2018 | % Change | Nine Months Ended September 29, 2019 | September 30, 2018 | % Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Amortization of intangible assets | $1,212 | $1,253 | (3) | $3,578 | $3,640 | (2) |
| As a percentage of Revenues | 9.6% | 9.4% |  | 9.2% | 9.2% |  |

Amortization of intangible assets decreased $42 million, or 3%, in the third quarter of 2019, compared to the same period in 2018, primarily due to the non-recurrence of amortization expense resulting from the impairment of sterile injectable products in the fourth quarter of 2018 and the contribution of our Consumer Healthcare business to the Consumer Healthcare joint venture with GSK, partially offset by an increase in amortization expense of intangible assets as a result of our acquisition of Array.

Amortization of intangible assets decreased $61 million, or 2%, in the first nine months of 2019, compared to same period in 2018, primarily due to the non-recurrence of amortization expense resulting from the impairment of sterile injectable products in 2018 and the contribution of our Consumer Healthcare business to the Consumer Healthcare joint venture with GSK, partially offset by an increase in amortization expense of assets recorded as a result of the approval of an additional indication for Xtandi in the U.S., and amortization of intangible assets as a result of our acquisition of Array.

For additional information, see Notes to Condensed Consolidated Financial Statements—*Note 2A. Acquisitions, Equity-Method Investment and Assets and Liabilities Held for Sale and Research and Development Arrangement: Acquisitions, —Note 2B. Acquisitions, Equity-Method Investment and Assets and Liabilities Held for Sale and Research and Development Arrangement: Equity-Method Investment and Assets and Liabilities Held for Sale* and —*Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.*

### Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives

| (MILLIONS OF DOLLARS) | Three Months Ended Sept. 29, 2019 | Sept. 30, 2018 | % Change | Nine Months Ended Sept. 29, 2019 | Sept. 30, 2018 | % Change |
| --- | ---: | ---: | --- | ---: | ---: | ---: |
| Restructuring charges/(credits)—acquisition-related costs(a) | $19 | $24 | (20) | $(196) | $5 | \* |
| Restructuring charges/(credits)—cost reduction initiatives(b) | 64 | (22) | \* | 145 | (37) | \* |
| Restructuring charges/(credits) | 83 | 1 | \* | (50) | (32) | 58 |
| Transaction costs(c) | 65 | 1 | \* | 65 | 1 | \* |
| Integration costs and other(c) | 217 | 82 | \* | 281 | 202 | 39 |
| Restructuring charges and certain acquisition-related costs | 365 | 85 | \* | 295 | 172 | 72 |
| Net periodic benefit costs | 9 | 41 | (78) | 19 | 103 | (81) |
| Additional depreciation—asset restructuring | 6 | 12 | (50) | 29 | 43 | (33) |
| Total implementation costs | 40 | 48 | (17) | 109 | 130 | (17) |
| Costs associated with acquisitions and cost-reduction/productivity initiatives(d) | $420 | $186 | \* | $452 | $447 | 1 |
| \* Calculation not meaningful or results are equal to or greater than 100%. |  |  |  |  |  |  |

(a) Restructuring charges/(credits)––acquisition-related costs include employee termination costs, asset impairments and other exit costs associated with business combinations. Charges for the third quarter of 2019 represent employee termination costs related to our acquisition of Array. Credits for the first nine months of 2019 were mostly due to the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of a U.S. IRS audit for multiple tax years. See Notes to Condensed Consolidated Financial Statements—*Note 5B. Tax Matters: Tax Contingencies.* Charges for the third quarter of 2018 were primarily due to accruals for exit costs and asset write downs related to our acquisition of Hospira, and charges for the first nine months of 2018 were mainly due to asset write downs related to our acquisition of Hospira, partially offset by the reversal of previously recorded accruals for employee termination costs related to our acquisition of Hospira.

(b) Restructuring charges/(credits)––cost reduction initiatives relate to employee termination costs, asset impairments and other exit costs not associated with acquisitions. For the third quarter of 2019, the charges were mainly composed of employee termination costs, and for the first nine months of 2019, the charges were mostly related to employee termination costs and exit costs. For the third quarter and first nine months of 2018, the credits were mostly related to the reversal of previously recorded accruals for employee termination costs.

(c) For additional information, see Notes to Condensed Consolidated Financial Statements—*Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.*

(d) Comprises *Restructuring charges and certain acquisition-related* costs as well as costs associated with our cost-reduction/productivity initiatives included in *Cost of sales, Research and development expenses, Selling, informational and administrative expenses* and/or *Other (income)/deductions––net* as appropriate. For additional information, see Notes to Condensed Consolidated Financial Statements—*Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.*

#### 2017-2019 Initiatives and Organizing for Growth

During 2018, as we reviewed our business opportunities and challenges and the way in which we think about our business operations, we determined that at the start of our 2019 fiscal year, we would begin operating under our new commercial structure, which reorganized our operations into three businesses––Biopharma, a science-based innovative medicines business; Upjohn, a global, primarily off-patent branded and generic established medicines business; and through July 31, 2019, a Consumer Healthcare business. To operate effectively in this structure and position ourselves for future growth, we are focused on creating a simpler, more efficient operating structure within each business as well as the functions that support them. Beginning in the fourth quarter of 2018, we reviewed previously planned initiatives and new initiatives to ensure that there was alignment around our new structure and have combined the 2017-2019 initiatives with our current Organizing for Growth initiatives to form one cohesive plan. For the combined programs, to achieve targeted savings of approximately $2.0 billion, we expect to incur approximately $2.0 billion in costs over the three-year period 2017-2019, and approximately $500 million beyond 2019, primarily on manufacturing activities. Of the total $2.5 billion, we expect approximately 50% to be related to manufacturing operations, and we expect approximately 20% of the charges to be non-cash. We expect anticipated savings through 2020 associated with the Organizing for Growth initiatives of approximately $500 million will be reinvested in our R&D pipeline and in selling and marketing to support our current and recently launched products and indications. For additional information about these programs and expected and actual total costs, see Notes to Condensed Consolidated Financial Statements—*Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.*

In addition to these major initiatives, we continuously monitor our operations for cost reduction and/or productivity opportunities, especially in light of the losses of exclusivity and the expiration of collaborative arrangements for various products.

### Other (Income)/Deductions—Net

| (MILLIONS OF DOLLARS) | Three Months Ended September 29, 2019 | September 30, 2018 | % Change | Nine Months Ended September 29, 2019 | September 30, 2018 | % Change |
| --- | ---: | ---: | --- | ---: | ---: | --- |
| Other (income)/deductions––net | $319 | $(414) | \* | $537 | $(1,143) | \* |
| \* Calculation not meaningful or results are equal to or greater than 100%. |  |  |  |  |  |  |

For information about the components of *Other (income)/deductions—net*, see Notes to Condensed Consolidated Financial Statements—*Note 4. Other (Income)/Deductions—Net.*

See also the “Analysis of Operating Segment Information” section of this MD&A.

### Provision for Taxes on Income

| (MILLIONS OF DOLLARS) | Three Months Ended September 29, 2019 | September 30, 2018 | % Change | Nine Months Ended September 29, 2019 | September 30, 2018 | % Change |
| --- | ---: | ---: | --- | ---: | ---: | --- |
| Provision for taxes on income | $3,047 | $66 | \* | $2,566 | $1,270 | \* |
| Effective tax rate on continuing operations | 28.4% | 1.6% |  | 13.4% | 9.9% |  |
| \* Calculation not meaningful or results are equal to or greater than 100%. |  |  |  |  |  |  |

For information about our effective tax rate and the events and circumstances contributing to the changes between periods, see Notes to Condensed Consolidated Financial Statements—*Note 5. Tax Matters.*

### Non-GAAP Financial Measure (Adjusted Income)

### General Description of Non-GAAP Financial Measure (Adjusted Income)

Adjusted income is an alternative view of performance used by management. We measure the performance of the overall Company on this basis in conjunction with other performance metrics. Because Adjusted income is an important internal measurement for Pfizer, we believe that investors’ understanding of our performance is enhanced by disclosing this performance measure. We report Adjusted income, certain components of Adjusted income, and Adjusted diluted earnings per share in order to portray the results of our major operations––the discovery, development, manufacture, marketing and sale of prescription medicines and vaccines––prior to considering certain income statement elements. We have defined Adjusted income as *Net income attributable to Pfizer Inc.* before the impact of purchase accounting for acquisitions, acquisition-related costs, discontinued operations and certain significant items, which are described below. Also, see the “Non-GAAP Financial Measure (Adjusted Income)––General Description of Non-GAAP Financial Measure (Adjusted Income)” section of our 2018 Financial Report for additional information. Similarly, we have defined the Adjusted income components as *Cost of sales, Selling, informational and administrative expenses, Research and development expenses, Amortization of intangible assets* and *Other (income)/deductions––net* each before the impact of purchase accounting for acquisitions, acquisition-related costs and certain significant items. We have defined Adjusted diluted earnings per share as *Earnings per common share attributable to Pfizer Inc.––diluted* before the impact of purchase accounting for acquisitions, acquisition-related costs, discontinued operations and certain significant items. The Adjusted income measure, the Adjusted income component measures and the Adjusted diluted earnings per share measure are not, and should not be viewed as, substitutes for U.S. GAAP net income, U.S. GAAP net income components or U.S. GAAP diluted earnings per share.

The following are examples of how the Adjusted income and Adjusted diluted earnings per share measures are utilized:

- senior management receives a monthly analysis of our operating results that is prepared on an Adjusted income and Adjusted diluted earnings per share basis;
- our annual budgets are prepared on an Adjusted income and Adjusted diluted earnings per share basis; and
- senior management’s annual compensation is derived, in part, using Adjusted income and Adjusted diluted earnings per share measures.

See the “Non-GAAP Financial Measure (Adjusted Income)––General Description of Non-GAAP Financial Measure (Adjusted Income)” section of our 2018 Financial Report for additional information.

Adjusted income and its components and Adjusted diluted earnings per share are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, are limited in their usefulness to investors. Because of their non-standardized definitions, Adjusted income and its components (unlike U.S. GAAP net income and its components) and Adjusted diluted earnings per share (unlike U.S. GAAP diluted earnings per share) may not be comparable to the calculation of similar measures of other companies. Adjusted income and its components and Adjusted diluted earnings per share are presented solely to permit investors to more fully understand how management assesses performance.

We also recognize that, as internal measures of performance, the Adjusted income and its components and Adjusted diluted earnings per share measures have limitations, and we do not restrict our performance-management process solely to these metrics. A limitation of these measures is that they provide a view of our operations without including all events during a period, such as the effects of an acquisition or amortization of purchased intangibles, and do not provide a comparable view of our performance to other companies in the biopharmaceutical industry. We also use other specifically tailored tools designed to achieve the highest levels of performance. For example, our R&D organization has productivity targets, upon which its effectiveness is measured. In addition, total shareholder return, both on an absolute basis and relative to a publicly-traded pharmaceutical index, plays a significant role in determining payouts under certain of Pfizer’s long-term incentive compensation plans.

See the accompanying reconciliations of certain GAAP reported to non-GAAP adjusted information for the third quarter and first nine months of 2019 and 2018 below.

### Purchase Accounting Adjustments

Adjusted income is calculated prior to considering certain significant purchase accounting impacts resulting from business combinations and net asset acquisitions. These impacts, primarily associated with Wyeth (acquired in 2009), Hospira (acquired in 2015), Anacor (acquired in 2016), Medivation (acquired in 2016) and Array (acquired in 2019), can include the incremental charge to cost of sales from the sale of acquired inventory that was written up to fair value, amortization related to the increase in fair value of the acquired finite-lived intangible assets, and to a much lesser extent, depreciation related to the increase/decrease in fair value of the acquired fixed assets (primarily manufacturing facilities), amortization related to the increase in fair value of acquired debt, and the fair value changes associated with contingent consideration. Therefore, the Adjusted income measure includes the revenues earned upon the sale of the acquired products without considering the acquisition cost of those products.

### Acquisition-Related Costs

Adjusted income is calculated prior to considering transaction, integration, restructuring and additional depreciation costs associated with business combinations because these costs are unique to each transaction and represent costs that were incurred to restructure and integrate two businesses as a result of the acquisition decision. For additional clarity, only transaction costs, additional depreciation and restructuring and integration activities that are associated with a business combination or a net-asset acquisition are included in acquisition-related costs. We have made no adjustments for the resulting synergies.

### Discontinued Operations

Adjusted income is calculated prior to considering the results of operations included in discontinued operations, as well as any related gains or losses on the disposal of such operations.

### Certain Significant Items

Adjusted income is calculated prior to considering certain significant items. Certain significant items represent substantive and/or unusual items that are evaluated on an individual basis. Such evaluation considers both the quantitative and the qualitative aspects of their nature. Certain significant items may be highly variable and difficult to predict. Furthermore, in some cases it is reasonably possible that they could reoccur in future periods. For example, major non-acquisition-related cost-reduction programs stand on their own as they are specific to an event or goal with a defined term, but we may have subsequent programs based on reorganizations of the business, cost productivity or in response to loss of exclusivity or economic conditions. Legal charges to resolve litigation are also related to specific cases, which are facts and circumstances specific and, in some cases, may also be the result of litigation matters at acquired companies that were inestimable, not probable or unresolved at the date of acquisition. Unusual items may represent items that are not part of our ongoing business; items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis; items that would be non-recurring; or items that relate to products we no longer sell. While not all-inclusive, examples of items that could be included as certain significant items would be gains on the completion of joint venture transactions such as the gain on the completion of the Consumer Healthcare joint venture transaction discussed in Notes to Condensed Consolidated Financial Statements—*Note 2B. Acquisitions, Equity-Method Investment and Assets and Liabilities Held for Sale and Research and Development Arrangement: Equity-Method Investment and Assets and Liabilities Held for Sale*, a major non-acquisition-related restructuring charge and associated implementation costs; amounts related to certain disposals of businesses, products or facilities that do not qualify as discontinued operations under U.S. GAAP; certain intangible asset impairments; adjustments related to the resolution of certain tax positions; the impact of adopting certain significant, event-driven tax legislation, such as the TCJA discussed in Notes to Condensed Consolidated Financial Statements—*Note 5A. Tax Matters: Taxes on Income from Continuing Operations;* or charges related to certain legal matters, such as certain of those discussed in Notes to Condensed Consolidated Financial Statements—*Note 12A. Contingencies and Certain Commitments: Legal Proceedings,* included in Part I, Item 1 of this Quarterly Report on Form 10-Q. Normal, ongoing defense costs of the Company or settlements of and accruals for legal matters made in the normal course of our business would not be considered certain significant items.

Beginning in 2019, we exclude the net gains and losses on investments in equity securities from our measure of Adjusted income because of their inherent volatility, which we do not control and cannot predict with any level of certainty and because we do not believe that including these gains and losses assists investors in understanding our business or is reflective of our core operations and business. We have revised Adjusted income and Adjusted diluted EPS for the third quarter and first nine months of 2018 to conform with our 2019 presentation.

### Reconciliations of GAAP Reported to Non-GAAP Adjusted Information––Certain Line Items

*IN MILLIONS, EXCEPT PER COMMON SHARE DATA*

|  | Three Months Ended September 29, 2019 GAAP Reported | Purchase Accounting Adjustments(a) | Acquisition-Related Items(a) | Discontinued Operations(a) | Certain Significant Items(a) | Non-GAAP Adjusted |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenues | **$12,680** | $— | $— | $— | $— | $12,680 |
| Cost of sales | **2,602** | 4 | — | — | (147) | 2,459 |
| Selling, informational and administrative expenses | **3,260** | 1 | — | — | (64) | 3,196 |
| Research and development expenses | **2,283** | 1 | — | — | (343) | 1,940 |
| Amortization of intangible assets | **1,212** | (1,140) | — | — | — | 72 |
| Restructuring charges and certain acquisition-related costs | **365** | — | (300) | — | (64) | — |
| (Gain) on completion of Consumer Healthcare JV transaction | **(8,087)** | — | — | — | 8,087 | — |
| Other (income)/deductions––net | **319** | (6) | — | — | (281) | 32 |
| Income from continuing operations before provision for taxes on income | **10,727** | 1,141 | 300 | — | (7,187) | 4,981 |
| Provision for taxes on income(b) | **3,047** | 239 | 58 | — | (2,581) | 763 |
| Income from continuing operations | **7,680** | 902 | 242 | — | (4,606) | 4,218 |
| Discontinued operations––net of tax | **4** | — | — | (4) | — | — |
| Net income attributable to noncontrolling interests | **4** | — | — | — | — | 4 |
| Net income attributable to Pfizer Inc. | **7,680** | 902 | 242 | (4) | (4,606) | 4,214 |
| Earnings per common share attributable to Pfizer Inc.––diluted | **1.36** | 0.16 | 0.04 | — | (0.82) | 0.75 |

See end of tables for notes (a) and (b).

*IN MILLIONS, EXCEPT PER COMMON SHARE DATA*

|  | Nine Months Ended September 29, 2019 GAAP Reported | Purchase Accounting Adjustments(a) | Acquisition-Related Items(a) | Discontinued Operations(a) | Certain Significant Items(a) | Non-GAAP Adjusted |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenues | **$39,062** | $— | $— | $— | $— | $39,062 |
| Cost of sales | **7,611** | 15 | — | — | (196) | 7,430 |
| Selling, informational and administrative expenses | **10,110** | 2 | (2) | — | (139) | 9,971 |
| Research and development expenses | **5,827** | 3 | — | — | (372) | 5,458 |
| Amortization of intangible assets | **3,578** | (3,377) | — | — | — | 201 |
| Restructuring charges and certain acquisition-related costs | **295** | — | (150) | — | (145) | — |
| (Gain) on completion of Consumer Healthcare JV transaction | **(8,087)** | — | — | — | 8,087 | — |
| Other (income)/deductions––net | **537** | — | — | — | (740) | (203) |
| Income from continuing operations before provision for taxes on income | **19,190** | 3,357 | 152 | — | (6,495) | 16,204 |
| Provision for taxes on income(b) | **2,566** | 685 | 69 | — | (759) | 2,560 |
| Income from continuing operations | **16,625** | 2,673 | 83 | — | (5,737) | 13,644 |
| Discontinued operations––net of tax | **4** | — | — | (4) | — | — |
| Net income attributable to noncontrolling interests | **19** | — | — | — | — | 19 |
| Net income attributable to Pfizer Inc. | **16,609** | 2,673 | 83 | (4) | (5,737) | 13,625 |
| Earnings per common share attributable to Pfizer Inc.––diluted | **2.92** | 0.47 | 0.01 | — | (1.01) | 2.39 |

*IN MILLIONS, EXCEPT PER COMMON SHARE DATA*

|  | Three Months Ended September 30, 2018 GAAP Reported | Purchase Accounting Adjustments(a) | Acquisition-Related Items(a) | Discontinued Operations(a) | Certain Significant Items(a) | Non-GAAP Adjusted |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenues | **$13,298** | $— | $— | $— | $— | $13,298 |
| Cost of sales | **2,694** | 1 | (3) | — | (19) | 2,673 |
| Selling, informational and administrative expenses | **3,494** | — | — | — | (23) | 3,471 |
| Research and development expenses | **2,008** | 1 | — | — | (11) | 1,998 |
| Amortization of intangible assets | **1,253** | (1,182) | — | — | — | 71 |
| Restructuring charges and certain acquisition-related costs | **85** | — | (107) | — | 22 | — |
| (Gain) on completion of Consumer Healthcare JV transaction | **—** | — | — | — | — | — |
| Other (income)/deductions––net | **(414)** | (130) | (2) | — | 329 | (217) |
| Income from continuing operations before provision for taxes on income | **4,177** | 1,309 | 112 | — | (298) | 5,300 |
| Provision for taxes on income(b) | **66** | 263 | 21 | — | 363 | 712 |
| Income from continuing operations | **4,111** | 1,047 | 91 | — | (661) | 4,588 |
| Discontinued operations––net of tax | **11** | — | — | (11) | — | — |
| Net income attributable to noncontrolling interests | **8** | — | — | — | — | 8 |
| Net income attributable to Pfizer Inc. | **4,114** | 1,047 | 91 | (11) | (661) | 4,580 |
| Earnings per common share attributable to Pfizer Inc.––diluted | **0.69** | 0.17 | 0.02 | — | (0.11) | 0.77 |

91

*IN MILLIONS, EXCEPT PER COMMON SHARE DATA*

|  | Nine Months Ended September 30, 2018 GAAP Reported | Purchase Accounting Adjustments(a) | Acquisition-Related Items(a) | Discontinued Operations(a) | Certain Significant Items(a) | Non-GAAP Adjusted |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenues | **$39,670** | $— | $— | $— | $— | $39,670 |
| Cost of sales | **8,173** | (2) | (9) | — | (77) | 8,086 |
| Selling, informational and administrative expenses | **10,448** | 1 | — | — | (185) | 10,264 |
| Research and development expenses | **5,549** | 3 | — | — | (26) | 5,526 |
| Amortization of intangible assets | **3,640** | (3,428) | — | — | — | 212 |
| Restructuring charges and certain acquisition-related costs | **172** | — | (209) | — | 37 | — |
| (Gain) on completion of Consumer Healthcare JV transaction | **—** | — | — | — | — | — |
| Other (income)/deductions––net | **(1,143)** | (238) | (4) | — | 702 | (683) |
| Income from continuing operations before provision for taxes on income | **12,831** | 3,665 | 221 | — | (452) | 16,265 |
| Provision for taxes on income(b) | **1,270** | 735 | 40 | — | 468 | 2,513 |
| Income from continuing operations | **11,562** | 2,930 | 182 | — | (921) | 13,752 |
| Discontinued operations––net of tax | **10** | — | — | (10) | — | — |
| Net income attributable to noncontrolling interests | **25** | — | — | — | — | 25 |
| Net income attributable to Pfizer Inc. | **11,546** | 2,930 | 182 | (10) | (921) | 13,727 |
| Earnings per common share attributable to Pfizer Inc.––diluted | **1.92** | 0.49 | 0.03 | — | (0.15) | 2.29 |

(a) For details of adjustments, see “Details of Income Statement Items Included in GAAP Reported but Excluded from Non-GAAP Adjusted Income” below.

(b) The effective tax rate on Non-GAAP Adjusted income was 15.3% in the third quarter of 2019, compared to 13.4% in the third quarter of 2018. The increase was primarily due to a decrease in tax benefits associated with the resolution of certain tax positions pertaining to prior years primarily with foreign tax authorities. The effective tax rate on Non-GAAP Adjusted income was 15.8% in the first nine months of 2019, compared to 15.4% in the first nine months of 2018. The increase was primarily due to a decrease in tax benefits associated with the resolution of certain tax positions pertaining to prior years primarily with foreign tax authorities, partially offset by the favorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business.

#### Details of Income Statement Items Included in GAAP Reported but Excluded from Non-GAAP Adjusted Income

| (MILLIONS OF DOLLARS) Purchase accounting adjustments | Three Months Ended September 29, 2019 | September 30, 2018 | Nine Months Ended September 29, 2019 | September 30, 2018 |
| --- | ---: | ---: | ---: | ---: |
| Amortization, depreciation and other(a) | $1,145 | $1,310 | $3,372 | $3,662 |
| Cost of sales | (4) | (1) | (15) | 2 |
| Total purchase accounting adjustments––pre-tax | 1,141 | 1,309 | 3,357 | 3,665 |
| Income taxes(b) | (239) | (263) | (685) | (735) |
| Total purchase accounting adjustments––net of tax | 902 | 1,047 | 2,673 | 2,930 |
| Acquisition-related items |  |  |  |  |
| Restructuring charges/(credits)(c) | 19 | 24 | (196) | 5 |
| Transaction costs(c) | 65 | 1 | 65 | 1 |
| Integration costs and other(c) | 217 | 82 | 281 | 202 |
| Net periodic benefit costs other than service costs | — | 2 | — | 4 |
| Additional depreciation––asset restructuring(d) | — | 3 | 2 | 9 |
| Total acquisition-related items––pre-tax | 300 | 112 | 152 | 221 |
| Income taxes(e) | (58) | (21) | (69) | (40) |
| Total acquisition-related items––net of tax | 242 | 91 | 83 | 182 |
| Discontinued operations |  |  |  |  |
| Total discontinued operations––net of tax, attributable to Pfizer Inc.(f) | (4) | (11) | (4) | (10) |
| Certain significant items |  |  |  |  |
| Restructuring charges/(credits)––cost reduction initiatives(g) | 64 | (22) | 145 | (37) |
| Implementation costs and additional depreciation––asset restructuring(h) | 46 | 57 | 135 | 164 |
| Certain legal matters, net(i) | 63 | 37 | 72 | (70) |
| Certain asset impairments(i) | — | — | 149 | 31 |
| Business and legal entity alignment costs(i) | 89 | 1 | 353 | 5 |
| Net gains recognized during the period on investments in equity securities(i) | (3) | (85) | (139) | (460) |
| (Gain) on completion of Consumer Healthcare JV transaction(j) | (8,087) | — | (8,087) | — |
| Net losses on early retirement of debt(i) | — | — | 138 | 3 |
| Other(k) | 641 | (286) | 738 | (89) |
| Total certain significant items––pre-tax | (7,187) | (298) | (6,495) | (452) |
| Income taxes(l) | 2,581 | (363) | 759 | (468) |
| Total certain significant items––net of tax | (4,606) | (661) | (5,737) | (921) |
| Total purchase accounting adjustments, acquisition-related items, discontinued operations and certain significant items––net of tax, attributable to Pfizer Inc. | $(3,466) | $466 | $(2,984) | $2,181 |

(a) Included primarily in *Amortization of intangible assets.*

(b) Included in *Provision for taxes on income.* Income taxes includes the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction’s applicable tax rate.

(c) Included in *Restructuring charges and certain acquisition-related costs.* Restructuring charges/(credits) includes employee termination costs, asset impairments and other exit costs associated with business combinations. Transaction costs represent external costs for banking, legal, accounting and other similar services. Integration costs and other represent external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. For additional information, see the “Costs and Expenses—Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives” section of this MD&A and Notes to Condensed Consolidated Financial Statements—*Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.*

(d) Included in *Selling, informational and administrative expenses* for the nine months ended September 29, 2019 and in *Cost of sales* for the three and nine months ended September 30, 2018. Represents the impact of changes in estimated useful lives of assets involved in restructuring actions related to acquisitions.

(e) Included in *Provision for taxes on income*. Income taxes includes the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction’s applicable tax rate. The first nine months of 2019 include the impact of the non-taxable reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of a U.S. IRS audit for multiple tax years.

(f) Included in *Discontinued operations––net of tax.*

(g) Amounts relate to employee termination costs, asset impairments and other exit costs not associated with acquisitions, which are included in *Restructuring charges and certain acquisition-related costs* (see the “Costs and Expenses—Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives” section of this MD&A and Notes to Condensed Consolidated Financial Statements—*Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives).*

(h) Amounts relate to our cost-reduction/productivity initiatives not related to acquisitions (see Notes to Condensed Consolidated Financial Statements—*Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives*). For the three months ended September 29, 2019, included in *Cost of sales (*$20 million), *Selling, informational and administrative expenses (*$23 million) and *Research and development expenses (*$3 million). For the nine months ended September 29, 2019, included in *Cost of sales (*$65 million), *Selling, informational and administrative expenses (*$48 million) and *Research and development expenses (*$21 million). For the three months ended September 30, 2018, included in *Cost of sales (*$30 million), *Selling, informational and administrative expenses (*$17 million) and *Research and development expenses (*$9 million). For the nine months ended September 30, 2018, included in *Cost of sales (*$91 million), *Selling, informational and administrative expenses (*$51 million) and *Research and development expenses (*$22 million).

(i) Included in *Other (income)/deductions—net* except for business and legal entity alignment costs that are primarily included in *Other (income)/deductions—net* (see Notes to Condensed Consolidated Financial Statements—*Note 4. Other (Income)/Deductions—Net).*

(j) Included in *(Gain) on completion of Consumer Healthcare JV transaction* (see notes to Condensed Consolidated Financial Statements––*Note 2B. Acquisitions, Equity-Method Investment and Assets and Liabilities Held for Sale and Research and Development Arrangement: Equity-Method Investment and Assets and Liabilities Held for Sale).*

(k) For the three months ended September 29, 2019, included in *Cost of sales (*$128 million), *Selling, informational and administrative expenses (*$39 million), *Research and development expenses (*$340 million) and *Other (income)/deductions––net (*$134 million). For the nine months ended September 29, 2019, included in *Cost of sales (*$130 million), *Selling, informational and administrative expenses (*$80 million), *Research and development expenses (*$351 million) and *Other (income)/deductions––net (*$178 million). For the three months ended September 30, 2018, included in *Cost of sales (*$12 million income), *Selling, informational and administrative expenses (*$6 million), *Research and development expenses (*$2 million) and *Other (income)/deductions––net (*$282 million income). For the nine months ended September 30, 2018, included in *Cost of sales (*$14 million income), *Selling, informational and administrative expenses (*$134 million), *Research and development expenses (*$3 million), and *Other (income)/deductions––net (*$212 million income). The third quarter and first nine months of 2019 include, among other things, (i) a $337 million charge in *Research and development expenses* related to our acquisition of Therachon and (ii) a $127 million charge for rivipansel in *Cost of sales,* primarily for inventory manufactured for expected future sale. In addition, the third quarter of 2019 includes charges of $161 million and the first nine months of 2019 include charges of $223 million, primarily in *Other (income)/deductions––net* and *Selling, informational and administrative expenses*, for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity associated with the formation of the GSK Consumer Healthcare joint venture. The third quarter and first nine months of 2018 include, among other things, a non-cash $343 million pre-tax gain in *Other (income)/deductions––net* associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and pre-clinical stage neuroscience assets primarily targeting disorders of the central nervous system. The first nine months of 2018 also includes (i) a $119 million charge, in the aggregate, in *Selling, informational and administrative expenses* for a special, one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the legislation commonly referred to as the TCJA and (ii) a non-cash $50 million pre-tax gain in *Other (income)/deductions––net* as a result of the contribution of our allogeneic chimeric antigen receptor T cell therapy development program assets in connection with our asset contribution agreement entered into with Allogene.

(l) Included in *Provision for taxes on income*. Income taxes includes the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction’s applicable tax rate. The third quarter and first nine months of 2019 were impacted by the tax expense associated with the gain related to the completion of the Consumer Healthcare joint venture transaction with GSK. The first nine months of 2019 were favorably impacted by a benefit of $1.4 billion, representing tax and interest, resulting from the favorable settlement of a U.S. IRS audit for multiple tax years, as well as the tax benefit recorded as a result of additional guidance issued by the U.S. Department of Treasury related to the TCJA. The third quarter and nine months ended September 30, 2018 were favorably impacted by the December 2017 enactment of the TCJA, primarily related to certain tax initiatives, as well as favorable adjustments to the provisional estimate of the impact of the legislation.

### Analysis of Operating Segment Information

The following tables and associated notes provide additional information about the performance of each of our two reportable operating segments—Biopharma and Upjohn and our Consumer Healthcare operating segment through July 31, 2019. For additional information about each operating segment, see the “Overview of Our Performance, Operating Environment, Strategy and Outlook—Our Strategy—Organizing for Growth” and “—Commercial Operations” sections of this MD&A and Notes to Condensed Consolidated Financial Statements—*Note 13. Segment, Geographic and Other Revenue Information.*

Acquisitions and the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture have impacted our results of operations in 2019. For additional information, see Notes to Condensed Consolidated Financial Statements—*Note 1A. Basis of Presentation and Significant Accounting Policies: Basis of Presentation.*

*The following tables provide revenue and cost information by reportable operating segment and a reconciliation of that information to our condensed consolidated statements of income:*

| (MILLIONS OF DOLLARS) | Third Quarter of 2019 Biopharma(a) | Upjohn(a) | Other(b) | Non-GAAP Adjusted(c) | Reconciling Items(d) | GAAP Reported |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenues | $10,108 | $2,195 | $377 | $12,680 | $— | **$12,680** |
| Cost of sales | 1,869 | 425 | 164 | 2,459 | 143 | **2,602** |
| % of revenue | 18.5% | 19.4% | \* | 19.4% | \* | **20.5%** |
| Selling, informational and administrative expenses | 1,602 | 360 | 1,234 | 3,196 | 64 | **3,260** |
| Research and development expenses | 256 | 57 | 1,628 | 1,940 | 343 | **2,283** |
| Amortization of intangible assets | 71 | — | — | 72 | 1,140 | **1,212** |
| Restructuring charges and certain acquisition-related costs | — | — | — | — | 365 | **365** |
| (Gain) on completion of Consumer Healthcare JV transaction | — | — | — | — | (8,087) | **(8,087)** |
| Other (income)/deductions––net | (193) | — | 226 | 32 | 287 | **319** |
| Income/(loss) from continuing operations before provision for taxes on income | 6,503 | 1,353 | (2,874) | 4,981 | 5,746 | **10,727** |

See end of tables for notes (a) through (d).

| (MILLIONS OF DOLLARS) | Nine Months Ended September 29, 2019 Biopharma(a) | Upjohn(a) | Other(b) | Non-GAAP Adjusted(c) | Reconciling Items(d) | GAAP Reported |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenues | $28,887 | $8,077 | $2,098 | $39,062 | $— | **$39,062** |
| Cost of sales | 5,488 | 1,268 | 674 | 7,430 | 181 | **7,611** |
| % of revenue | 19.0% | 15.7% | \* | 19.0% | \* | **19.5%** |
| Selling, informational and administrative expenses | 4,821 | 1,064 | 4,087 | 9,971 | 139 | **10,110** |
| Research and development expenses | 623 | 169 | 4,667 | 5,458 | 369 | **5,827** |
| Amortization of intangible assets | 201 | 1 | — | 201 | 3,377 | **3,578** |
| Restructuring charges and certain acquisition-related costs | — | — | — | — | 295 | **295** |
| (Gain) on completion of Consumer Healthcare JV transaction | — | — | — | — | (8,087) | **(8,087)** |
| Other (income)/deductions––net | (729) | (2) | 528 | (203) | 740 | **537** |
| Income/(loss) from continuing operations before provision for taxes on income | 18,484 | 5,577 | (7,857) | 16,204 | 2,986 | **19,190** |

| (MILLIONS OF DOLLARS) | Third Quarter of 2018 Biopharma(a) | Upjohn(a) | Other(b) | Non-GAAP Adjusted(c) | Reconciling Items(d) | GAAP Reported |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenues | $9,422 | $3,036 | $839 | $13,298 | $— | **$13,298** |
| Cost of sales | 1,673 | 476 | 524 | 2,673 | 21 | **2,694** |
| % of revenue | 17.8% | 15.7% | \* | 20.1% | \* | **20.3%** |
| Selling, informational and administrative expenses | 1,626 | 439 | 1,406 | 3,471 | 23 | **3,494** |
| Research and development expenses | 215 | 67 | 1,717 | 1,998 | 10 | **2,008** |
| Amortization of intangible assets | 66 | — | 5 | 71 | 1,182 | **1,253** |
| Restructuring charges and certain acquisition-related costs | — | — | — | — | 85 | **85** |
| (Gain) on completion of Consumer Healthcare JV transaction | — | — | — | — | — | **—** |
| Other (income)/deductions––net | (364) | 3 | 144 | (217) | (197) | **(414)** |
| Income/(loss) from continuing operations before provision for taxes on income | 6,206 | 2,051 | (2,956) | 5,300 | (1,123) | **4,177** |

95

| (MILLIONS OF DOLLARS) | Nine Months Ended September 30, 2018 Biopharma(a) | Upjohn(a) | Other(b) | Non-GAAP Adjusted(c) | Reconciling Items(d) | GAAP Reported |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenues | $27,737 | $9,302 | $2,631 | $39,670 | $— | **$39,670** |
| Cost of sales | 5,242 | 1,453 | 1,391 | 8,086 | 87 | **8,173** |
| % of revenue | 18.9% | 15.6% | \* | 20.4% | \* | **20.6%** |
| Selling, informational and administrative expenses | 4,765 | 1,239 | 4,261 | 10,264 | 183 | **10,448** |
| Research and development expenses | 583 | 173 | 4,770 | 5,526 | 23 | **5,549** |
| Amortization of intangible assets | 177 | — | 34 | 212 | 3,428 | **3,640** |
| Restructuring charges and certain acquisition-related costs | — | — | — | — | 172 | **172** |
| (Gain) on completion of Consumer Healthcare JV transaction | — | — | — | — | — | **—** |
| Other (income)/deductions––net | (1,016) | (4) | 337 | (683) | (460) | **(1,143)** |
| Income/(loss) from continuing operations before provision for taxes on income | 17,987 | 6,442 | (8,163) | 16,265 | (3,434) | **12,831** |

\* Indicates calculation not meaningful or result is equal to or greater than 100%.

(a) Amounts represent the revenues and costs managed by each of the Biopharma and Upjohn reportable operating segments for the periods presented. The expenses generally include only those costs directly attributable to the operating segment.

(b) Other comprises the revenues and costs included in our Adjusted income components (see footnote (c) below) that are managed outside Biopharma and Upjohn and includes the following:

| (MILLIONS OF DOLLARS) | Third Quarter of 2019 Other Business Activities WRDM(i) | GPD(ii) | Other(iii) | Corporate and Other Unallocated(iv) | Total |
| --- | ---: | ---: | ---: | ---: | ---: |
| Revenues | $— | $— | $377 | $— | $377 |
| Cost of sales | — | — | 113 | 51 | 164 |
| Selling, informational and administrative expenses | 34 | — | 263 | 936 | 1,234 |
| Research and development expenses | 582 | 816 | 19 | 210 | 1,628 |
| Amortization of intangible assets | — | — | — | — | — |
| Restructuring charges and certain acquisition-related costs | — | — | — | — | — |
| (Gain) on completion of Consumer Healthcare JV transaction | — | — | — | — | — |
| Other (income)/deductions––net | (9) | 1 | — | 234 | 226 |
| Income/(loss) from continuing operations before provision for taxes on income | (608) | (817) | (19) | (1,431) | (2,874) |

| (MILLIONS OF DOLLARS) | Nine Months Ended September 29, 2019 Other Business Activities WRDM(i) | GPD(ii) | Other(iii) | Corporate and Other Unallocated(iv) | Total |
| --- | ---: | ---: | ---: | ---: | ---: |
| Revenues | $— | $— | $2,098 | $— | $2,098 |
| Cost of sales | — | 1 | 663 | 9 | 674 |
| Selling, informational and administrative expenses | 84 | — | 1,058 | 2,944 | 4,087 |
| Research and development expenses | 1,662 | 2,306 | 82 | 617 | 4,667 |
| Amortization of intangible assets | — | — | — | — | — |
| Restructuring charges and certain acquisition-related costs | — | — | — | — | — |
| (Gain) on completion of Consumer Healthcare JV transaction | — | — | — | — | — |
| Other (income)/deductions––net | (11) | — | — | 538 | 528 |
| Income/(loss) from continuing operations before provision for taxes on income | (1,736) | (2,308) | 294 | (4,108) | (7,857) |

96

| (MILLIONS OF DOLLARS) | Third Quarter of 2018 Other Business Activities WRDM(i) | GPD(ii) | Other(iii) | Corporate and Other Unallocated(iv) | Total |
| --- | ---: | ---: | ---: | ---: | ---: |
| Revenues | $— | $— | $839 | $— | $839 |
| Cost of sales | — | 3 | 281 | 240 | 524 |
| Selling, informational and administrative expenses | 35 | — | 416 | 955 | 1,406 |
| Research and development expenses | 546 | 806 | 42 | 323 | 1,717 |
| Amortization of intangible assets | — | — | 11 | (6) | 5 |
| Restructuring charges and certain acquisition-related costs | — | — | — | — | — |
| (Gain) on completion of Consumer Healthcare JV transaction | — | — | — | — | — |
| Other (income)/deductions––net | (3) | (8) | 9 | 146 | 144 |
| Income/(loss) from continuing operations before provision for taxes on income | (578) | (801) | 80 | (1,658) | (2,956) |

| (MILLIONS OF DOLLARS) | Nine Months Ended September 30, 2018 Other Business Activities WRDM(i) | GPD(ii) | Other(iii) | Corporate and Other Unallocated(iv) | Total |
| --- | ---: | ---: | ---: | ---: | ---: |
| Revenues | $— | $— | $2,631 | $— | $2,631 |
| Cost of sales | — | — | 870 | 521 | 1,391 |
| Selling, informational and administrative expenses | 98 | — | 1,250 | 2,913 | 4,261 |
| Research and development expenses | 1,644 | 2,318 | 130 | 678 | 4,770 |
| Amortization of intangible assets | — | — | 34 | — | 34 |
| Restructuring charges and certain acquisition-related costs | — | — | — | — | — |
| (Gain) on completion of Consumer Healthcare JV transaction | — | — | — | — | — |
| Other (income)/deductions––net | (107) | (10) | 8 | 446 | 337 |
| Income/(loss) from continuing operations before provision for taxes on income | (1,636) | (2,308) | 339 | (4,558) | (8,163) |

(i) WRDM—the R&D and Medical expenses managed by our WRDM organization, which is generally responsible for research projects for our Biopharma portfolio until proof-of-concept is achieved and then for transitioning those projects to the GPD organization for possible clinical and commercial development. R&D spending may include upfront and milestone payments for intellectual property rights. The WRDM organization also has responsibility for certain science-based and other platform-services organizations, which provide end-to-end technical expertise and other services to the various R&D projects, as well as the Worldwide Medical and Safety group, which ensures that Pfizer provides all stakeholders––including patients, healthcare providers, pharmacists, payers and health authorities––with complete and up-to-date information on the risks and benefits associated with Pfizer products so that they can make appropriate decisions on how and when to use Pfizer’s medicines.

(ii) GPD––the costs associated with our GPD organization, which is generally responsible for clinical trials from WRDM in the Biopharma portfolio, including late stage portfolio spend. GPD also provides technical support and other services to Pfizer R&D projects. GPD is responsible for facilitating all regulatory submissions and interactions with regulatory agencies.

(iii) Other—the operating results of our Consumer Healthcare business, through July 31, 2019, and costs associated with other commercial activities not managed as part of Biopharma or Upjohn, including all strategy, business development, portfolio management and valuation capabilities, which previously had been reported in various parts of the organization.

(iv) Corporate and Other Unallocated––the costs associated with platform functions (such as worldwide technology, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance and worldwide procurement), patient advocacy activities and certain compensation and other corporate costs, such as interest income and expense, and gains and losses on investments, as well as overhead expenses associated with our manufacturing (which include manufacturing variances associated with production) and commercial operations that are not directly assessed to an operating segment, as business unit (segment) management does not manage these costs.

We recognized the following amounts in *Cost of sales* related to forward-exchange contracts designated as cash flow hedges of a portion of our foreign exchange-denominated forecasted intercompany inventory sales:

- a $66 million gain in the third quarter of 2019;
- a $169 million gain in the first nine months of 2019;
- a $14 million gain in the third quarter of 2018; and
- a $47 million loss in the first nine months of 2018.

For additional information, see Notes to Condensed Consolidated Financial Statements––*Note 7E. Financial Instruments: Derivative Financial Instruments and Hedging Activities.*

For information purposes only, the following tables present reconciliations of the Biopharma segment operating results and Upjohn segment operating results to Biopharma and Upjohn operating results including estimated Other costs generally associated with the Biopharma and Upjohn operating segments. While we do not manage our segments or have performance goals under such an allocated manner, we believe that some investors may find this information useful in their analyses.

The estimated Other costs generally associated with our operating segments do not purport to reflect the additional amounts that each of our operating segments would have incurred had each segment operated as a standalone company during the periods presented.

For information purposes only, for the first nine months of 2019, we estimate that Other costs attributable to our Biopharma and Upjohn segments, as described above, for combined WRDM, GPD and other business activities costs are $4.4 billion, and combined Corporate and Other Unallocated costs are $3.2 billion, which excludes income and costs associated with our Consumer Healthcare business. The combined Corporate and Other Unallocated costs also exclude (i) net interest-related expense not attributable to an operating segment included in Corporate (approximately $987 million for the first nine months of 2019 in *Other (income)/deductions––net*); and (ii) net income from investments and other assets not attributable to an operating segment included in Corporate (approximately $127 million for the first nine months of 2019 in *Other (income)/deductions––net*). The remaining costs have been attributed to our Biopharma and Upjohn operating segments, as follows:

| (MILLIONS OF DOLLARS) | Nine Months Ended September 29, 2019 Biopharma Non-GAAP Adjusted(i), (iii) | Estimated Other Costs Associated with Biopharma(ii) Estimated WRDM/ GPD/Other Business Activities(ii) | Estimated Corporate/Other Unallocated(ii) | Biopharma with Estimated Other Costs Associated with Biopharma Non-GAAP Adjusted(ii), (iii) |
| --- | ---: | ---: | ---: | ---: |
| Revenues | $28,887 | $— | $— | $28,887 |
| Cost of sales | 5,488 | 1 | 6 | 5,495 |
| Selling, informational and administrative expenses | 4,821 | 400 | 2,183 | 7,403 |
| Research and development expenses | 623 | 3,977 | 582 | 5,182 |
| Amortization of intangible assets | 201 | — | — | 201 |
| Restructuring charges and certain acquisition-related costs | — | — | — | — |
| (Gain) on completion of Consumer Healthcare JV transaction | — | — | — | — |
| Other (income)/deductions––net | (729) | (9) | (255) | (992) |
| Income/(loss) from continuing operations before provision for taxes on income | 18,484 | (4,369) | (2,517) | 11,598 |

| (MILLIONS OF DOLLARS) | Nine Months Ended September 29, 2019 Upjohn Non-GAAP Adjusted(i), (iii) | Estimated Other Costs Associated with Upjohn(ii) Estimated WRDM/ GPD/Other Business Activities(ii) | Estimated Corporate/Other Unallocated(ii) | Upjohn with Estimated Other Costs Associated with Upjohn Non-GAAP Adjusted(ii), (iii) |
| --- | ---: | ---: | ---: | ---: |
| Revenues | $8,077 | $— | $— | $8,077 |
| Cost of sales | 1,268 | — | (19) | 1,249 |
| Selling, informational and administrative expenses | 1,064 | 24 | 599 | 1,687 |
| Research and development expenses | 169 | 1 | 20 | 190 |
| Amortization of intangible assets | 1 | — | — | 1 |
| Restructuring charges and certain acquisition-related costs | — | — | — | — |
| (Gain) on completion of Consumer Healthcare JV transaction | — | — | — | — |
| Other (income)/deductions––net | (2) | — | (44) | (46) |
| Income/(loss) from continuing operations before provision for taxes on income | 5,577 | (25) | (556) | 4,996 |

(i) Amount represents the revenues and costs managed by the operating segments. The expenses generally include only those costs directly attributable to the operating segment. See note (a) above for more information.

(ii) Represents costs not assessed to an operating segment, as business unit (segment) management does not manage these costs. For a description of these other costs and business activities, see note (b) above.

- WRDM/GPD/Other Business Activities––The information provided for WRDM, GPD and Other Business Activities was substantially all derived from our estimates of the costs incurred in connection with the R&D projects associated with the Biopharma and Upjohn operating segments as well as specific identification and estimates of costs incurred in connection with activities associated with the Biopharma and Upjohn operating segments.
- Corporate/Other Unallocated––The information provided for Corporate and Other Unallocated was derived mainly using proportional allocation methods based on global, regional or country revenues or global, regional or country headcount, as well as certain cost metrics, as appropriate, such as those derived from research and development and manufacturing costs, and, to a lesser extent, specific identification and estimates. Management believes that the allocations of Corporate and Other Unallocated costs are reasonable.

The estimated Other costs generally associated with our Biopharma and Upjohn operating segments do not purport to reflect the additional amounts that each of the operating segments would have incurred had each segment operated as a standalone company during the period presented.

(iii) See note (c) below for an explanation of our Non-GAAP Adjusted financial measure.

(c) See the “Non-GAAP Financial Measure (Adjusted Income)” section of this MD&A for a definition of these “Adjusted Income” components.

(d) Includes costs associated with (i) purchase accounting adjustments; (ii) acquisition-related costs; and (iii) certain significant items, which are substantive and/or unusual, and in some cases recurring, items (such as gains on the completion of joint venture transactions, restructuring charges, legal charges or net gains and losses on investment in equity securities), that are evaluated on an individual basis by management. For additional information about these reconciling items and/or our Non-GAAP adjusted measure of performance, see the “Non-GAAP Financial Measure (Adjusted Income)” section of this MD&A.

### Third Quarter of 2019 vs. Third Quarter of 2018

### Biopharma Operating Segment

#### Revenues

Biopharma *Revenues* increased $686 million, or 7%, to $10.1 billion, reflecting an operational increase of $852 million, or 9%, partially offset by the unfavorable impact of foreign exchange of $166 million, or 2%.

The following provides an analysis of the increase in Biopharma worldwide *Revenues:*

| (MILLIONS OF DOLLARS) |  |
| --- | ---: |
| Biopharma Revenues, for the three months ended September 30, 2018 | $9,422 |
| Operational growth/(decline): |  |
| Continued worldwide growth from certain key brands(a) | 621 |
| Higher revenues for the Hospital products business, primarily driven by continued growth from anti-infective products in China as well as the November 2018 U.S. launch of Panzyga | 112 |
| Higher revenues for rare disease products driven by Vyndaqel following the U.S. launch in May 2019 for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM); and in international markets, primarily driven by continued uptake for the transthyretin amyloid polyneuropathy indication, primarily in developed Europe, as well as the March 2019 launch of the ATTR-CM indication in Japan, partially offset by lower revenues for the hemophilia franchises (Refacto AF/Xyntha and BeneFIX), primarily due to competitive pressures, and Genotropin in developed markets, mainly due to unfavorable channel mix in the U.S. | 86 |
| Higher revenues for Inlyta, primarily in the U.S. driven by increased demand resulting from the second quarter of 2019 U.S. FDA approvals for the combinations of certain checkpoint inhibitors plus Inlyta for the first-line treatment of patients with advanced RCC, partially offset by the decline in other developed markets due to increased competition | 70 |
| Growth from Biosimilars, primarily in the U.S. | 44 |
| Lower revenues for Enbrel internationally, reflecting continued biosimilar competition in most developed Europe markets | (99) |
| Lower revenues for Prevnar 13 in the U.S., primarily reflecting lower government purchases for the pediatric indication as well as the continued decline in revenues for the adult indication due to a declining “catch up” opportunity compared to the prior year quarter, partially offset by an increase in international revenues mostly due to higher volumes reflecting continued uptake following the 2017 launch in China, partially offset by the unfavorable impact of timing associated with government purchases for the pediatric indication in certain emerging markets | (43) |
| Other operational factors, net | 62 |
| Operational growth, net | 852 |
| Unfavorable impact of foreign exchange | (166) |
| Biopharma Revenues increase | 686 |
| Biopharma Revenues, for the three months ended September 29, 2019 | $10,108 |

(a) Certain key brands represent Ibrance, Eliquis and Xeljanz. See the “Analysis of the Condensed Consolidated Statements of Income––Revenues––Selected Product Discussion” section of this MD&A for product analysis information.

Total Biopharma revenues from emerging markets increased $174 million, or 9%, to $2.0 billion from $1.8 billion, reflecting 15% operational growth. Foreign exchange had an unfavorable impact of 5% on total Biopharma revenues from emerging markets. The operational increase in emerging markets was primarily driven by Ibrance, Eliquis and Prevenar 13.

#### Costs and Expenses

- *Cost of sales* as a percentage of *Revenues* increased 0.7 percentage points driven by an unfavorable impact of foreign exchange and higher royalty expenses, partially offset by a favorable change in product mix.
- The increase in *Cost of sales* of 12% was mainly driven by the unfavorable impact of foreign exchange, as well as an increase in royalty expenses based on the mix of products sold, an increase in sales volumes for various products within our product portfolio and an unfavorable change in product mix.
- The decrease in *Selling, informational and administrative expenses* of 1% was mostly driven by lower investment in certain products and a favorable impact of foreign exchange, partially offset by additional investment across several of our products, including recently acquired Array products.
- The increase in *Research and development expenses* of 19% was mostly driven by investment in newly acquired Array products.
- The unfavorable change in *Other (income)/deductions––net* primarily reflects a $96 million decrease in income from collaborations, out-licensing arrangements and sales of compound/product rights, and a $47 million decrease in dividend income from our investment in ViiV, partially offset by a favorable impact of foreign exchange.

### Upjohn Operating Segment

#### Revenues

Upjohn *Revenues* decreased $841 million, or 28%, to $2.2 billion, reflecting an operational decrease of $804 million, or 26%, and the unfavorable impact of foreign exchange of $37 million, or 1%.

The following provides an analysis of the decrease in Upjohn worldwide *Revenues:*

| (MILLIONS OF DOLLARS) |  |
| --- | ---: |
| Upjohn Revenues, for the three months ended September 30, 2018 | $3,036 |
| Operational decline: |  |
| Lower worldwide revenues for Lyrica, primarily in the U.S., reflecting the expected significantly lower volumes associated with multi-source generic competition that began in July 2019 | (687) |
| Decline in revenues for Revatio driven by lower U.S. Oral Suspension formulation sales and pricing pressures due to a recent generic entry, and for Relpax, driven by continued generic competition across developed markets | (53) |
| Decline from Norvasc and Lipitor, primarily in China, driven by pricing pressures from the March 2019 government implementation of the VBP in certain cities. The decline in Lipitor was also due to discontinued sales in Saudi Arabia and lower volumes in Japan. The decline in Norvasc was also due to lower volumes in Japan and South Korea. These declines were partially offset by volume growth and geographic expansion in provinces in China where the VBP has not yet been implemented | (35) |
| Lower revenues for Viagra primarily in the U.S. resulting from the loss of exclusivity in December 2017 | (14) |
| Other operational factors, net | (14) |
| Operational decline, net | (804) |
| Unfavorable impact of foreign exchange | (37) |
| Upjohn Revenues decrease | (841) |
| Upjohn Revenues, for the three months ended September 29, 2019 | $2,195 |

Total Upjohn revenues from emerging markets decreased $46 million, or 5%, to $955 million from $1.0 billion, reflecting a 1% operational decline. Foreign exchange had an unfavorable impact of 3% on total Upjohn revenues from emerging markets. The operational decrease in emerging markets was primarily driven by Lipitor and Norvasc.

#### Costs and Expenses

- *Cost of sales* as a percentage of *Revenues* increased 3.7 percentage points driven by lower Lyrica revenues in developed markets, primarily related to the June 2019 loss of exclusivity for Lyrica in the U.S., as well as an unfavorable impact of foreign exchange, partially offset by lower royalty expense for Lyrica due to the patent expiration.
- The decrease in *Cost of sales* of 11% was driven by lower royalty expense resulting from the June 2019 loss of exclusivity for Lyrica in the U.S., as well as lower volumes for certain products, partially offset by an unfavorable impact of foreign exchange.
- *Selling, informational and administrative expenses* decreased 18% mostly driven by a reduction in field force expense as well as advertising and promotion expenses in developed markets, primarily related to Lyrica in the U.S., partially offset by the non-recurrence of a one-time general and administrative expense reversal in the third quarter of 2018.
- *Research and development expenses* and *Other (income)/deductions––net* were relatively unchanged.

### First Nine Months of 2019 vs. First Nine Months of 2018

### Biopharma Operating Segment

#### Revenues

Biopharma *Revenues* increased $1.1 billion, or 4%, to $28.9 billion, reflecting an operational increase of $2.0 billion, or 7%, and an unfavorable impact of foreign exchange of $891 million, or 3%.

The following provides an analysis of the increase in Biopharma worldwide *Revenues:*

| (MILLIONS OF DOLLARS) |  |
| --- | ---: |
| Biopharma Revenues, for the nine months ended September 30, 2018 | $27,737 |
| Operational growth/(decline): |  |
| Continued worldwide growth from certain key brands(a) | 1,978 |
| Higher revenues for Inlyta, primarily in the U.S. driven by increased demand resulting from the second quarter of 2019 U.S. FDA approvals for the combinations of certain checkpoint inhibitors plus Inlyta for the first-line treatment of patients with advanced RCC, partially offset by the decline in other developed markets due to increased competition | 100 |
| Growth from Biosimilars, primarily in the U.S. | 95 |
| Higher revenues for rare disease products driven by Vyndaqel following the U.S. launch in May 2019 for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM); and in international markets, primarily driven by continued uptake for the transthyretin amyloid polyneuropathy indication, primarily in developed Europe, as well as the March 2019 launch of the ATTR-CM indication in Japan, partially offset by lower revenues for certain rare disease products, including the hemophilia franchises (Refacto AF/Xyntha and BeneFIX), primarily due to competitive pressures, and Genotropin in developed markets, mainly due to unfavorable channel mix | 21 |
| Lower revenues for Enbrel internationally, reflecting continued biosimilar competition in most developed Europe markets | (200) |
| Lower revenues for the Hospital products business, primarily reflecting declines in developed markets, mostly due to the continued expected negative impact from generic competition for products that have previously lost marketing exclusivity, partially offset by continued growth from anti-infective products in China as well as the 2018 U.S. launches of our immune globulin intravenous products (Panzyga and Octagam) | (46) |
| Other operational factors, net | 92 |
| Operational growth, net | 2,040 |
| Unfavorable impact of foreign exchange | (891) |
| Biopharma Revenues increase | 1,150 |
| Biopharma Revenues, for the nine months ended September 29, 2019 | $28,887 |

(a) Certain key brands represent Ibrance, Eliquis, Xeljanz and Prevnar/Prevenar 13. See the “Analysis of the Condensed Consolidated Statements of Income––Revenues––Selected Product Discussion” section of this MD&A for product analysis information.

Total Biopharma revenues from emerging markets increased $288 million, or 5%, to $5.9 billion from $5.7 billion, reflecting 14% operational growth. Foreign exchange had unfavorable impact of 9% on total Biopharma revenues from emerging markets. The operational increase in emerging markets was primarily driven by Prevenar 13, Ibrance and Eliquis.

#### Costs and Expenses

- *Cost of sales* as a percentage of *Revenues* was relatively flat.
- The increase in *Cost of sales* of 5% was mainly driven by an unfavorable change in product mix, an increase in royalty expenses based on the mix of products sold and an increase in sales volumes for various products within our product portfolio, partially offset by a favorable impact of foreign exchange.
- The increase in *Selling, informational and administrative expenses* of 1% was mostly driven by additional investment across several of our products, including recently acquired Array products, as well as the non-recurrence of a favorable true-up of healthcare reform expenses in the first quarter of 2018, partially offset by a favorable impact of foreign exchange and decreased investment in certain products.
- *Research and development expenses* of 7% was mostly driven by investment in newly acquired Array products, partially offset by a favorable impact of foreign exchange.
- The unfavorable change in *Other (income)/deductions––net* primarily reflects a $301 million decrease in income from collaborations, out-licensing arrangements and sales of compound/product rights and a $42 million decrease in dividend income from our investment in ViiV, partially offset by an increase in royalty-related income mainly due to a one-time favorable resolution in the second quarter of 2019 of a legal dispute for $82 million.

### Upjohn Operating Segment

#### Revenues

Upjohn *Revenues* decreased $1.2 billion, or 13%, to $8.1 billion, reflecting an operational decrease of $992 million, or 11%, and the unfavorable impact of foreign exchange of $233 million, or 2%.

The following provides an analysis of the decrease in Upjohn worldwide *Revenues:*

| (MILLIONS OF DOLLARS) |  |
| --- | ---: |
| Upjohn Revenues, for the nine months ended September 30, 2018 | $9,302 |
| Operational growth/(decline): |  |
| Lower worldwide revenues for Lyrica, primarily in the U.S., reflecting the expected significantly lower volumes associated with multi-source generic competition that began in July 2019 | (736) |
| Lower revenues for Viagra and Upjohn’s authorized generic for Viagra in the U.S. resulting from increased generic competition following Viagra's December 2017 patent expiration | (181) |
| Decline in revenues for Revatio driven by lower U.S. Oral Suspension formulation sales and pricing pressures due to a recent generic entry, and for Relpax, driven by continued generic competition across developed markets | (98) |
| Volume-driven growth from Celebrex and Effexor, primarily in Japan and China | 68 |
| Growth from Lipitor, primarily due to volume growth and geographic expansion in provinces in China where the VBP has not yet been implemented, partially offset by pricing pressures for Lipitor and Norvasc from the implementation of the VBP in certain cities in China, lower volumes in Japan for Norvasc and the discontinued sales of Lipitor in Saudi Arabia | 37 |
| Other operational factors, net | (82) |
| Operational decline, net | (992) |
| Unfavorable impact of foreign exchange | (233) |
| Upjohn Revenues decrease | (1,225) |
| Upjohn Revenues, for the nine months ended September 29, 2019 | $8,077 |

Total Upjohn revenues from emerging markets decreased $52 million, or 2%, to $3.0 billion, reflecting 4% operational growth more than offset by the unfavorable impact of foreign exchange of 6% on total Upjohn revenues from emerging markets. The operational increase in emerging markets was primarily driven by Lipitor, Viagra, Celebrex and Norvasc.

#### Costs and Expenses

- *Cost of sales* as a percentage of *Revenues* increased 0.1 percentage points driven by lower Lyrica revenues in developed markets, primarily related to the June 2019 loss of exclusivity for Lyrica in the U.S., partially offset by lower royalty expense for Lyrica due to the patent expiration, and a favorable impact of foreign exchange.
- The decrease in *Cost of sales* of 13% was primarily driven by lower royalty expense due to the June 2019 loss of exclusivity for Lyrica in the U.S., a favorable impact of foreign exchange, as well as lower atorvastatin active product ingredients import duties in China.
- *Selling, informational and administrative expenses* decreased 14% driven by a reduction in field force expense as well as advertising and promotion expenses in developed markets, primarily related to Lyrica in the U.S., as well as a favorable impact of foreign exchange, partially offset by the non-recurrence of one-time general and administrative expense reversals in the second and third quarters of 2018, and investments in China across key brands.
- *Research and development expenses* and *Other (income)/deductions––net* were relatively unchanged.

### ANALYSIS OF THE CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

Changes in the components of *Accumulated other comprehensive loss* reflect the following:

- For *Foreign currency translation adjustments, net,* the third quarter and first nine months of 2019 primarily reflect the reclassification resulting from the contribution of our Consumer Healthcare business to the Consumer Healthcare joint venture with GSK, and the strengthening of the U.S. dollar against the euro, partially offset by the weakening of the U.S. dollar against the Japanese yen and the results of our net investment hedging program. The first nine months of 2019 also reflect the strengthening of the U.S. dollar against the Australian dollar. For additional information, see Notes to Consolidated Financial Statements—*Note 2B. Acquisitions, Equity-Method Investment and Assets and Liabilities Held for Sale and Research and Development Arrangement: Equity-Method Investment and Assets and Liabilities Held for Sale.*
- For *Unrealized holding gains on derivative financial instruments, net* and *Unrealized holding gains/(losses) on available-for-sale securities, net,* the third quarter and first nine months of 2019 reflect the impact of fair value remeasurements and the reclassification of amounts into income. For additional information, see Notes to Condensed Consolidated Financial Statements—*Note 7. Financial Instruments.*
- For *Benefit plans: actuarial gains/(losses), net,* mainly reflects for the third quarter and the first nine months of 2019 (i) the amortization of changes in the pension benefit obligation previously recognized in Other comprehensive income, (ii) the favorable impact of foreign exchange, (iii) settlement activity and (iv) a $194 million increase in the plan liability due to interim plan remeasurements. For additional information, see Notes to Condensed Consolidated Financial Statements—*Note 10. Pension and Postretirement Benefit Plans.*
- For *Benefit plans: prior service costs and other, net*, the third quarter and the first nine months of 2019 reflect the reclassification into income of amounts related to amortization of changes in prior service costs and credits previously recognized in *Other comprehensive income.* For additional information, see Notes to Condensed Consolidated Financial Statements—*Note 10. Pension and Postretirement Benefit Plans.*

### ANALYSIS OF THE CONDENSED CONSOLIDATED BALANCE SHEETS

For information about certain of our financial assets and liabilities, including *Cash and cash equivalents, Short-term investments, Equity-method investments, Long-term investments, Short-term borrowings, including current portion of long-term debt*, and *Long-term debt*, see the “Analysis of the Condensed Consolidated Statements of Cash Flows” section of this MD&A, the “Analysis of Financial Condition, Liquidity and Capital Resources: Selected Measures of Liquidity and Capital Resources” section of this MD&A and Notes to Condensed Consolidated Financial Statements—*Note 7. Financial Instruments.*

For information about events and circumstances impacting our tax-related accounts, see Notes to Condensed Consolidated Financial Statements—*Note 5. Tax Matters.*

For a description of changes in *Total Equity,* see the consolidated statements of equity.

For information related to changes in *Accumulated other comprehensive loss*, see the “Analysis of the Condensed Consolidated Statements of Comprehensive Income” section of this MD&A and Notes to Condensed Consolidated Financial Statements—*Note 6. Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests.*

The changes in our asset and liability accounts as of September 29, 2019, compared to December 31, 2018, generally reflect, and the following explanations exclude, fluctuations in foreign currency exchange rates, the impact of the adoption of new accounting standards in the first quarter of 2019, our Consumer Healthcare business joint venture with GSK, and our acquisitions of Array and Therachon (see Notes to Condensed Consolidated Financial Statements—*Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards* and *Note 2. Acquisitions, Equity-Method Investment and Assets and Liabilities Held for Sale and Research and Development Arrangement* for additional information).

- For *Trade accounts receivable, less allowance for doubtful accounts,* the change reflects the timing of sales and collections in the normal course of business.
- For *Inventories,* the change reflects the increases for certain products to meet targeted levels in the normal course of business, including inventory build for supply recovery, new product launches and market demand, partially offset by the write off of rivipansel inventory previously expected to be sold (see Notes to Condensed Consolidated Financial Statements—*Note 2C. Acquisitions, Equity-Method Investment and Assets and Liabilities Held for Sale and Research and Development Arrangement: Research and Development Arrangement* for additional information).
- For *Other current assets,* the change reflects increases in receivables in the normal course of business.
- For *PP&E,* the change primarily reflects capital additions in the normal course of business, partially offset by depreciation during the period.
- For *Identifiable intangible assets, less accumulated amortization*, the change primarily reflects amortization for the period and intangible asset impairment charges (see Notes to Condensed Consolidated Financial Statements—*Note 4. Other (Income)/Deductions—Net*), partially offset by additions for the period.
- For *Other noncurrent assets,* the change reflects a net increase in assets in the normal course of business, and an increase in receivables associated with derivative financial instruments.
- For *Trade accounts payable,* the change reflects the timing of purchases and payments in the normal course of business.
- For *Other current liabilities*, the change reflects a decrease in liabilities associated with:
- payments and accruals in the normal course of business;
- payments for restructuring activities; and
- payments for contingent consideration obligations,

partially offset by:

- an increase due to reclassifications from noncurrent to current.
- For *Pension benefit obligations, net*, the change reflects pension contributions and direct employer benefit payments, partially offset by interim plan remeasurements.
- For *Other noncurrent liabilities*, the change reflects:
- a decrease in payables associated with derivative financial instruments;
- a decrease in restructuring liabilities related to the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of a U.S. IRS audit for multiple tax years (see Notes to Condensed Consolidated Financial Statements—*Note 5B. Tax Contingencies*); and
- a decrease due to reclassifications from noncurrent to current,

partially offset by:

- an increase in accruals in the normal course of business.
- For *Treasury stock,* the change reflects $8.9 billion of share repurchases, composed of $6.8 billion paid to GS&Co. in February 2019 pursuant to the terms of an accelerated share repurchase agreement as well as $2.1 billion of open-market share repurchases. See Notes to Condensed Consolidated Financial Statements—*Note 12C. Contingencies and Certain Commitments: Certain Commitments* for additional information.

### ANALYSIS OF THE CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

| (MILLIONS OF DOLLARS) Cash provided by/(used in): | Nine Months Ended September 29, 2019 | September 30, 2018 | % Change |
| --- | ---: | ---: | ---: |
| Operating activities | $8,819 | $11,089 | (20) |
| Investing activities | (1,112) | 5,289 | \* |
| Financing activities | (6,045) | (14,034) | (57) |
| Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents | (41) | (116) | (65) |
| Net increase in Cash and cash equivalents and restricted cash and cash equivalents | $1,620 | $2,227 | (27) |

### Operating Activities

Our net cash provided by operating activities was $8.8 billion in the first nine months of 2019, compared to $11.1 billion in the same period in 2018. The decrease in net cash provided by operating activities reflects the timing of receipts from customers and payments to vendors in the ordinary course of business, and the upfront cash payment associated with our acquisition of Therachon (see Notes to Condensed Consolidated Financial Statements––*Note 2A. Acquisitions, Equity-Method Investment and Assets and Liabilities Held for Sale and Research and Development Arrangement: Acquisitions*), partially offset by an increase in net income and a decrease in benefit plan contributions.

In the first nine months of 2019, the change in the line item *Other adjustments, net* primarily reflects, among other items:

- the non-recurrence of a non-cash gain associated with our transaction with Bain Capital to create a new biopharmaceutical company to continue development of a portfolio of clinical and pre-clinical stage neuroscience assets in 2018;
- a reduction in net unrealized gains on equity securities;
- a reduction in net realized gains on equity securities; and
- the non-recurrence of a non-cash gain on the contribution of Pfizer’s allogeneic CAR T developmental program assets, in connection with our contribution agreement with Allogene in 2018,

partially offset by:

- net gains on foreign exchange contracts hedging a portion of our forecasted intercompany inventory sales (that fixes the cost of inventory sold later to customers).

In the condensed consolidated statements of cash flows, the line item *Other changes in assets and liabilities, net of acquisitions and divestitures* is presented excluding the effects of changes in foreign currency exchange rates, as these changes do not reflect actual cash inflows or outflows, and excluding any other significant non-cash movements. Accordingly, the amounts shown will not necessarily agree with the changes in the assets and liabilities that are presented in our condensed consolidated balance sheets. In the first nine months of 2019 and 2018, the line item *Other changes in assets and liabilities, net of acquisitions and divestitures,* primarily reflects changes, in the normal course of business, in trade accounts receivable, inventories, other current assets, other noncurrent assets, trade accounts payable, accrued compensation, other current and noncurrent liabilities, as well as in the first nine months of 2019, the adjustment necessary to reflect the non-cash nature of a favorable settlement of a U.S. IRS audit for multiple tax years (see Notes to Condensed Consolidated Financial Statements––*Note 5A. Tax Matters: Taxes on Income from Continuing Operations).*

For additional information about changes in other assets and liabilities account balances, see the “Analysis of the Condensed Consolidated Balance Sheets” in this MD&A.

### Investing Activities

Our net cash used in investing activities was $1.1 billion in the first nine months of 2019, compared to net cash provided by investing activities of $5.3 billion in the same period in 2018. The change in net cash provided by/(used in) investing activities was primarily attributable to:

- cash used for the acquisition of Array, net of cash acquired, of $10.9 billion in the third quarter of 2019,

partially offset by:

- an increase in net proceeds generated from the sale of investments of $5.0 billion for cash needs, including financing the acquisition of Array (see Notes to Condensed Consolidated Financial Statements––*Note 2A. Acquisitions, Equity-Method Investment and Assets and Liabilities Held for Sale and Research and Development Arrangement: Acquisitions).*

### Financing Activities

Our net cash used by financing activities was $6.0 billion in the first nine months of 2019, compared to $14.0 billion in the same period in 2018. The decrease in net cash used in financing activities was primarily attributable to:

- $10.1 billion net proceeds raised from short-term borrowings in the first nine months of 2019, primarily in connection with the acquisition of Array, compared to net payments on short-term borrowings of $3.3 billion in the first nine months of 2018,

partially offset by:

- higher repayments on long-term debt of $2.7 billion;
- higher purchases of common stock of $1.7 billion; and
- lower proceeds from the exercise of stock options of $796 million.

### ANALYSIS OF FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES

We rely largely on operating cash flows, short-term investments, short-term commercial paper borrowings and long-term debt to provide for our liquidity requirements. We continue our efforts to improve cash inflows through working capital efficiencies. We target specific areas of focus including accounts receivable, inventories, accounts payable, and other working capital, which allows us to optimize our operating cash flows. Due to our significant operating cash flows as well as our financial assets, access to capital markets and available lines of credit and revolving credit agreements, we believe that we have, and will maintain, the ability to meet our liquidity needs for the foreseeable future, which include:

- the working capital requirements of our operations, including our R&D activities;
- investments in our business;
- dividend payments and potential increases in the dividend rate;
- share repurchases;
- the cash requirements associated with our cost-reduction/productivity initiatives;
- paying down outstanding debt;
- contributions to our pension and postretirement plans; and
- business-development activities.

Our long-term debt is rated high-quality by both S&P and Moody’s. See the “Credit Ratings” section below. As market conditions change, we continue to monitor our liquidity position. We have taken and will continue to take a conservative approach to our financial investments. Both short-term and long-term investments consist primarily of high-quality, highly liquid, well-diversified available-for-sale debt securities.

### Selected Measures of Liquidity and Capital Resources

*The following table provides certain relevant measures of our liquidity and capital resources:*

| (MILLIONS OF DOLLARS, EXCEPT RATIOS AND PER COMMON SHARE DATA) Selected financial assets(a): | September 29, 2019 | December 31, 2018 |
| --- | ---: | ---: |
| Cash and cash equivalents | $2,785 | $1,139 |
| Short-term investments | 6,302 | 17,694 |
| Long-term investments, excluding private equity investments at cost | 1,981 | 1,823 |
|  | 11,067 | 20,656 |
| Debt: |  |  |
| Short-term borrowings, including current portion of long-term debt | 16,617 | 8,831 |
| Long-term debt | 36,044 | 32,909 |
|  | 52,662 | 41,740 |
| Selected net financial liabilities(b) | $(41,595) | $(21,084) |
| Working capital(c) | $(3,515) | $18,068 |
| Ratio of current assets to current liabilities | 0.90:1 | 1.57:1 |
| Total Pfizer Inc. shareholders’ equity per common share(d) | $11.77 | $11.09 |

(a) See Notes to Condensed Consolidated Financial Statements––*Note 7. Financial Instruments* for a description of certain assets held and for a description of credit risk related to our financial instruments held.

(b) The increase in selected net financial liabilities was primarily driven by a decrease in short-term investments and a net increase in short-term debt, mainly as a result of cash paid for the acquisition of Array. We retain a strong financial liquidity position as a result of our net cash provided by operating activities, our high-quality financial asset portfolio and access to capital markets. For additional information, see the “Credit Ratings” section of this MD&A.

(c) The decrease in working capital was primarily due to:

- a decrease in S*hort-term investments* mainly driven by the financing requirements for the acquisition of Array, share repurchase activities, dividend payments, capital expenditures and debt repayment, partially offset by operating cash flow generation, cash from employee stock option exercises and the long-term debt issuance;
- the impact of the deconsolidation of the Consumer Healthcare business as a result of the completion of the Consumer Healthcare joint venture transaction;
- an increase in short-term borrowings as a result of the issuance of commercial paper, mostly to finance the acquisition of Array; and
- the net impact of foreign currency exchange,

partially offset by:

- the timing of accruals, cash receipts and payments in the ordinary course of business; and
- an increase in inventory related to increases for certain products to meet targeted levels in the normal course of business, including inventory build for supply recovery, new product launches and market demand, partially offset by the write off of rivipansel inventory previously expected to be sold (see Notes to Condensed Consolidated Financial Statements—*Note 2C. Acquisitions, Equity-Method Investment and Assets and Liabilities Held for Sale and Research and Development Arrangement: Research and Development Arrangement* for additional information).

(d) Represents total Pfizer Inc. shareholders’ equity divided by the actual number of common shares outstanding (which excludes treasury stock).

In March 2019, we completed a public offering of $5.0 billion aggregate principal amount of senior unsecured notes (see Notes to Condensed Consolidated Financial Statements––*Note 7D. Financial Instruments: Long-Term Debt).*

For additional information about the sources and uses of our funds, see the “Analysis of the Condensed Consolidated Balance Sheets” and the “Analysis of the Condensed Consolidated Statements of Cash Flows” sections of this MD&A.

#### Domestic and International Selected Financial Assets

Many of our operations are conducted outside the U.S., and significant portions of our selected financial assets are held internationally. The amount of funds held in U.S. tax jurisdictions can fluctuate due to the timing of receipts and payments in the ordinary course of business and due to other reasons, such as business-development activities. As part of our ongoing liquidity assessments, we regularly monitor the mix of domestic and international cash flows (both inflows and outflows). The changes in tax law under the TCJA, which includes transitioning U.S. international taxation from a worldwide tax system to a territorial tax system, allow us to more easily access our selected financial assets globally. The majority of our cash we held internationally as of year-end 2017 was repatriated in 2018.

#### Agreement to Combine Upjohn with Mylan

In connection with the recently-announced agreement to combine Upjohn with Mylan discussed in the “Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Business” and “––Our Strategy––Our Business Development Initiatives” sections of this MD&A, Upjohn will incur $12 billion of debt prior to the closing of the transaction. Immediately prior to the separation, Upjohn will make a cash distribution of $12 billion to Pfizer, which will be funded by the proceeds of such debt. Following the separation, Upjohn will remain the obligor with respect to the debt.

#### Credit Ratings

Two major corporate debt-rating organizations, Moody’s and S&P, assign ratings to our short-term and long-term debt. A security rating is not a recommendation to buy, sell or hold securities and the rating is subject to revision or withdrawal at any time by the rating organization. Each rating should be evaluated independently of any other rating.

In June 2019, S&P placed Pfizer on “CreditWatch Negative” following the announcement of Pfizer’s intention to acquire Array. The CreditWatch placement was resolved with a one-notch downgrade of Pfizer’s debt rating to ‘AA-’ upon the consummation of the transaction. In July 2019, we announced that we entered into a definitive agreement to combine Upjohn with Mylan, which resulted in actions from both Moody’s and S&P. Moody’s placed Pfizer’s long-term rating under review for downgrade (limited to one-notch, or ‘A2’ upon close of the Mylan transaction) while S&P lowered Pfizer’s rating to ‘AA-’ (as a result of the Array transaction) and confirmed it will still remain on CreditWatch Negative (with the expectation the rating will be lowered one additional notch to ‘A+’ upon close of the Mylan transaction).

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| The following table provides the current ratings assigned by these rating agencies to our commercial paper and senior unsecured long-term debt: |  |  |  |  |  |  |
| NAME OF RATING AGENCY |  | Pfizer Commercial Paper |  | Pfizer Long-Term Debt | Outlook/Watch | Date of Last Rating Change |
|  | Rating |  | Rating |  |  |  |
| Moody’s |  | P-1 |  | A1 | Under Review for Downgrade | October 2009 |
| S&P |  | A-1+ |  | AA- | CreditWatch Negative | July 2019 |

#### Debt Capacity––Lines of Credit

We have available lines of credit and revolving credit agreements with a group of banks and other financial intermediaries. We typically maintain cash and cash equivalent balances and short-term investments which, together with our available revolving credit facilities, are in excess of our commercial paper and other short-term borrowings. As of September 29, 2019, we had access to a total of $15.0 billion in U.S. revolving credit facilities consisting of a $7.0 billion facility expiring in 2023 and an $8.0 billion facility expiring in September 2020, which may be used to support our commercial paper borrowings. In addition to the U.S. revolving credit facilities, our lenders have provided us an additional $526 million lines of credit, of which $497 million expire within one year. Of these total lines of credit, $15.5 billion were unused as of September 29, 2019. In connection with the recently-announced agreement to combine Upjohn with Mylan discussed in the “Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Business” and “––Our Strategy––Our Business Development Initiatives” sections of this MD&A, Upjohn entered into a fully underwritten, 364-day senior unsecured bridge facility for up to $12 billion. This bridge facility is expected to terminate upon the issuance of $12 billion of debt securities, loans or a combination of the two by Upjohn prior to the transaction close.

#### LIBOR

From time to time, we issue variable rate debt based on LIBOR, or undertake interest rate swaps that contain a variable element based on LIBOR. Banks currently reporting information used to set LIBOR will stop doing so after 2021. Various parties, including government agencies, are seeking to identify an alternative rate to replace LIBOR. We are monitoring their efforts, and we will likely amend contracts to accommodate any replacement rate where it is not already provided.

#### Global Economic Conditions––General

The global economic environment has not had, nor do we anticipate it will have, a material impact on our liquidity or capital resources. Due to our significant operating cash flows, financial assets, access to capital markets and available lines of credit and revolving credit agreements, we continue to believe that we have, and will maintain, the ability to meet our liquidity needs for the foreseeable future. We monitor our liquidity position continuously in the face of evolving economic conditions. For additional information see the “Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Operating Environment––The Global Economic Environment” section in this MD&A.

#### Global Economic Conditions––Venezuela and Argentina Operations

Our Venezuela and Argentina operations function in hyperinflationary economies. The impact to Pfizer is not considered material.

#### Off-Balance Sheet Arrangements

In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with a transaction or that are related to events and activities prior to or following a transaction. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we may be required to reimburse the loss. These indemnification obligations generally are subject to various restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of September 29, 2019, the estimated fair value of our indemnity obligations was not significant.

Certain of our co-promotion or license agreements give our licensors or partners the rights to negotiate for, or in some cases to obtain under certain financial conditions, co-promotion or other rights in specified countries with respect to certain of our products.

#### Share-Purchase Plans and Accelerated Share Repurchase Agreements

Our December 2017 $10 billion share repurchase program was exhausted in the first quarter of 2019.

In December 2018, the Board of Directors authorized a new $10 billion share repurchase program to be utilized over time (the 2018 program) and share repurchases commenced thereunder in the first quarter of 2019.

On February 7, 2019, we entered into an accelerated share repurchase agreement with GS&Co. to repurchase approximately $6.8 billion of our common stock, and on August 1, 2019, the accelerated share repurchase agreement with GS&Co. was completed. For additional information, see Notes to Condensed Consolidated Financial Statements––*Note 12C. Contingencies and Certain Commitments: Certain Commitments* and “Unregistered Sales of Equity Securities and Use of Proceeds––Issuer Purchases of Equity Securities” in Part II, Item 2 of this Quarterly Report on Form 10-Q.

*The following table provides the number of shares of our common stock purchased and the cost of purchases under our publicly announced share purchase plans, including our accelerated share repurchase agreements:*

*(SHARES IN MILLIONS, DOLLARS IN BILLIONS)*

|  | Three Months Ended September 29, 2019(a) | September 30, 2018(b) | Nine Months Ended September 29, 2019(a) | September 30, 2018(b) |
| --- | ---: | ---: | ---: | ---: |
| Shares of common stock purchased | 34 | 47 | 213 | 192 |
| Cost of purchase | $— | $1.1 | $8.9 | $7.2 |

(a) Represents shares purchased pursuant to an accelerated share repurchase agreement with GS&Co. entered into on February 7, 2019, as well as other share repurchases. For additional information, see Notes to Condensed Consolidated Financial Statements––*Note 12C. Contingencies and Certain Commitments: Certain Commitments* and “Unregistered Sales of Equity Securities and Use of Proceeds––Issuer Purchases of Equity Securities” in Part II, Item 2 of this Quarterly Report on Form 10-Q.

(b) Represents shares purchased pursuant to an accelerated share repurchase agreement with Citibank entered into on March 12, 2018, as well as other share repurchases. For additional information, see Notes to Consolidated Financial Statements––*Note 12. Equity* in our 2018 Financial Report.

After giving effect to the accelerated share repurchase agreement and other share repurchases through September 29, 2019, our remaining share-purchase authorization was approximately $5.3 billion on September 29, 2019.

#### Dividends on Common Stock

In September 2019, our Board of Directors declared a dividend of $0.36 per share, payable on December 2, 2019, to shareholders of record at the close of business on November 8, 2019.

### NEW ACCOUNTING STANDARDS

#### Recently Adopted Accounting Standards

See Notes to Condensed Consolidated Financial Statements––*Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards.*

|  |  |  |
| --- | --- | --- |
| Recently Issued Accounting Standards, Not Adopted as of September 29, 2019 |  |  |
| **Standard/Description** | **Effective Date** | **Effect on the Financial Statements or Other Significant Matters** |
| In June 2016, the FASB issued new guidance on accounting for credit losses of financial instruments. The new guidance replaces the probable initial recognition threshold for incurred loss estimates in current GAAP with a methodology that reflects expected credit loss estimates. | January 1, 2020. | We are assessing the impact of the provisions of this new guidance on our consolidated financial statements. This standard includes our financial instruments, such as accounts receivable, and investments that are generally of high credit quality. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires us to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for our financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonable supportable forecast information. We do not expect this new guidance to have a material impact on our consolidated financial statements. |
| In January 2017, the FASB issued new guidance for goodwill impairment testing. The new guidance eliminates the requirement to perform a hypothetical purchase price allocation to measure goodwill impairment. Under the new guidance the goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount, and recognizing an impairment charge for the amount by which the carrying amount of the reporting unit exceeds its fair value, although it cannot exceed the total amount of goodwill allocated to that reporting unit. | January 1, 2020. | We do not expect this new guidance to have a material impact on our consolidated financial statements. |
| In August 2018, the FASB issued new guidance related to customers’ accounting for implementation costs incurred in a cloud computing arrangement that is considered a service contract. The new guidance aligns the requirements for capitalizing implementation costs in such arrangements with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The new guidance can be adopted either prospectively or retrospectively. | January 1, 2020. | We are assessing the impact of the provisions of this new guidance on our consolidated financial statements. We do not expect this new guidance to have a material impact on our consolidated financial statements. |
| In November 2018, the FASB issued new guidance clarifying the interaction between the accounting guidance for collaboration agreements and revenue from contracts with customers. | January 1, 2020. | We have assessed the impact of the provisions of this new guidance and do not expect it will have a material impact on our consolidated financial statements. |

109

### FORWARD-LOOKING INFORMATION AND FACTORS THAT MAY AFFECT FUTURE RESULTS

This report and other written or oral statements that we make from time to time contain forward-looking statements. Such forward-looking statements involve substantial risks and uncertainties. We have tried, wherever possible, to identify such statements by using words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek” and other words and terms of similar meaning or by using future dates in connection with any discussion of, among other things, our anticipated operating and financial performance, business plans and prospects, expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, revenue contribution, growth, performance, timing of exclusivity and potential benefits, strategic reviews, capital allocation objectives, plans for and prospects of our acquisitions and other business-development activities, benefits anticipated from the reorganization of our commercial operations in 2019, sales efforts, expenses, interest rates, foreign exchange rates, the outcome of contingencies, such as legal proceedings, government regulation, our ability to successfully capitalize on growth opportunities or prospects, manufacturing and product supply and plans relating to share repurchases and dividends. In particular, these include statements relating to future actions, including, among others, the anticipated progress in remediation efforts at certain of our Hospira manufacturing facilities and the expectations related to our supply issues set forth in the “Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Business––Product Manufacturing” section of this MD&A, the expected impact of patent expiries on our business set forth in the “Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Operating Environment––Industry-Specific Challenges––Intellectual Property Rights and Collaboration/Licensing Rights” section of this MD&A, the expected pricing pressures on our products in the U.S. and internationally and the anticipated impact to our business set forth in the “Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Operating Environment––Industry-Specific Challenges––Regulatory Environment/Pricing and Access––Government and Other Payer Group Pressures” section of this MD&A, the benefits expected from the reorganization of our commercial operations in 2019 and our expectations regarding growth set forth in the “Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Strategy––Organizing for Growth” section of this MD&A, the expected timing and benefits of our agreement to combine Upjohn with Mylan to create a new global pharmaceutical company set forth in the “Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Business,” and “––Our Strategy––Our Business Development Initiatives” sections of this MD&A, the anticipated costs related to our preparations for Brexit set forth in the “Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Operating Environment––The Global Economic Environment” section of this MD&A, our anticipated liquidity position set forth in the “Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Operating Environment––The Global Economic Environment” and the “Analysis of Financial Condition, Liquidity and Capital Resources” sections of this MD&A, our plans for increasing investment in the U.S. set forth in the “Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Strategy––Capital Allocation and Expense Management––Increasing Investment in the U.S.” section of this MD&A, the financial guidance set forth in the “Overview of Our Performance, Operating Environment, Strategy and Outlook––Our Financial Guidance for 2019” section of this MD&A, the expected impact of ACIP’s latest recommendation for Prevnar 13 for adults 65 and older on Prevnar 13’s revenues set forth in the “Analysis of the Condensed Consolidated Statements of Income––Revenues––Selected Product Discussion––Prevnar 13/Prevenar 13” section of this MD&A, the expected impact of updates to the prescribing information for Xeljanz on its prescribing and growth set forth in the “Analysis of the Condensed Consolidated Statements of Income––Revenues––Selected Product Discussion––Xeljanz” section of this MD&A, the anticipated costs and savings from our 2017-2019 initiatives and our Organizing for Growth initiative, set forth in the “Costs and Expenses––Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives” section of this MD&A and in Notes to Condensed Consolidated Financial Statements––*Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives,* the benefits expected from our business development transactions and the contributions that we expect to make from our general assets to the company’s pension and postretirement plans during 2019 set forth in Notes to Condensed Consolidated Financial Statements––*Note 10. Pension and Postretirement Benefit Plans*. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following:

- the outcome of R&D activities, including, without limitation, the ability to meet anticipated pre-clinical or clinical endpoints, commencement and/or completion dates for our pre-clinical or clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable pre-clinical and clinical trial results, including the possibility of unfavorable new clinical data and further analyses of existing clinical data;
- the risk we may not be able to successfully address all of the comments received from regulatory authorities such as the FDA or the EMA, or obtain approval from regulators, which will depend on myriad factors, including such regulator making a determination as to whether a product’s benefits outweigh its known risks and a determination of the product’s efficacy; regulatory decisions impacting labeling, manufacturing processes, safety and/or other matters; and recommendations by technical or advisory committees, such as ACIP, that may impact the use of our vaccines;
- the speed with which regulatory authorizations, pricing approvals and product launches may be achieved;
- the outcome of post-approval clinical trials, which could result in the loss of marketing approval, changes in product labeling, and/or new or increased concerns about the side effects or efficacy of, a product that could affect its availability or commercial potential, such as the update to the U.S. prescribing information for Xeljanz and Xeljanz extended release;
- the success of external business-development activities, including the ability to identify and execute on potential business development opportunities, the ability to satisfy the conditions to closing of announced transactions in the anticipated time frame or at all, the ability to realize the anticipated benefits of any such transactions, and the potential need to obtain additional equity or debt financing to pursue these opportunities, which could result in increased leverage and impact our credit ratings;
- competitive developments, including the impact on our competitive position of new product entrants, in-line branded products, generic products, private label products, biosimilars and product candidates that treat diseases and conditions similar to those treated by our in-line drugs and drug candidates;
- the implementation by the FDA and regulatory authorities in certain countries of an abbreviated legal pathway to approve biosimilar products, which could subject our biologic products to competition from biosimilar products, with attendant competitive pressures, after the expiration of any applicable exclusivity period and patent rights;
- risks related to our ability to develop and launch biosimilars, including risks associated with “at risk” launches, defined as the marketing of a product by Pfizer before the final resolution of litigation (including any appeals) brought by a third party alleging that such marketing would infringe one or more patents owned or controlled by the third party, and access challenges for our biosimilar products where our product may not receive appropriate formulary access or remains in a disadvantaged position relative to the innovator product;
- the ability to meet competition from generic, branded and biosimilar products after the loss or expiration of patent protection for our products or competitor products;
- the ability to successfully market both new and existing products domestically and internationally;
- difficulties or delays in manufacturing, including delays caused by natural events, such as hurricanes; supply shortages at our facilities; and legal or regulatory actions, such as warning letters, suspension of manufacturing, seizure of product, injunctions, debarment, voluntary recall of a product or failure to secure product approvals;
- trade buying patterns;
- the impact of existing and future legislation and regulatory provisions on product exclusivity;
- trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for our products;
- the impact of any significant spending reductions or cost controls affecting Medicare, Medicaid or other publicly funded or subsidized health programs or changes in the tax treatment of employer-sponsored health insurance that may be implemented;
- the impact of any U.S. healthcare reform or legislation, including any replacement, repeal, modification or invalidation of some or all of the provisions of the U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act;
- U.S. federal or state legislation or regulatory action and/or policy efforts affecting, among other things, pharmaceutical product pricing, intellectual property, reimbursement or access, including under Medicaid, Medicare and other publicly funded or subsidized health programs; patient out-of-pocket costs for medicines, manufacturer prices and/or price increases that could result in new mandatory rebates and discounts or other pricing restrictions; general budget control actions; the importation of prescription drugs from outside the U.S. at prices that are regulated by governments of various foreign countries; revisions to reimbursement of biopharmaceuticals under government programs; restrictions on U.S. direct-to-consumer advertising; limitations on interactions with healthcare professionals; or the use of comparative effectiveness methodologies that could be implemented in a manner that focuses primarily on the cost differences and minimizes the therapeutic differences among pharmaceutical products and restricts access to innovative medicines; as well as pricing pressures for our products as a result of highly competitive insurance markets;
- legislation or regulatory action in markets outside the U.S., including China, affecting pharmaceutical product pricing, intellectual property, reimbursement or access, including, in particular, continued government-mandated reductions in prices and access restrictions for certain biopharmaceutical products to control costs in those markets;
- the exposure of our operations outside the U.S. to possible capital and exchange controls, economic conditions, expropriation and other restrictive government actions, changes in intellectual property legal protections and remedies, as well as political unrest, unstable governments and legal systems and inter-governmental disputes;
- contingencies related to actual or alleged environmental contamination;
- claims and concerns that may arise regarding the safety or efficacy of in-line products and product candidates;
- any significant breakdown, infiltration or interruption of our information technology systems and infrastructure;
- legal defense costs, insurance expenses and settlement costs;
- the risk of an adverse decision or settlement and the adequacy of reserves related to legal proceedings, including patent litigation, such as claims that our patents are invalid and/or do not cover the product of the generic drug manufacturer or where one or more third parties seeks damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities, product liability and other product-related litigation, including personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, commercial, environmental, government investigations, employment and other legal proceedings, including various means for resolving asbestos litigation, as well as tax issues;
- the risk that our currently pending or future patent applications may not result in issued patents, or be granted on a timely basis, or any patent-term extensions that we seek may not be granted on a timely basis, if at all;
- our ability to protect our patents and other intellectual property, both domestically and internationally;
- interest rate and foreign currency exchange rate fluctuations, including the impact of possible currency devaluations in countries experiencing high inflation rates;
- governmental laws and regulations affecting domestic and foreign operations, including, without limitation, tax obligations and changes affecting the tax treatment by the U.S. of income earned outside the U.S. that may result from pending and possible future proposals, including further clarifications and/or interpretations of the TCJA enacted in 2017;
- any significant issues involving our largest wholesale distributors, which account for a substantial portion of our revenues;
- the possible impact of the increased presence of counterfeit medicines in the pharmaceutical supply chain on our revenues and on patient confidence in the integrity of our medicines;
- the end result of any negotiations between the U.K. government and the EU regarding the terms of the U.K.’s exit from the EU, which could have implications on our research, commercial and general business operations in the U.K. and the EU, including the approval and supply of our products;
- any significant issues that may arise related to the outsourcing of certain operational and staff functions to third parties, including with regard to quality, timeliness and compliance with applicable legal or regulatory requirements and industry standards;
- any significant issues that may arise related to our joint ventures and other third-party business arrangements;
- changes in U.S. generally accepted accounting principles;
- further clarifications and/or changes in interpretations of existing laws and regulations, or changes in laws and regulations, in the U.S. and other countries;
- uncertainties related to general economic, political, business, industry, regulatory and market conditions including, without limitation, uncertainties related to the impact on us, our customers, suppliers and lenders and counterparties to our foreign-exchange and interest-rate agreements of challenging global economic conditions and recent and possible future changes in global financial markets; the related risk that our allowance for doubtful accounts may not be adequate; and the risks related to volatility of our income due to changes in the market value of equity investments;
- any changes in business, political and economic conditions due to actual or threatened terrorist activity in the U.S. and other parts of the world, and related U.S. military action overseas;
- growth in costs and expenses;
- changes in our product, segment and geographic mix;
- the impact of purchase accounting adjustments, acquisition-related costs, discontinued operations and certain significant items;
- the impact of acquisitions, divestitures, restructurings and internal reorganizations, including the reorganization of our commercial operations in 2019, the transaction with GSK which combined our respective consumer healthcare businesses into a new consumer healthcare joint venture and our agreement to combine Upjohn with Mylan, as well as any other corporate strategic initiatives, and cost-reduction and productivity initiatives, each of which requires upfront costs but may fail to yield anticipated benefits and may result in unexpected costs or organizational disruption;
- the impact of product recalls, withdrawals and other unusual items;
- the risk of an impairment charge related to our intangible assets, goodwill or equity-method investments;
- risks related to internal control over financial reporting;
- risks and uncertainties related to acquisitions, such as the acquisition of Array, including, among other things, the ability to realize the anticipated benefits of those acquisitions, including the possibility that the expected cost savings and/or accretion from certain of those acquisitions will not be realized or will not be realized within the expected time frame; the risk that the businesses will not be integrated successfully; disruption from the transactions making it more difficult to maintain business and operational relationships; risks related to our ability to grow revenues for certain acquired products; significant transaction costs; and unknown liabilities;
- risks and uncertainties related to our transaction with GSK, which combined our respective consumer healthcare businesses into a new consumer healthcare joint venture, including, among other things, risks related to the ability to realize the anticipated benefits of the transaction, including the possibility that the expected benefits and cost synergies from the transaction will not be realized or will not be realized within the expected time period, the risk that the businesses will not be integrated successfully, the possibility that a future separation of the joint venture as an independent company via a demerger of GSK’s equity interest to GSK’s shareholders and a listing of the joint venture on the U.K. equity market may not occur, disruption from the transaction making it more difficult to maintain business and operational relationships, negative effects of the transaction on the market price of Pfizer’s common stock and on Pfizer’s operating results, significant transaction costs, unknown liabilities, the risk of litigation and/or regulatory actions related to the transaction, other business effects, including the effects of industry, market, economic, political or regulatory conditions, future exchange and interest rates, changes in tax and other laws, regulations, rates and policies, future business combinations or disposals and competitive developments; and
- risks and uncertainties related to our agreement to combine Upjohn with Mylan to create a new global pharmaceutical company, including, among other things, risks related to the satisfaction of the conditions to closing the transaction (including the failure to obtain necessary shareholder and regulatory approvals) in the anticipated timeframe or at all and the possibility that the transaction does not close, risks related to the ability to realize the anticipated benefits of the transaction, including the possibility that the expected benefits and cost synergies from the proposed transaction will not be realized or will not be realized within the expected time period, the risk that the businesses will not be integrated successfully, disruption from the transaction making it more difficult to maintain business and operational relationships, negative effects of the announcement or the consummation of the proposed transaction on the market price of Pfizer’s common stock, Pfizer’s credit ratings and/or on Pfizer’s or the combined company’s operating results, significant transaction costs, unknown liabilities, the risk of litigation and/or regulatory actions related to the proposed transaction, other business effects, including the effects of industry, market, economic, political or regulatory conditions, future exchange and interest rates, changes in tax and other laws, regulations, rates and policies, future business combinations or disposals and competitive developments.

We cannot guarantee that any forward-looking statement will be realized. Achievement of anticipated results is subject to substantial risks, uncertainties and inaccurate assumptions. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors should bear this in mind as they consider forward-looking statements, and are cautioned not to put undue reliance on forward-looking statements.

We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law or by the rules and regulations of the SEC. You are advised, however, to consult any further disclosures we make on related subjects.

Additional discussion regarding certain risks, uncertainties and assumptions described above, as well as other material risks to our business, is included under the heading entitled “Risk Factors” in Part I, Item 1A. of our 2018 Form 10-K. These risks could cause actual results to differ materially from past and projected future results. We note these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. We incorporate that section of the 2018 Form 10-K in this filing and investors should refer to it. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider any such list to be a complete set of all potential risks or uncertainties.

The operating segment information provided in this report does not purport to represent the revenues, costs and income from continuing operations before provision for taxes on income that each of our operating segments would have recorded had each segment operated as a standalone company during the periods presented.

This report includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.

### Legal Proceedings and Contingencies

Information with respect to legal proceedings and contingencies required by this Item is incorporated herein by reference to Notes to Condensed Consolidated Financial Statements––*Note 12A. Contingencies and Certain Commitments: Legal Proceedings* in Part I, Item 1, of this Quarterly Report on Form 10-Q.

## Market risk

As filed, 158 characters.

Information required by this item is incorporated by reference from the discussion under the heading *Financial Risk Management* in our 2018 Financial Report.

## Controls and procedures

As filed, 983 characters.

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures are effective in alerting them in a timely manner to material information required to be disclosed in our periodic reports filed with the SEC.

During our most recent fiscal quarter, there has not been any change in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 400 characters.

We refer to the “Our Operating Environment”, “The Global Economic Environment” and “Forward-Looking Information and Factors That May Affect Future Results” sections of the MD&A of this Quarterly Report on Form 10-Q and Part I, Item 1A, “Risk Factors”, of our 2018 Form 10-K. There have been no material changes from the risk factors discussed in Part I, Item 1A, “Risk Factors” of our 2018 Form 10-K.

Filed Nov 7, 2019.
Source: SEC EDGAR, the filing index for accession 0000078003-19-000082. Last ingested by Listed: Nov 12, 2026, 18:08 ET. No prices; not investment advice.
